

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83750 A2

(51) International Patent Classification⁷: **C12N 15/12**,
15/62, C07K 14/705, 16/28, A61K 38/17, 48/00

20833 (US). TSUCHIYA, Haruo [JP/US]; 6 Stoneridge Court, Baltimore, MD 21239 (US). GORSKI, Kevin, S. [US/US]; 16 W. Mt. Vernon Place, Baltimore, MD 21201 (US). TSENG, Su-Yi [US/US]; 3032 St. Paul Street, Baltimore, MD 21218 (US).

(21) International Application Number: PCT/US01/13430

(74) Agent: LIVNAT, Shmuel; Venable, Baetjer, Howard & Civiletti, LLP, 1201 New York Avenue, NW, Suite 1000, P.O. Box 34385, Washington, DC 20043-9998 (US).

(22) International Filing Date: 27 April 2001 (27.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/200,580 28 April 2000 (28.04.2000) US
60/240,169 13 October 2000 (13.10.2000) US
09/ 28 February 2001 (28.02.2001) US


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (for all designated States except US): JOHN HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NEW DENDRITIC CELL CO-STIMULATORY MOLECULES



WO 01/83750 A2

(57) Abstract: A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.



Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NEW DENDRITIC CELL CO-STIMULATORY MOLECULES

BACKGROUND OF THE INVENTION

Field of the Invention

5 The invention in the field of biochemistry and medicine relates to novel proteins that are selectively expressed on the surface of dendritic cells and can be used as cell surface molecules or in soluble form in vaccine compositions to stimulate immune responses.

Description of the Background Art

0 The generation of a T lymphocyte response is a complex process involving cell-cell interactions and production of soluble mediators (cytokines or lymphokines). This response is regulated by several T-cell surface molecules acting as "receptors," including the T-cell receptor (TCR) complex and other "accessory" surface molecules many of which are cell surface "differentiation antigens" that were first defined by monoclonal antibodies ("CD molecules")

5 Optimal activation of all lymphocytes is believed to require two signals: an antigen specific or clonal signal, as well as a second, antigen non-specific signal (Janeway, C., *Cold Spring Harbor Symp. Quant. Biol.* 54:1-14 (1989)). If a lymphocyte encounters an antigen alone, without co-stimulation by so-called co-stimulatory molecules (such as B7 described below), it will respond with either clonal inactivation also called "anergy" (Schwartz, R. *Science* 248:1349 (1990)) or apoptosis (programmed cell death); if the co-stimulatory signal is provided 0 it will respond with clonal expansion specific for the stimulating antigen. No significant amplification of an immune response against a given antigen occurs without co-stimulation (June *et al.* (*Immunology Today* 15:321-331, 1994); Chen *et.al.* (*Immunology Today* 14:483-486); Townsend, SE and Allison, JP (1993) *Science* 259:368-370).

5 The quality and potency of an immune response depends in large part on the type of antigen presenting cells (APC) that process and present the antigen to T cells. The density of the peptide antigen/MHC ligand available for engagement of the TCR and the provision of soluble and/or membrane-bound co-stimulatory signals by APCs at the time of T cell engagement and activation is critical. It is for these reasons that immunotherapeutic strategies have begun to focus on providing (a) the target antigen to the appropriate APC types and (b) appropriate co-stimulatory molecules to enhance T cell activation.

APCs that provide the signals required for activation of T cells include monocytes/macrophages, B lymphocytes, and, most importantly dendritic cells (DCs). In the past, activated macrophages were believed to be the critical APCs that initiated T cell responses *in vivo*. This notion was based on their ability to phagocytose antigens effectively and process them for surface display and presentation. More recently, attention has shifted to DC as the major initiator *in vivo* of antigen-specific T cell responses. DCs have a distinct phenotype from activated macrophages and are classified into different subtypes capable of initiating distinct immune responses. A functional hallmark of DCs is their approximately 100-fold greater potency than macrophages to activate naïve T cells *in vitro*. To date, the explanation of this potency has been based on quantitative differences in molecules known to be important for antigen presentation. The present invention is based on the discovery of an important qualitative difference.

The first signal in antigen presentation is initiated by interaction of the TCR with antigen presented in the context of class II major histocompatibility complex (MHC) molecules on the APC (Allen, *Immunol. Today* 8:270 (1987)). Co-stimulatory signals come from other molecules, the best characterized of which is the B7 family (namely B7.1, B7.2, and possibly B7.3) which are also present on APCs

Two proteins expressed on the surface of T cells are the best-characterized ligands or counter-receptors for co-stimulatory molecules such as B7. CD28 is a homodimeric glycoprotein of the immunoglobulin (Ig) superfamily (Aruffo and Seed, *Proc. Natl. Acad. Sci.* 84:8573-8577 (1987)) found on most mature human T cells that functions in T cell activation. CD28, is constitutively expressed on resting T cells and increases after activation. After signaling through the T cell receptor, ligation of CD28 induces T cells to proliferate and secrete IL-2 (Linsley, PS, *et al.* (1991) *J. Exp. Med.* 173, 721-730; Gimmi, CD, *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88, 6575-6579; Thompson, C. B., *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86, 1333-1337; June, C. H., *et al.* (1990) *Immunol. Today* 11, 211-6; Harding, F. A., *et al.* (1992) *Nature* 356, 607-609.). CD28 mediates cell-cell contact ("intercellular adhesion"), a form of antigen-independent intercellular interaction that is essential for immune responses (Springer *et al.*, *Ann. Rev. Immunol.* 5:223-252 (1987)). ,

CTLA4 is a T cell surface molecule highly homologous to CD28 but is not expressed on resting T cells and appears following T cell activation (Brunet, J. F., *et al.*, (1987) *Nature* 328,

267-270). CTLA-4 was originally identified by differential screening of a murine cytolytic T cell cDNA library, Brunet *et al. supra*. The role of CTLA-4 as a second receptor for B7 is discussed in Linsley *et al.* (1991) *J. Exp. Med.* 174:561-569, which also noted that B7 has a higher affinity for CTLA4 than for CD28. Freeman *et al.* (1993) *Science* 262:907-909 discussed 5 CTLA-4 in B7 deficient mice. Ligands for CTLA-4 are described in Lenschow *et al.* (1993) *Proc. Nat'l. Acad. Sci.* 90:11054-11058.

Th cells secrete growth and differentiation-inducing cytokines such as IL-2, IL-4 and IL-6 possibly in a focused manner in the area of Th-B cell contact which serves to ensure activation of only B cells presenting antigen to Th cells and avoid activation of bystander B cells.

0 CD28 and CTLA-4 interact with a co-stimulatory molecule generally known as B7. B7 was originally described as a B cell activation antigen because it was found on B cells and was termed B7/BB-1 (Linsley et al, *Proc. Natl. Acad. Sci. USA* 87:5031-5035 (1990)). Hereafter, this molecule will be referred to as B7, B7-1 or B7.1). B7 and more recently described B7 5 homologues are also members of the Ig superfamily. In contrast to CD28 and CTLA-4, B7 comprises two extracellular Ig domains, an N-terminal variable (V)-like domain followed by a constant (C)-like domain.

B7 family members are generally expressed on APCs and, as noted, are of critical importance to the activation of naive T cells.. These family members include B7-1 (=B7, also designated CD80) and B7-2 (also designated CD86). References describing B7-1 include 0 Schwartz, R. H. *Cell* 71:1065-1068, 1992; Chen, L. *et al.* *Cell* 71:1093-1102, 1992; Freeman, G. J. *et al.* *J. Immunol* 143:2714-2722, 1989; and Freeman, G. J. *et al.* *J. Exp. Med.* 174:625-631, 1991)). References describing B7-2 include (Freeman, G. J. *et al.* *Science* 262:909-911 813-960, 1993). To date, both murine B7-1 and B7-2 and human B7-1 and B7-2 have been 5 described (Freeman *et al.*, 1989, *supra*; 1991,, *supra*; and 1993, *supra*). Activated human B lymphocytes express CTLA4/CD28 binding counter-receptors B7-2 and B7-3, both of which can deliver costimulatory signals to T cells via either CD28 or CTLA4.

B7-2 is expressed by B cells at about 24 hours following stimulation with either anti-Ig or anti-MHC class II mAbs. B7-2 induces detectable IL-2 secretion and T cell proliferation. At about 48 to 72 hours post activation, B cells express both B7-1 and a third CTLA4 counter-receptor identified by a mAb BB-1 (Yokochi, T, *et al.* (1982) *J. Immunol.* 128, 823-827), termed B7-3. B7-3 is also expressed on B7-negative activated B cells and can costimulate T cell

proliferation without detectable IL-2 production, indicating that the B7-1 and B7-3 molecules are distinct. B7-3 is expressed on a wide variety of cells including activated B cells, activated monocytes, dendritic cells, Langerhans cells and keratinocytes. At 72 hours post B cell activation, the expression of B7-1 and B7-3 begins to decline. The presence of these 5 CTLA4/CD28 binding counter-receptors on the surface of activated B lymphocytes indicates that T cell costimulation is regulated, in part, by the temporal expression of these molecules following B cell activation.

The importance of the B7:CD28/CTLA4 costimulatory pathway(s) has been demonstrated *in vitro* and *in vivo*. A direct relationship exists between increased T cell activity 0 and increased B7 expression (Razi-Wolf *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:4210-4214 (1992)). T cells are rendered anergic when they, encounter peptides antigens on cells lacking a costimulatory ligand that binds CD28 Blockade of this costimulatory pathway results in the development of antigen specific tolerance in murine and humans systems (Harding *et al.*, *supra*; Lenschow, D. J. *et al.* (1992) *Science*. 257, 789-792; Turka, LA *et al.* (1992) *Proc. Natl. Acad. 5 Sci. USA*. 89, 11102-11105; Gimmi, CD *et al.* (1993) *Proc. Natl. Acad. Sci USA* 90, 6586-6590; Boussiotis, V. *et al.* (1993) *J. Exp. Med.* 178, 1753-1763). Conversely, expression of B7 by B7-negative murine tumor cells induces T-cell mediated specific immunity accompanied by tumor rejection and long lasting protection to tumor challenge (Chen, L, *et al.* (1992) *Cell* 71:1093-1102; Townsend *et al.*, *supra*; Baskar, S, *et al.* (1993) *Proc. Natl. Acad. Sci.* 90, 5687-0 5690.). Therefore, manipulation of the B7:CD28/CTLA4 pathway offers great potential to stimulate or suppress immune responses in humans.

Interactions between CD28 and B7 have been characterized using genetic fusions of the extracellular portions of B7 or CD28 with Ig Cy1 chains (Linsley et al, *J. Exp. Med.* 173:721-730 (1991)). When B7Ig fusion proteins are immobilized, or when B7 is expressed on the 5 surface of a cell, such as a transfected CHO cell, they costimulate T cell proliferation. T cell stimulation with B7+ CHO cells also specifically stimulates increased levels of transcripts for IL-2.

U.S. 5,521,288 describes a method for regulating immune responses by contacting CD28 positive T cells with fragments encoded by parts of DNA encoding B7, primarily corresponding 0 to the extracellular domain (ECD) of B7. Immune responses were also regulated by derivatives of B7 that were are fusion protein constructs including at least a portion of B7 ECD and another

protein, such as the human IgC γ 1 domain that altered the solubility, binding affinity and/or valency of B7. For example DNA encoding amino acid residues from positions 1-215 of the B7 ECD was joined to DNA encoding amino acid residues of the sequences corresponding to the hinge, CH2 and CH3 regions of human IgC γ 1 to form a DNA fusion product which encoded a 5 B7Ig fusion protein. Also disclosed was a method for treating an immune system disease mediated by T cells by administering B7 or B7Ig fusion protein to react with T cells by binding the CD28 receptor. T cell proliferation in graft versus host disease was inhibited by reacting CD28+ T cells with B7 antigen or B7Ig fusion protein in combination with an immunosuppressant.

0 US Patent 5,861,310 discloses tumor cells modified to express one or more T cell costimulatory molecules, including B7-2 and B7-3. One embodiment includes further expression of B7. Modification was by transfection with nucleic acid encoding the B7-2, B7-3 or B7 proteins. Tumor cells could also be genetically modified *in vivo*. Such modified tumor cells said to be useful for treating a patient with a tumor, to prevent or inhibit metastatic spread 5 or inhibit recurrence of the tumor. This document disclosed a method for specifically inducing a CD4+ T cell response against a tumor.

0 U.S. Patent 5,942,607 discloses isolated nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation. In one embodiment, the isolated nucleic acid encoded B7-2. Also disclosed was a nucleic acid comprising at least a portion of the disclosed full length B7-2 sequence. According to this document, the nucleic acid sequences could be 5 integrated into various expression vectors which could direct the synthesis of the corresponding proteins or peptides in a variety of host cells including mammalian and insect cells. Also disclosed were host cells transformed to produce proteins or peptides encoded by these nucleic acid sequences and isolated proteins and peptides which comprise at least a portion of the B7-2 sequence.

0 Dong H *et al.*, *Nat Med* 1999 5:1365-1399, described a third member of the B7 family, designated B7-H1 that does not bind CD28, CTLA4 or ICOS (inducible co-stimulator). Ligation of B7-H1 co-stimulated T-cell responses to polyclonal stimuli and alloantigens, and preferentially stimulated the production of interleukin-10. IL-2, produced in small amounts, was required for the effect of B7-H1 co-stimulation. This study defined a previously unknown co-stimulatory molecule that may be involved in the negative regulation of cell-mediated immune

responses. The same laboratory (Wang S *et al.*, *Blood*. 2000;96:2808-2813) described a new human B7-like gene designated B7-H2, the expression of which was detected on the surface of monocyte-derived immature DCs. Soluble B7-H2 and an Ig fusion protein, B7-H2Ig, bound to activated, but not resting, T cells. This binding was inhibited by a soluble form of ICOS (ICOSIg) but not by CTLA4Ig. ICOSIg stained CHO cells transfected with the B7-H2 gene. Using suboptimal cross-linking of CD3 as a stimulus, costimulation of T-cell proliferation by B7-H2Ig was found to be dose-dependent and correlated with secretion of IL-2, whereas optimal CD3 ligation preferentially stimulated IL-10 production. The authors concluded that B7-H2 is a putative ligand for the ICOS T-cell molecule.

0 Swallow MM *et al.*, *Immunity*, 1999, 11:423-432 reported cloning of a novel gene, *b7h*,
a is a close homolog of B7 molecules that are expressed on APCs. B7h costimulated
proliferation of purified T cells by acting on a receptor distinct from CD28 or CTLA-4.
Surprisingly, although B7h was expressed in unstimulated B cells, its expression was induced in
5 nonlymphoid cells (3T3 cells; embryonic fibroblasts) treated with TNF α and was upregulated in
nonlymphoid tissue of mice treated with LPS, a potent activator of TNF α . These studies defined
a novel costimulatory ligand of T cells and suggested that induction of B7h by TNF α may
directly augment recognition of self during inflammation

Yoshinaga SK *et al.*, *Nature*, 1999, 402:827-832, described a new murine costimulatory
receptor-ligand pair. The receptor, related to CD28, was the murine homologue of the human
protein ICOS, and was expressed on activated T cells and resting memory T cells. The ligand,
which was homologous to B7 molecules was designated B7-related protein-1 (B7RP-1). B7RP-
1 is a type 1 transmembrane protein with 20% and 19% amino acid identity to murine B7.1
(CD80) and B7.2 (CD86), respectively. This homology is significant as B7.1 and B7.2 share
only 27% amino acid identity (Freeman, GJ *et al.*, *J. Exp. Med.* 178:2185-2192 (1993)). This
homology includes the cysteines that are important for Ig loop formation at conserved locations
(residues 62, 138, 185 and 242 from the initiating methionine). The overall length and relative
position of the transmembrane domain of B7RP-1 are similar to those of the B7 molecules
(Greenfield, EA *et al.*, *Crit. Rev. Immunol.* 18:389-418 (1998)). B7RP-1 was shown to be
expressed on B cells and macrophages. ICOS and B7RP-I did not interact with proteins in the
CD28-B7 pathway, and B7RP-1 co-stimulated T cells independently of CD28. Transgenic mice
expressing a fusion protein between B7RP-1 and the Fc portion of Ig ("B7-RP1-Fc") had

lymphoid hyperplasia in spleen, lymph nodes and Peyer's patches. Co stimulatory activity of B7RP-1 *in vivo* was found by demonstrating enhanced delayed-type hypersensitivity in antigen-presensitized mice treated with B7RP-1-Fc at the time of antigen challenge. The authors concluded that ICOS and B7RP-1 define a distinct new receptor-ligand pair that is structurally related to CD28-B7 and is involved in the adaptive immune response.

Yoshinaga SK *et al.*, Int Immunol, 2000 Oct, 12:1439-1447, reported co-stimulation of human T cells through the human B7RP-1 and ICOS interaction. This ligand-receptor pair interacted with a K_D of approximately 33 nM and an off-rate having a $t_{(1/2)}$ of >10 min. TNF α differentially regulated expression of human B7RP-1 on B cells, monocytes and DC. TNF α enhanced B7RP-1 expression on B cells and monocytes, but inhibits expression on DC. A human B7RP-1-Fc protein, or cells that expressed membrane-bound B7RP-1, co-stimulated T cell proliferation *in vitro*. Specific cytokines, such as IFN γ and IL-10, were induced by B7RP-1 co-stimulation. Although IL-2 levels were not significantly increased, B7RP-1-induced co-stimulation was dependent on IL-2. These studies defined the human ortholog to murine B7RP-1 and characterized its interaction with human ICOS.

PD-1 is an immuno-inhibitory receptor expressed by activated T, B and myeloid cells. Mice deficient in PD-1 showed multiple forms of autoimmunity due to the loss of peripheral tolerance. Freeman, GJ et al., J. Exp. Med. 192:1027- 1034(2000) reported that the ligand of PD-1 (PD-L1) is a member of the B7 gene family. Engagement of PD-1 by PD-L1 resulted in inhibition of TCR-mediated lymphocyte activation (proliferation, cytokine secretion). In addition, PD-1 signaling inhibited suboptimal levels of CD28-mediated costimulation. PD-L1 is expressed by APCs (human monocytes stimulated with IFN γ , activated human DCs). In addition, PD-L1 was shown to be expressed in heart and lung. The authors speculated that relative magnitude of inhibitory PD-L1 signals and costimulatory B7-1/B7-2 signals on APCs may determine the extent of T cell activation and the threshold between tolerance and autoimmunity. The presence of PD-L1 on nonlymphoid tissues may contribute to the magnitude of immune responses at sites of inflammation.

Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents

of these documents is based on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.

SUMMARY OF THE INVENTION

In order to identify genes encoding novel dendritic cell (DC) specific costimulatory molecules for T cell activation, the inventors screened a subtracted cDNA library between DCs and activated macrophages. This cDNA subtraction approach defines genes expressed by DCs but not by activated macrophages. Use of this approach has led to discovery of several novel DC-specific genes that are useful in enhancing the potency of vaccines that depend on activation of T cells. The present application focuses on one such gene.

Based on presence in the DC library and absence from the activated macrophage library, a novel coding sequence, termed "B7-DC" was identified. The B7-DC gene is a member of the B7 family of genes encoding costimulatory molecules. B7-DC is the first B7 family member with DC-specific expression and different receptor specificity. The product of this gene has an important role in mediating the unique ability of DCs to stimulate T cells. Functional analysis indicated that B7-DC is more active than B7-1 in stimulating IFN γ production by T cells. B7-DC DNA and polypeptides are therefore useful in compositions and methods to enhance the efficacy of cellular and molecular vaccine compositions, whether antigen-specific or not.

In one embodiment, the present invention provides an isolated nucleic acid molecule that encodes a mammalian protein termed B7-DC that is selectively expressed on dendritic cells as compared to activated macrophages. The nucleic acid molecule preferably comprises a nucleotide sequence selected from SEQ ID NO:1 (of human origin) or SEQ ID NO:5. (of murine origin). The invention is also directed to an isolated nucleic acid that hybridizes with the above nucleic acid molecule under stringent hybridization conditions. Preferred stringent conditions include incubation in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash in about 0.2X SSC at a temperature of about 50°C. Preferably the above nucleic acid molecule comprises the nucleotide sequence SEQ ID NO:1. A preferred nucleic acid molecule as above encodes a protein having an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4 or encodes a biologically active fragment, homologue or other functional derivative of the protein. Preferably, the nucleic acid molecule encodes the protein having the sequence SEQ ID NO:2 (B7-DC of human origin) or encodes the biologically active fragment, homologue or other functional derivative of SEQ ID NO:2.

In a preferred embodiment, the nucleic acid molecule encodes the extracellular domain of the B7-DC protein, which includes residues 26-221, which encodes a co-stimulatory homologue, fragment or other functional derivative thereof.

5 In another embodiment, the above nucleic acid molecule encodes a B7-DC fusion protein which comprises:

- (a) a first nucleic acid sequence encoding a first polypeptide that is all or a part of a B7-DC protein (preferably SEQ ID NO:2 or SEQ ID NO:4);
- (b) optionally, fused in frame with the first nucleic acid sequence a linker nucleic acid sequence encoding a linker peptide; and
- 0 (c) a second nucleic acid sequence that is linked in frame to the first nucleic acid sequence or to the linker nucleic acid sequence and that encodes a second polypeptide.

The second polypeptide preferably consists of one or more domains of an Ig heavy chain constant region, preferably the two C domains of human IgG, preferably IgG1.

Also provided is an expression vector comprising any of the above nucleic acid 5 molecules operatively linked to

- (a) a promoter and
- (b) optionally, additional regulatory sequences that regulate expression of the nucleic acid in a eukaryotic cell.

The above expression vector may be a plasmid or a viral vector. These vectors include 0 self replicating RNA replicons (DNA-launched or RNA), suicide RNA vectors DNA viruses (such as adenovirus, vaccina virus, *etc.*) and RNA virions grown on packaging cell lines.

The vector DNA or RNA may be complexed to gold particles for gene gun -mediated introduction to a host or complexed with other polymers, for example, in controlled release formulations, that enhance delivery to the desired target cells and tissues.

5 Also included is a vector composition which comprises:

- (a) a first recombinant expression vector having incorporated in its sequence a nucleotide sequence encoding an antigen of interest against which an immune response is to be induced; and
- (b) a second recombinant expression vector having incorporated in its nucleic acid sequence 0 or more nucleotide sequences encoding a co-stimulator polypeptide, at least one of which polypeptides is B7-DC, or a biologically active fragment, homologue or other functional derivative thereof,

wherein the expression vectors are able to co-infect or co-transfected a host cell resulting in co-expression of the antigen and the costimulator polypeptide, fragment, homologue or derivative.

In a modification of the above embodiment, the invention provides a third nucleic sequence encoding a targeting protein that (i) promotes spread of the expressed product (antigen) between cells, preferably APCs, (ii) increases the display of the antigen on APCs in which the nucleic acid is expressed., and/or (iii) promotes the re-presentation (cross-priming) and display of the antigen in APCs of a host into which the vector is introduced. The targeting protein-encoding nucleic acid may be fused to the nucleic acid encoding the antigen or the co-stimulator or both. acid the first or the second vector includes nucleic acid. In one embodiment, the vector composition combines the antigen-encoding nucleic acid, the co-stimulator-encoding nucleic acid (preferably B7-DC) and a “targeting” protein-encoding nucleic acid into a single fused construct.

This invention includes a cell transformed or transfected with any of the above nucleic acid molecules or expression vectors. The cell is preferably a eukaryotic cell, more preferably a mammalian cell, most preferably a human cell. The cell may be a dendritic cell or a progenitor thereof. In another embodiment, the cell is a tumor cell, preferably a tumor cell that bears an antigen that is the same as, or cross-reactive with,, an antigen on a tumor in the host against which an immune response is desired.

A preferred embodiment is an isolated mammalian tumor cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-DC protein (preferably SEQ ID NO:2 or SEQ ID NO:4) or a biologically active fragment, homologue or other functional derivative thereof, such that when the protein, fragment, homologue or derivative is expressed by the tumor cell, and the tumor cell is contacted with T cells

- (i) the B7-DC protein, fragment,, homologue or derivative binds to the T cells; and
- (ii) the tumor cell costimulates the T cells to proliferate and/or to produce and secrete cytokines.

The present invention is also directed to a polypeptide that is selectively expressed on dendritic cells as compared to activated macrophages and has the following functional properties:

- (a) binds to a binding partner on T cells; and
- (b) costimulates T cells to proliferate and/or to produce and secrete cytokines.

Also included are biologically active fragments, homologues or other functional derivatives of the polypeptide.

The polypeptide, fragment, homologues or functional derivative is preferably encoded by a nucleic acid molecule having the sequence SEQ ID NO:1 or SEQ ID NO:5, or a fragment, 5 homologue or equivalent of the nucleic acid molecule. A preferred polypeptide has the amino acid sequence SEQ ID NO:2 or SEQ ID NO:4.

The polypeptide or a biologically active fragment, homologues or other functional derivative of the polypeptide may be produced by recombinant expression of one of the above nucleic acids.

0 A preferred polypeptide comprises the extracellular domain of the B7-DC protein, preferably

- (a) amino acid residues 26-221 of SEQ ID NO:2 (*human*) or
- (b) amino acid residues 26-221 of SEQ ID NO:4 (*mouse*).

The above polypeptide may consist essentially of the extracellular domain of B7-DC

5 Also provided is a B7-DC fusion polypeptide having a first fusion partner comprising all or a part of a B7-DC protein fused

- (i) directly to a second polypeptide or,
- (ii) optionally, fused to a linker peptide sequence that is fused to the second polypeptide.

The above A B7-DC fusion protein may also be fused to a second polypeptide, 0 preferably one or more domains of an Ig heavy chain constant region, preferably having an amino acid sequence corresponding to the hinge, C_H2 and C_H3 regions of a human immunoglobulin C_y1 chain.

In one embodiment of the above fusion protein, the first fusion partner is the extracellular domain of a B7-DC protein, the full length sequence of which is SEQ ID NO:2 or 5 SEQ ID NO:4.

The fusion protein preferably binds to a binding partner on T cells and co-stimulates T cells in the presence of an adequate stimulus to the T cell receptor.

Also provided is a dimeric or trimeric fusion protein which is a **dimer** or trimer of the above fusion proteins. Preferably, the chains are tandemly linked via disulfide bonds or other 0 interchain covalent bonds.

In a preferred dimeric fusion protein, the dimer results from the covalent bonding of Cys residue in the C_H regions of two of the Ig heavy chains that are the same Cys residues that are disulfide linked in dimerized normal Ig H chains.

The fusion protein of the invention may comprise a multimer of two or more repeats of the first fusion partner linked end to end, directly or with a linker sequence between one or more monomers.

The present invention also provides an antibody that is specific for an epitope of a B7-DC protein, which epitope is not present in a known member of a B7 family protein. The epitope may be a linear or conformational epitope of a polypeptide of SEQ ID NO:2 or SEQ ID NO:4. The antibody is preferably a monoclonal antibody, more preferably a human or humanized (via engineering) monoclonal antibody.

Also provided is a method of using the above antibody to identify or quantitate cells expressing a B7-DC polypeptide on their surface in a cell population, comprising

- (a) contacting cells of the population with the above antibody so that the antibody binds to cells expressing the epitope;
- (b) assessing the presence of or quantitating the number of cells to which the antibody is bound.

Another method is provided for isolating cells expressing a B7-DC polypeptide on their surface from a cell population, comprising

- (a) contacting the population with the above antibody so that the antibody binds to cells expressing the epitope;
- (b) positively selecting cells to which the antibody has bound or negatively selecting cells to which the antibody has not bound.

Also provided is a method of detecting the presence or quantitating a B7-DC polypeptide, fragment or homologue in a sample, comprising the steps of:

- (a) contacting the sample with the antibody of claim 43 such that the antibody binds to any polypeptides or fragments bearing the epitope;
- (b) detecting the presence of, or quantitating the polypeptides or fragments bound to the antibody.

The present invention is also directed to a method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of the cell to co-stimulate T cells *in vitro* or *in vivo* in the presence of an

adequate stimulus to the T cell receptor, comprising transforming or transfecting the antigen presenting cell or progenitor cell with the expression vector as described above, such that the expression of the B7-DC polypeptide is induced or increased on the cells. The antigen presenting cells are preferably dendritic cells and the progenitors are dendritic cell progenitors.

5 The present invention provides method for stimulating immune responses using cellular co-stimulatory compositions as well as polypeptide co-stimulators. One method for increasing the T cell response of a mammalian subject to antigenic stimulation comprises administering to the subject an effective amount of cells as described above, preferably tumor cells, in conjunction with an antigenic stimulus, wherein the cells are effective to increase the T cell response of the subject to the antigenic stimulation. The foregoing is preferably accomplished by co-injection of the antigen and the co-stimulatory composition.

0 A method for increasing the T cell response of a mammalian subject to antigenic stimulation with a tumor-associated antigen, comprises administering to the subject an effective amount of tumor cells as described above, , wherein the tumor cells express the antigen, the administration of the tumor cells being effective to increase the T cell response of the subject to the tumor antigen stimulation.

5 A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to the subject an effective amount of a polypeptide, fragment, homologue or functional derivative as above, or a fusion polypeptide or protein as above, in conjunction with an antigenic stimulus, wherein the administration of the polypeptide is effective to increase the T cell response of the subject to the antigenic stimulation.

This invention also provides a method for inhibiting a T cell response of a mammalian subject to antigenic stimulation, comprising administering to the subject an effective amount of an antibody as described, wherein the administration of the antibody is effective to block stimulation of T cells or to eliminate antigen-reactive T cells, thereby inhibiting the T cell response. These methods are particularly useful for treating a subject with a tissue or organ transplant to inhibit transplant rejection and/or to promote engraftment. In the case of an autoantigen, the method blocks or diminishes autoimmune reactions and their pathologic sequelae.

0 The present invention provides therapeutic methods using T cells that have undergone *ex vivo* stimulation with the compositions of this invention. One method for increasing the immune response of a mammalian subject to antigenic stimulation comprises:

(a) obtaining T cells from the subject, from an immunologically compatible donor for said subject, or from an immunologically acceptable cultured cell line;

(b) contacting the T cells *ex vivo* with an effective amount of cells as described above, wherein the contacting is effective to increase the response of the T cells to antigenic stimulation; and

5 (c) administering the T cells of step (b) to the subject, thereby increasing the immune response of the subject.

In another embodiment, the method for increasing the immune response of a mammalian subject to antigenic stimulation comprises:

0 (a) obtaining T cells from obtaining T cells from the subject, from an immunologically compatible donor for said subject, or from an immunologically acceptable cultured cell line;

(b) contacting the T cells *ex vivo* with an effective amount of (i) a polypeptide, fragment, homologue or functional derivative as described above, or (ii) a fusion polypeptide as 5 above, wherein the contacting is effective to increase the response of the T cells to antigenic stimulation; and

(c) administering the T cells of step (b) to the subject, thereby increasing (or generating) an immune response of the subject.

Also provided herein is a vaccine composition comprising

0 (a) (i) cells as described above that express a B7-DC construct, (ii) a B7-DC polypeptide, fragment, homologue or functional derivative , (iii) a B7-DC fusion polypeptide or protein

(b) generally, an additional source of antigen to which an immune response is desired -- though this may not be required in the case of the cell-based vaccine wherein the cells 5 themselves expresses the antigen (as in the case of tumor antigen-bearing tumor cells);

(c) optionally, a general immunostimulatory agent or adjuvant; and

(d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

A method for inducing or enhancing an immune response to an antigen in a mammalian

0 subject comprises administering to the subject an effective amount of the above vaccine composition.

Also provided is a co-stimulatory composition for use with an antigen or a vaccine, comprising:

- (a) a B7-DC polypeptide (preferably SEQ ID NO:2 or SEQ ID NO:4), a fragment, a homologue or a functional derivative thereof, or a B7-DC fusion polypeptide, and
- 5 (b) a pharmaceutically and immunologically acceptable excipient or carrier.

A method for potentiating an immune response to an antigen or a vaccine in a mammalian subject, comprises administering to the subject, in combination with the antigen or vaccine, the above costimulatory composition.

A method of stimulating a systemic immune response to a tumor in a subject, comprises
0 administering to the subject genetically altered tumor cells which cells

- (a) are derived from a tumor in the subject, and
- (b) are genetically altered by introduction *ex vivo* of a B7-DC nucleic acid as described above, the expression of which provides a costimulatory signal in the subject, wherein the administering results in stimulation of the systemic immune response directed to the
5 tumor.

The tumor cells are preferably treated, preferably by irradiation, to prevent their growth after they have been administered.

The subject may be subjected to a tumor-reducing regimen of chemotherapy, irradiation or surgical resection prior to the administering of the above therapeutic compositions.

0 Also provided is a method of inducing an antitumor response in a mammal having an antigen-positive tumor, comprising:

- (a) providing cells of the tumor or of a tumor cell line that
 - (i) express antigens shared with the tumor of the mammal;
 - (ii) are transfected with a B7-DC-encoding nucleic acid vector as above, that when expressed, a B7-DC molecule causes the cells to co-stimulate a T cell response to antigens of the tumor;
 - (iii) optionally, are irradiated prior to step (b);
- 5 (b) administering an effective number of the cells to the mammal, which cells express the antigens and the B7-DC molecule;
- 0 thereby inducing an antitumor response

In the above method, the antitumor response is characterized by:

- (A) at least a 50% decrease in the sum of the products of maximal perpendicular diameters of all measurable lesions;
- (B) no evidence of new lesions, and
- (C) no progression of any preexisting lesions.

5 Also provided is a method of inducing regression or attenuation of primary growth or regrowth of a tumor in a mammal bearing the tumor, comprising:

- (a) providing cells of the tumor or of a tumor cell line that
 - (i) express antigens shared with the tumor of the mammal;
 - (ii) are transfected with a B7-DC-encoding nucleic acid vector as above, that, when expressed, as a B7-DC molecule causes the cells to co-stimulate a T cell response to antigens of the tumor;
 - (iii) optionally, are irradiated prior to step (b);
- (b) administering an effective number of the cells to the mammal, which cells express the antigens and the B7-DC molecule;

5 thereby inducing a systemic immune response specific to the tumor antigens of the melanoma, thereby inducing the regression or the attenuation

A method of inhibiting recurrent growth of an antigen-positive tumor in a mammal, comprises:

- (a) providing cells of the tumor or of a tumor cell line that
 - (i) express antigens shared with the tumor of the mammal;
 - (ii) are transfected with a B7-DC-encoding nucleic acid vector as above, that, when expressed, causes the cells to co-stimulate a T cell response to antigens of the tumor;
 - (iii) optionally, are irradiated prior to step (b);
- (b) administering an effective number of the cells to the mammal, which cells express the antigens and the B7-DC molecule;

.5 thereby inducing a systemic immune response specific to the tumor antigens in the mammal, which immune response inhibits the recurrent growth of the tumor.

10 Another embodiment is directed to a method of providing a co-stimulatory signal in the vicinity of locally-administered antigen in a mammalian subject to promote the local generation

of an inflammatory and immune response that results in a state of systemic immunity to the antigen, the method comprising administering to a local site in the subject

(a) cells that express a costimulation-effective amount of B7-DC polypeptide, fragment, homologue or functional derivative as above, and

5 (b) the antigen

such that costimulation in physical proximity with the antigen promotes the local generation of the response and results in the state of systemic immunity.

In the above method, the antigen is preferably a tumor antigen that is administered in (b) in the form of tumor cells or subcellular antigenic material. The tumor cells may also be the) cells that express the B7-DC polypeptide, fragment, homologue or derivative in (a).

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram showing shows the map of hB7-DC which is localized on human chromosome 9p24. hB7-DC maps to BAC clone RPCI-11.2.

5 **Figure 2** shows that B7-DC is differentially expressed between DCs and macrophages. Distribution of B7-DC mRNA in bone marrow DCs, splenic DCs, macrophages, macrophage lines and tissues was assessed by virtual Northern blot analysis using 0.5 µg/lane purified DNA run on a 1% agarose gel. G3PDH was used as control. J774A1, Raw264.7, Pu5-1.8 and WEHI cells are macrophage cell lines. BM: bone marrow.

) **Figure 3** shows a virtual Northern blot of B7-DC expression on human DCs. Lane 1 shows human DCs cultured with GM-CSF + Flt-3L, lane 2 shows human placenta and lane 3 shows human DCs cultured with GM-CSF + IL4. Oligonucleotides from the 5'and 3' UTR of human B7-DC were used to make PCR DNA probe for virtual Northern analysis of total RNA of human DCs. β-actin was used as control to ensure the quality of mRNA.

5 **Figure 4** represents is a flow cytometric analysis showing surface expression of B7-DC on mature BM-DCs. Day 9 murine BM-DCs were Fc-blocked and stained with control antibody or B7-DC antisera. Specificity of binding was demonstrated by adding B7-DC-Ig to compete for the binding of anti-B7-DC to the surface of DCs.

0 **Figure 5** shows the binding of B7-DC to PD-1 but not CTLA-4 or CD28. 293T cells were transiently transfected with pCAGGS-B7.1 o pCAGGS-B7-DC. Transfectants were

stained with PD-1-Ig, 28-Ig and CTLA-4-Ig fusion molecules followed by PE-labeled secondary antibody. Staining of pCAGGS (empty vector) transfectants was negative (not shown)

Figure 6 (left and right panel) shows the costimulation of T cell proliferation by anti-CD3 and B7-DC-Ig. Left graph: purified T cells (CD4 + CD8) were cultured in wells pre-coated with increasing concentrations of anti-CD3 (mAb 2C11) and a fixed concentration (0.1 µg/ml) of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲). Results depict one representative experiment of three. Cells were incubated for 72h and labeled with ³H-thymidine. CPM, counts per minute. Right Graph: purified CD8 T cells were cultured in wells pre-coated with increasing concentrations of anti-CD3 and fixed concentration of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲) as in (a). Results are of one representative experiment of two. Cells were incubated for 72h and labeled with ³H-thymidine. CPM, counts per minute.

Figure 7 shows the costimulation of antigen-specific T cell proliferative responses RENCA cells were treated with IFN γ for 72hrs to induce MHC class II expression and incubated with 12.5 µg/ml of HA110-120 peptide. Purified HA + I-E^d specific transgenic T cells were added together with increasing concentrations of either B7.1-Ig (◆), B7-DC-Ig (●) or Isotype control (▲) in soluble form. Cells were incubated for 48h and labeled with ³H-thymidine. CPM, counts per minute. Results are one representative experiment of three.

Figure 8 shows cytokine secretion of T cells costimulated by B7-DC.

Upper panels: purified T cells were cultured in wells pre-coated with anti-CD3 (0.12 µg/ml) and 0.1 µg/ml of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲) as in Fig. 6 (left). Results depict one representative experiment of three.
Lower panels: γ -IFN treated RENCA cells loaded with 12.5 µg/ml HA(110-120) peptide were incubated with purified HA + I-E^d specific transgenic T cells together with 2 µg/ml of soluble B7.1-Ig, B7-DC-Ig or isotype control (symbols as above). Results depict one representative experiment of two. Supernatants were collected after 24h and 48h culture and assayed for the indicated lymphokines using ELISA.

Figure 9 shows that B7-DC-Ig greatly enhances antigen specific proliferation after *in vivo* co-stimulation. After adoptive transfer of 2.5×10^6 TCR transgenic cells specific for HA, three groups of mice were immunized s.c., in their hind footpads with either HA peptide (110-120), incomplete Freund's adjuvant (IFA) alone or in combination with either B7-DC-Ig + IFA

or an isotype control antibody with IFA. Draining lymph nodes were harvested on day 7. 1.5 x 10⁵ LN cells were incubated with the HA peptide for 48h, pulsed with 1μCi [³H]thymidine and the radioactivity incorporated after 12h was determined.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The present inventors have now identified new proteins and nucleic acids that serve as the basis for improved immunotherapeutic compositions and methods. Human and murine forms of a novel costimulatory protein named B7-DC have been discovered and are disclosed herein.

DNA encoding human B7-DC has the nucleotide sequence SEQ ID NO:1, show below.

```

1  atgatcttcctccgtcaatgttggcctggaaattgcagttcaccagatagcagctta
61  ttcacagtgcacgtccctaaggaaactgtacataatagagcatggcagcaatgtgaccctg
121 gaatgcaactttgacacttggaaagtcatgtgaaccttggagcaataacagccaggttgcaa
181 aagggtggaaaatgatacatccccacaccgtgaaagagccactttgtggaggagcagctg
241 cccctaggaaaggcctcgccatcacatcaacttcaagtccaaactgaggacgaaggacagtac
301 caatgcataatcatctatgggtcgccctggactacaagtacactgtgaaagtcaaa
361 gcttcctacaggaaaataaacactcacatcctaaagggtccagaaacagatgaggttagag
421 ctcacctgccaggctacagggttatcctctggcagaagtatcctggccaaacgtcagcgtt
481 cctgccaacaccagccactccaggaccccctgaaggccttaccaggtcaccagtgttctg
541 cgcctaaagccacccctggcagaaacttcaagttgtgttctggaaatactcacgtgagg
601 gaacttactttggccagcattgaccttcaaagtcaagatggaacccaggacccatccaact
661 tggctgcttcacatttcatccccctcgcatcattgtttcatttcatagccacagtg
721 atagccctaagaaaacaacttgtcaaaagctgttattcttcaaaagacacaacaaaaga
781 cctgtcaccacaacaaagagggaaagtgaacagtgtatc 819

```

5 The human B7-DC protein has the amino acid sequence SEQ ID NO:2, shown below (with leader sequence, transmembrane domain and cytoplasmic tail annotated):

<i>putative leader sequence</i>	
1 MIFLLLMLSL ELQLHQIAAL FTVTVPKELY IIEHGSNVTL ECNFDTGSHV	50
51 NLGAIITASLQ KVENDTSPHR ERATLLEEQL PLGKASFHIP QVQVRDEGQY	100
101 QCIIIYGVAW DYKYLTALKVK ASYRKINTHI LKVPEDEVE LTCQATGYPL	150
151 AEVSWPNVSV PANTSHSRTP EGLYQVTSVL RLKPPGRNF SCVFWNTHVR	200
<i>putative TM domain</i>	
201 ELTLASIDLQ SQMEPRTHPT WLLHIFIPSC II A FIFIATV IALRKOLCQKL	250
<i>cytoplasmic tail</i>	
251 LYSSKD TT KR PV TTT KREVN SAI	273

The extracellular domain of this protein is from residue P²⁶ through residue W²²¹.

A DNA clone that includes the coding sequence encoding murine B7-DC has the nucleotide sequence SEQ ID NO:3, show below. The coding sequence (underscored, set off in 0 triplets) begins from the methionine codon **a_tg** (bolded) beginning at nucleotide 210 and terminates with the **t_ag** stop codon (bolded) (nucleotides 951-953)

	gaattcggcacgaggtaaaatgtggcatatcttgttgtctccttctgtctcccaactag	60
	agagaacacactaacggctccgtccggcagggtgggtgtcggtgtattggctcc	120
	agggAACCTgatacaaggagcaactgtgtgcctttctgtgtcttgaggagc	180
	tgtgctgggtgctgatattgacacagacc	209
5	atg ctg ctc ctg ctg ccg ata ctg aac ctg agc tta caa ctt cat cct	257
	gta gca gct tta ttc acc gtg aca gcc cct aaa gaa gtg tac acc gta	305
	gac gtc ggc agc agt gtg agc ctg gag tgc gat ttt gac cgc aga gaa	353
	tgc act gaa ctg gaa ggg ata aga gcc agt ttg cag aag gta gaa aat	401
	gat acg tct ctg caa agt gaa aga gcc acc ctg ctg gag gag cag ctg	449
)	ccc ctg gga aag gct ttg ttc cac atc cct agt gtc caa gtg aga gat	497
	tcc ggg cag tac cgt tgc ctg gtc atc tgc ggg gcc gcc tgg gac tac	545
)	aag tac ctg acg gtg aaa gtc aaa gct tct tac atg agg ata gac act	593
	agg atc ctg gag gtt cca ggt aca ggg gag gtg cag ctt acc tgc cag	641
	gct aga ggt tat ccc cta gca gaa gtg tcc tgg caa aat gtc agt gtt	689
5	cct gcc aac acc agc cac atc agg acc ccc gaa ggc ctc tac cag gtc	737
	acc agt gtt ctg cgc ctc aag cct cag ctc agc aga aac ttc agc tgc	785
	atg ttc tgg aat gct cac atg aag gag ctg act tca gcc atc att gac	833
)	cct ctg agt cgq atg gaa ccc aaa gtc ccc aga acg tgg cca ctt cat	881
	gtt ttc atc ccg gcc tgc acc atc gct ttg atc ttc ctg gcc ata gtg	929
)	ata atc cag aqa aag agg atc tag	953
	gggaagctgtattacggaagaagtggctcttcttcccagatctggacctcggtcttgg	1013
	gagttggaaaggatctgatggaaaaccctcaagagacttctggactcaaagtgagaatctt	1073
	gcaggacactgccattgcactttgaacccttggacggtgaccaggctccgaagagg	1133
5	agctttaagactgacaatctccctctgtctcaagactctctgaacagcaagaccccaa	1193
	tggactttagacttacccctggatctggaccccagtggacttgcattttatccatg	1253
	actttcagggtgagaacaaaaggaaattgtctccggccaccccccacctctgtttccg	1313
	cagggagacatggaaattccagttactaaaatagattgtcaatagattttatagcc	1373
	ctcatttcccgggacttggaaacttgcacatccatcggcagctctgaagttctaattactggaa	1433
)	tgatgtgttttacagcatctagaatctggcagctctgaagttctaattactggaa	1493
	catttaagcaacacgtcaagtgcctctgtgttatgtttctactttctgtttta	1553
	aagtgtgagtccaaaggtaattgtgttaacctgtgatatcactgtttctgtctttc	1613
	tttcaactacatctttaaaacaaaaaaaaaaaaaaaaaaaaaa	1655

SEQ ID NO:5 is the coding sequence part of SEQ ID NO:3.

The murine B7-DC protein, encoded by the coding region of SEQ ID NO:3, (i.e., by SEQ ID NO:5) has the amino acid sequence SEQ ID NO:4 shown below (with leader sequence, transmembrane domain and cytoplasmic tail annotated):

<i>putative leader sequence</i>		
1	MLLLLPILNL S LQLHPVAAL FTVTAPKEVY TVDVGSSVSL ECDFDRRECT	50
51	ELEGIRASLQ KVENDTSLQS ERATLLEEQ L PLGKALFHIP SVQVRDSGQY	100
0	RCLVICGAAW DYKYLTVKVK ASYMRIDTRI LEVPGTGEVQ LTCQARGYPL	150
101	AEVSWQNVS V PANTSHIRTP EGLYQVTSVL RLKPQPSRNF SCMFWNNAHMK	200
151		
<i>putative TM domain</i>		
201	ELTSAIIDPL SRMEPKVPRT WPLHVFIPAC TIALIFLAIV II QRKRI	247
	<i>cyto. tail</i>	

5 The extracellular domain of this protein is from residue P²⁶ through residue W²²¹. The complete DNA sequence of murine B7-DC (originally termed “butyrophilin-like protein” or “Btdc”) has the Genbank accession number AF142780.2

Basic Molecular Approach

This approach is described in more detail in the Examples. The inventors utilized the PCR Select approach which incorporate two important features. First, the initial PCR reaction prior to the hybridization steps requires only small quantity of RNA. This technique allows the
5 use of highly purified mature DCs that have been rendered substantially free of contaminating macrophages, progenitor cells or other potential contaminating cells. Such highly purified DCs are known to be difficult to obtain in very large numbers. Second, the PCR Select procedure enabled cloning of low copy number, differentially expressed genes.

To identify genes differentially expressed by DCs relative to their cellular counterpart,
0 the activated macrophage, and to identify genes associated with DC-specific functions, the present inventors applied a cDNA subtraction approach. They used a modified PCR-based “representative differential analysis” (RDA) combined with suppression PCR (PCR SelectTM) (Diatchenko, L. et al., *Proc. Natl. Acad. Sci USA* 93:66025-6030 (1996)).

GENERAL RECOMBINANT DNA METHODS

5 Basic texts disclosing general methods of molecular biology, all of which are incorporated by reference, include: Sambrook, J et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989; Ausubel, FM et al. *Current Protocols in Molecular Biology*, Vol. 2, Wiley-Interscience, New York, (current edition); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); Glover, DM, 0 ed, *DNA Cloning: A Practical Approach*, vol. I & II, IRL Press, 1985; Albers, B. et al., *Molecular Biology of the Cell*, 2nd Ed., Garland Publishing, Inc., New York, NY (1989); Watson, JD et al., *Recombinant DNA*, 2nd Ed., Scientific American Books, New York, 1992; and Old, RW et al., *Principles of Gene Manipulation: An Introduction to Genetic Engineering*, 2nd Ed., University of California Press, Berkeley, CA (1981).

5 Unless otherwise indicated, a particular nucleic acid sequence is intended to encompasses conservative substitution variants thereof (e.g., degenerate codon substitutions) and a complementary sequence. The term “nucleic acid” is synonymous with “polynucleotide” and is intended to include a gene, a cDNA molecule, an mRNA molecule, as well as a fragment of any of these such as an oligonucleotide, and further, equivalents thereof (explained more fully 0 below). Sizes of nucleic acids are stated either as kilobases (kb) or base pairs (bp). These are estimates derived from agarose or polyacrylamide gel electrophoresis (PAGE), from nucleic acid

sequences which are determined by the user or published. Protein size is stated as molecular mass in kilodaltons (kDa) or as length (number of amino acid residues). Protein size is estimated from PAGE, from sequencing, from presumptive amino acid sequences based on the coding nucleic acid sequence or from published amino acid sequences.

5 Specifically, cDNA molecules encoding the amino acid sequence corresponding to B7-DC or fragments or derivatives thereof can be synthesized by the polymerase chain reaction (PCR) (see, for example, U.S. 4,683,202) using primers derived the sequence of the protein disclosed herein. These cDNA sequences can then be assembled into a eukaryotic or prokaryotic expression vector and the resulting vector can be used to direct the synthesis of 0 B7-DC, or its fragment or derivative by appropriate host cells, for example COS or CHO cells.

This invention includes isolated nucleic acids having a nucleotide sequence encoding the novel B7-DC, fragments thereof or equivalents thereof. The term nucleic acid as used herein is intended to include such fragments or equivalents. The nucleic acid sequences of this invention can be DNA or RNA. A preferred nucleic acid is cDNA encoding human B7-DC having the 5 sequence SEQ ID NO:1 or equivalents thereof.

Preferably, the nucleic acid of the present invention is a cDNA molecule encoding at least a portion of B7-DC. This cDNA can be made from mRNA extracted from mature DCs or other cells naturally expressing this protein. A nucleic acid sequence encoding B7-DC is obtainable from DC genomic DNA. Thus, DNA encoding B7-DC can be cloned from a cDNA 0 or a genomic library in accordance with known protocols.

A cDNA nucleotide sequence encoding B7-DC can be obtained by isolating total mRNA from an appropriate cell line. Double stranded cDNA is prepared from total mRNA. cDNA can be inserted into a suitable plasmid, bacteriophage or viral vector using any one of a number of known techniques.

5 In reference to a nucleotide sequence, the term "equivalent" is intended to include sequences encoding structurally homologous and/or a functionally equivalent proteins. For example, a natural polymorphism of the B7-DC nucleotide sequence (especially at the third base of a codon) may be manifest as "silent" mutations which do not change the amino acid sequence. However, polymorphisms that involve amino acid sequence changes in B7-DC may 0 exist in a human (or other mammalian) population. Those of skill in the art will appreciate that these allelic variants that have changes in one or more nucleotides (up to about 3-4% of the total coding sequence) will likely be found in a human population due to natural allelic variation. Any

and all such allelic variations and resulting nucleic acid and polypeptide polymorphisms in the DNA encoding B7-DC are within the scope of the invention.

Furthermore, there may be one or more naturally occurring isoforms or related, immunologically cross-reactive family members of the B7-DC protein described herein. Such isoforms or family members are defined as proteins that share function amino acid sequence similarity to B7-DC, even if they are encoded by genes at different loci.

Fragment of Nucleic Acid

A fragment of the nucleic acid sequence is defined as a nucleotide sequence having fewer nucleotides than the nucleotide sequence encoding the full length B7-DC protein. This invention includes such nucleic acid fragments that encode polypeptides which retain (1) the ability of B7-DC to bind to its natural ligand(s) on T cells and (2) to enhance or inhibit (depending on how they are presented) activated T cell mediated immune responses (measured as cytokine production and/or T cell proliferation by T cells that have received a primary activation signal).

For example, a nucleic acid fragment as intended herein encodes a B7-DC polypeptide that retains the ability to bind to the surface of T cells to a receptor that has not yet been identified (but is does not appear to be CD28 or CTLA-4) and deliver a costimulatory signal to T lymphocytes. By another criterion, the present nucleic acid fragment is one that hybridizes with a nucleic acid from another animal species and is therefore useful in screening assays to detect novel proteins that are "cross-reactive" with B7-DC.

Generally, the nucleic acid sequence encoding a fragment of the B7-DC polypeptide comprises of nucleotides from the sequence encoding the mature protein. However, in some instances it may be desirable to include all or part of the leader sequence portion of the nucleic acid. Nucleic acid sequences of this invention may also include linker sequences, natural or modified restriction endonuclease sites and other sequences that are useful for manipulations related to cloning, expression or purification of encoded protein or fragments. These and other modifications of nucleic acid sequences are described herein or are well-known in the art.

In one embodiment, DNA encoding the amino acid sequence corresponding to the ECD of B7-DC, containing amino acids from about position 26-221, is joined to DNA encoding the amino acid sequences corresponding to the hinge, C_H2 and C_H3 regions of human Ig Cy1, using PCR, to form a construct that is expressed as B7-DC-Ig fusion protein.

An analogous DNA molecule encoding a B7-Ig fusion protein was disclosed in U.S. 5,521,288 and deposited with the American Type Culture Collection in Rockville, Md., under accession number 68627.

The techniques for assembling and expressing DNA encoding B7-DC and soluble B7-DC fusion proteins such as synthesis of oligonucleotides, PCR, transforming cells, constructing vectors, expression systems, and the like are well-established in the art. Those of ordinary skill are familiar with the standard resource materials for specific conditions and procedures.

In other embodiments, the DNA encoding a domain or fragment of B7-DC is fused with a nucleic acid encoding most or all of the remaining portion of another B7 family protein, such as B7.1, B7.2 or B7.3. The complete DNA sequence of human B7.1 (CD80) has the Genbank accession number X60958; the accession number for the mouse sequence is X60958; the accession number for the rat sequence is U05593. The complete cDNA sequence of human B7.2 (CD86) has the Genbank accession number L25259; the accession number for the mouse sequence is L25606.

EXPRESSION VECTORS AND HOST CELLS

This invention includes an expression vector comprising a nucleic acid sequence encoding a B7-DC polypeptide operably linked to at least one regulatory sequence. "Operably linked" means that the coding sequence is linked to a regulatory sequence in a manner that allows expression of the coding sequence. Known regulatory sequences are selected to direct expression of the desired protein in an appropriate host cell. Accordingly, the term "regulatory sequence" includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in, for example, Goeddel, *Gene Expression Technology. Methods in Enzymology*, vol. 185, Academic Press, San Diego, Calif. (1990)).

Those skilled in the art appreciate that the particular design of an expression vector of this invention depends on considerations such as the host cell to be transfected and/or the type of protein to be expressed.

The present expression vectors comprise the full range of nucleic acid molecules encoding the various embodiments of B7-DC: full length protein and its functional derivatives (defined herein) including polypeptide fragments, variants, fusion proteins, etc. Thus, in one embodiment, the expression vector comprises a nucleic acid encoding at least a portion of the B7-DC protein such as the ECD, alone or fused to another protein.

Such expression vectors are used to transfect host cells for expression of the DNA and production of the encoded proteins which include fusion proteins or peptides. It will be understood that a genetically modified cell expressing the B7-DC polypeptide may transiently express the exogenous DNA for a time sufficient for the cell to be useful for its stated purpose.

5 Thus, if the cell is to serve as an immunogen having an augmented costimulatory capacity *in vivo* or *ex vivo*, the length of time that expression is required, or that the cell remain alive, is the time necessary for the cell to exert its immunogenic and/or costimulatory function. For example, in the case of a transduced tumor cell expressing the B7-DC of the present invention, expression of B7-DC may be for as little as 6 hours, preferably 24 hours, more preferably for at 0 least 2-4 days. Of course, expression may also be stable (*i.e.*, for the life of the cell). Appropriate expression vectors and regulatory elements (*e.g.*, *e.g.*, inducible or constitutive promoters) discussed below are selected in accordance with the desired or required stability of expression.

The present invention provides methods for producing the B7-DC protein, fragments 5 and derivatives. For example, a host cell transfected with a nucleic acid vector that encodes at least a portion of the B7-DC protein is cultured under appropriate conditions to allow expression of B7-DC polypeptide.

Host cells may also be transfected with one or more expression vectors that singly or in combination comprise DNA encoding at least a portion of the B7-DC protein and DNA 0 encoding at least a portion of a second protein, so that the host cells produce fusion polypeptides that include both the portions.

When the recombinant expression vector comprises DNA encoding a portion of B7-DC and DNA encoding another protein, such as human IgC γ 1, the resulting fusion protein may have altered solubility, binding affinity and/or valency. A B7-DC Ig fusion protein, for example, is 5 ~~preferably secreted by transfected host cells in cultures and is therefore isolated from the culture~~

Purification and Related Techniques", *Methods in Enzymology*, 22: 233-577 (1971)). Once purified, partially or to homogeneity, the recombinant B7-DC proteins of the invention can be utilized in pharmaceutical compositions as described in more detail herein.

5 Prokaryotic or eukaryotic host cells transformed or transfected to express B7-DC or a homologue or functional derivative thereof are within the scope of the invention. For example, B7-DC may be expressed in bacterial cells such as *E. coli*, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO) or human cells. Other suitable host cells may be found in Goeddel, (1990) *supra* or are otherwise known to those skilled in the art.

0 Expression in eukaryotic cells leads to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of the recombinant protein.

Examples of vectors for expression in yeast *S. cerevisiae* include pYEpSec1 (Baldari *et al.*, (1987) *EMBO J.* 6:229-234), pMFA (Kurjan *et al.* (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

5 Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith *et al.*, (1983) *Mol. Cell Biol.* 3: 2156-2165,) and the pVL series (Lucklow, V. A., and Summers, M. D., (1989) *Virology* 170: 31-39). Generally, COS cells (Gluzman, Y., (1981) *Cell* 23: 175-182) are used in conjunction with such vectors as pCDM 8 (Aruffo A. and Seed, B., *supra*, for transient amplification/expression in mammalian cells, while CHO (*dhfr*-negative CHO) cells are used with vectors such as pMT2PC (Kaufman *et al.* (1987), 0 *EMBO J.* 6: 187-195) for stable amplification/expression in mammalian cells. The NS myeloma cell line (a glutamine synthetase expression system.) is available from Celltech Ltd.

Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the reporter group and the target protein to enable separation of the target protein from the reporter group subsequent to purification of the fusion protein. Proteolytic enzymes for such cleavage and their recognition sequences include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein.

0 Inducible non-fusion expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69: 301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 60-89). While target gene expression relies on

host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pET 11d relies on transcription from the T7 gn10-lacO fusion promoter mediated by coexpressed viral RNA polymerase (T7gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7gn1 under the transcriptional control of the lacUV 5 promoter.

One embodiment of this invention is a transfected cell which expresses novel B7-DC *de novo*. In the case of a cell already expressing B7-DC, such as a mature DC, the transfected cell expresses increased amounts of B7-DC proteins or fragments thereof on the cell surface.

For example, a tumor cell such as a sarcoma, melanoma, leukemia, lymphoma, carcinoma or neuroblastoma is transfected with an expression vector directing the expression of B7-DC on the tumor cell surface. Such transfected tumor cells can be used as immunogens to induce therapeutic antitumor immunity as described herein.

Vector Construction

Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction techniques which are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and re-ligated in the form desired.

The DNA sequences which form the vectors are available from a number of sources. Backbone vectors and control systems are generally found on available "host" vectors which are used for the bulk of the sequences in construction. For the pertinent coding sequence, initial construction may be, and usually is, a matter of retrieving the appropriate sequences from cDNA or genomic DNA libraries. However, once the sequence is disclosed it is possible to synthesize the entire gene sequence *in vitro* starting from the individual nucleotide derivatives. The entire gene sequence for genes of sizeable length, e.g., 500-1000 bp may be prepared by synthesizing individual overlapping complementary oligonucleotides and filling in single stranded nonoverlapping portions using DNA polymerase in the presence of the deoxyribonucleotide triphosphates. This approach has been used successfully in the construction of several genes of known sequence. See, for example, Edge, M. D., *Nature* (1981) 292:756; Nambair, K. P., *et al.*, *Science* (1984) 223:1299; and Jay, E., *J Biol Chem* (1984) 259:6311.

Synthetic oligonucleotides are prepared by either the phosphotriester method as described by references cited above or the phosphoramidite method as described by Beaucage,

S. L., and Caruthers, M. H., *Tet Lett* (1981) 22:1859; and Matteucci, M. D., and Caruthers, M. H., *J Am Chem Soc* (1981) 103:3185 and can be prepared using commercially available automated oligonucleotide synthesizers. Kinase treatment of single strands prior to annealing or for labeling is achieved using an excess, e.g., about 10 units of polynucleotide kinase to 1 nmole substrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl₂, 5 mM dithiothreitol, 1-2 mM ATP, 1.7 pmoles γ -³²P-ATP (2.9 mCi/mmole), 0.1 mM spermidine, 0.1 mM EDTA.

Once the components of the desired vectors are thus available, they can be excised and ligated using standard restriction and ligation procedures. Site-specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 mg of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 ml of buffer solution; in the examples herein, typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37°C. are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in *Methods in Enzymology* (1980) 65:499-560.

Restriction cleaved fragments may be blunt ended by treating with the large fragment of *E. coli* DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20° to 25° C. in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl₂, 6 mM DTT and 0.1-1.0 mM dNTPs. The Klenow fragment fills in at 5' single-stranded overhangs but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the, or selected, dNTPs within the limitations dictated by the nature of the overhang. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or BAL-31 results in hydrolysis of any single-stranded portion.

Ligations are typically performed in 15-50 ml volumes under the following standard conditions and temperatures: for example, 20 mM Tris-HCl pH 7.5, 10mM MgCl₂ , 10 mM

DTT, 33 µg/ml BSA, 10-50mM NaCl, and either 40 µM ATP, 0.01-0.02 (Weiss) units T4 DNA ligase at 0° C. (for “sticky end” ligation) or 1mM ATP, 0.3-0.6 (Weiss) units T4 DNA ligase at 14° C. (for “blunt end” ligation). Intermolecular “sticky end” ligations are usually performed at 33-100 µg/ml total DNA concentrations (5-100 nM total end concentration). Intermolecular blunt end ligations are performed at 1 mM total ends concentration.

In vector construction employing “vector fragments”, the fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase (CIAP) in order to remove the 5' phosphate and prevent self-ligation. Digestions are conducted at pH 8 in approximately 10 mM Tris-HCl, 1 mM EDTA using BAP or CIAP at about 1 unit/mg vector at 60° for about one hour. The preparation is extracted with phenol/chloroform and ethanol precipitated. Alternatively, re-ligation can be prevented in vectors which have been double digested by additional restriction enzyme and separation of the unwanted fragments.

Any of a number of methods are used to introduce mutations into the coding sequence to generate the variants of the invention. These mutations include simple deletions or insertions, systematic deletions, insertions or substitutions of clusters of bases or substitutions of single bases.

For example, modifications of B7-DC DNA sequence (cDNA or genomic DNA) are created by site-directed mutagenesis, a well-known technique for which protocols and reagents are commercially available (Zoller, MJ *et al.*, *Nucleic Acids Res* (1982) 10:6487-6500 and Adelman, JP *et al.*, *DNA* (1983) 2:183-193)). Correct ligations for plasmid construction are confirmed, for example, by first transforming *E. coli* strain MC1061 (Casadaban, M., *et al.*, *J Mol Biol* (1980) 138:179-207) or other suitable host with the ligation mixture. Using conventional methods, transformants are selected based on the presence of the ampicillin-, tetracycline- or other antibiotic resistance gene (or other selectable marker) depending on the mode of plasmid construction. Plasmids are then prepared from the transformants with optional chloramphenicol amplification optionally following chloramphenicol amplification ((Clewell, DB *et al.*, *Proc Natl Acad Sci USA* (1969) 62:1159; Clewell, D. B., *J Bacteriol* (1972) 110:667). Several mini DNA preps are commonly used. See, e.g., Holmes, DS, *et al.*, *Anal Biochem* (1981) 114:193-197; Birnboim, HC *et al.*, *Nucleic Acids Res* (1979) 7:1513-1523. The isolated DNA is analyzed by restriction and/or sequenced by the dideoxy nucleotide method of Sanger (*Proc Natl Acad Sci USA* (1977) 74:5463) as further described by Messing, *et al.*,

Nucleic Acids Res (1981) 9:309, or by the method of Maxam *et al.* *Methods in Enzymology* (1980) 65:499.

5 Vector DNA can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming host cells can be found in Sambrook *et al. supra* and other standard texts.

) Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the reporter group and the target protein to enable separation of the target protein from the reporter group subsequent to purification of the fusion protein. Proteolytic enzymes for such cleavage and their recognition sequences include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein.

5 Inducible non-fusion expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69: 301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pET 11d relies on transcription from the T7 gn10-lacO fusion promoter mediated by coexpressed viral RNA polymerase (T7gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7gn1 under the transcriptional control of the lacUV 5 promoter.

Promoters and Enhancers

A promoter region of a DNA or RNA molecule binds RNA polymerase and promotes the transcription of an "operably linked" nucleic acid sequence. As used herein, a "promoter sequence" is the nucleotide sequence of the promoter which is found on that strand of the DNA or RNA which is transcribed by the RNA polymerase. Two sequences of a nucleic acid molecule, such as a promoter and a coding sequence, are "operably linked" when they are linked to each other in a manner which permits both sequences to be transcribed onto the same RNA transcript or permits an RNA transcript begun in one sequence to be extended into the second sequence. Thus, two sequences, such as a promoter sequence and a coding sequence of DNA or

RNA are operably linked if transcription commencing in the promoter sequence will produce an RNA transcript of the operably linked coding sequence. In order to be "operably linked" it is not necessary that two sequences be immediately adjacent to one another in the linear sequence.

The preferred promoter sequences of the present invention must be operable in 5 mammalian cells and may be either eukaryotic or viral promoters. Suitable promoters may be inducible, repressible or constitutive. An example of a constitutive promoter is the viral promoter MSV-LTR, which is efficient and active in a variety of cell types, and, in contrast to most other promoters, has the same enhancing activity in arrested and growing cells. Other preferred viral promoters include that present in the CMV-LTR (from cytomegalovirus) 0 (Bashart, M. *et al.*, *Cell* 41:521 (1985)) or in the RSV-LTR (from Rous sarcoma virus) (Gorman, C.M., *Proc. Natl. Acad. Sci. USA* 79:6777 (1982)). Also useful are the promoter of the mouse metallothionein I gene (Hamer, D., *et al.*, *J. Mol. Appl. Gen.* 1:273-288 (1982)); the TK promoter of Herpes virus (McKnight, S., *Cell* 31:355-365 (1982)); the SV40 early promoter (Benoist, C., *et al.*, *Nature* 290:304-310 (1981)); and the yeast *gal4* gene promoter (Johnston, 5 S.A., *et al.*, *Proc. Natl. Acad. Sci. (USA)* 79:6971-6975 (1982); Silver, P.A., *et al.*, *Proc. Natl. Acad. Sci. (USA)* 81:5951-5955 (1984)). Other illustrative descriptions of transcriptional factor association with promoter regions and the separate activation and DNA binding of transcription factors include: Keegan *et al.*, *Nature* (1986) 231:699; Fields *et al.*, *Nature* (1989) 340:245; Jones, *Cell* (1990) 61:9; Lewin, *Cell* (1990) 61:1161; Ptashne *et al.*, *Nature* (1990) 346:329; 0 Adams *et al.*, *Cell* (1993) 72:306. The relevant disclosure of all of these above-listed references is hereby incorporated by reference.

The promoter region may further include an octamer region which may also function as a tissue specific enhancer, by interacting with certain proteins found in the specific tissue. The enhancer domain of the DNA construct of the present invention is one which is specific for the 5 target cells to be transfected, or is highly activated by cellular factors of such target cells. Examples of vectors (plasmid or retrovirus) are disclosed in (Roy-Burman *et al.*, U.S. Patent No. 5,112,767). For a general discussion of enhancers and their actions in transcription, see, Lewin, B.M., *Genes IV*, Oxford University Press, Oxford, (1990), pp. 552-576. Particularly useful are retroviral enhancers (*e.g.*, viral LTR). The enhancer is preferably placed upstream from the 0 promoter with which it interacts to stimulate gene expression. For use with retroviral vectors, the endogenous viral LTR may be rendered enhancer-less and substituted with other desired

enhancer sequences which confer tissue specificity or other desirable properties such as transcriptional efficiency on the B7-DC-encoding DNA molecule of the present invention.

The nucleic acid sequences of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated with commercially available DNA synthesizers (See, e.g., Itakura *et al.* U.S. Pat. No. 4,598,049; Caruthers *et al.* U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071, incorporated by reference herein).

PROTEINS AND POLYPEPTIDES

The present invention includes an "isolated" B7-DC protein having the sequence SEQ ID NO:2 or SEQ ID NO:4. While the present disclosure exemplifies the full length human and murine B7-DC protein (and DNA), it is to be understood that homologues of B7-DC from other mammalian species and mutants thereof that possess the characteristics disclosed herein are intended within the scope of this invention.

Also included is a "functional derivative" of B7-DC which means an amino acid substitution variant, a "fragment," or a "chemical derivative" of B7-DC, which terms are defined below. A functional derivative retains measurable B7-DC activity, preferably that of binding to a receptor on T cells and costimulating T cell activity, which permits its utility in accordance with the present invention. "Functional derivatives" encompass "variants" and "fragments" regardless of whether the terms are used in the conjunctive or the alternative herein.

A functional homologue must possess the above biochemical and biological activity. In view of this functional characterization, use of homologous proteins B7-DC from other species, including proteins not yet discovered, fall within the scope of the invention if these proteins have sequence similarity and the recited biochemical and biological activity.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred method of alignment, Cys residues are aligned.

In a preferred embodiment, the length of a sequence being compared is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and

even more preferably at least 70%, 80%, or 90% of the length of the reference sequence. For example, when aligning a second sequence to the human B7-DC protein amino acid sequence (SEQ ID NO:2) having 276 amino acid residues, at least 83, preferably at least 110, more preferably at least 138, even more preferably at least 166, and even more preferably at least 193, 5 221 or 248 amino acid residues are aligned). The amino acid residues (or nucleotides) at corresponding amino acid positions (or nucleotide) positions are then compared. When a position in the first sequence is occupied by the same amino acid residue (or nucleotide) as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid 0 "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the 5 percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* 48:444-453 (1970) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity 0 between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated 5 into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases, for example, to identify other family members or related sequences. Such searches can be performed using the NBLAST and 0 XBLAST programs (version 2.0) of Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to human or murine B7-DC nucleic acid molecules.

BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to human or murine B7-DC protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing 5 BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

Thus, a homologue of the B7-DC protein described above is characterized as having (a) functional activity of native B7-DC, and (b) sequence similarity to a native B7-DC protein (such 0 as SEQ ID NO:2 or SEQ ID NO:4, when determined above, of at least about 30% (at the amino acid level), preferably at least about 50%, more preferably at least about 70%, even more preferably at least about 90%.

It is within the skill in the art to obtain and express such a protein using DNA probes based on the disclosed sequences of B7-DC. Then, the protein's biochemical and biological activity can be tested readily using art-recognized methods such as those described herein, for 5 example, a standard T cell proliferation or cytokine secretion assay. A biological assay of T cell co-stimulation will indicate whether the homologue has the requisite activity to qualify as a "functional" homologue.

Preferred assays measure the functional characteristics of B7-DC such as stimulating T cells synthesis of cytokines, which depends on binding or cross-linking of the TCR ("primary activation signal"), as well as delivery of a costimulatory signal. The binding of B7-DC to its 0 natural ligand(s) on T cells transmits a signal that induces increased cytokine production, such as IL-2, which in turn stimulates proliferation which can also be measured routinely.

A "variant" of B6-DC refers to a molecule substantially identical to either the full protein or to a fragment thereof in which one or more amino acid residues have been replaced 5 (substitution variant) or which has one or several residues deleted (deletion variant) or added (addition variant). A "fragment" of B6-DC refers to any subset of the molecule, preferably one that includes the ECD, that is, a shorter polypeptide of the full-length protein.

A number of processes can be used to generate fragments, mutants and variants of the isolated DNA sequence. Small subregions or fragments of the nucleic acid encoding the B7-DC 0 protein, for example 1-30 bases in length, can be prepared by standard, chemical synthesis. Antisense oligonucleotides and primers for use in the generation of larger synthetic fragment.

A preferred functional derivative is a fusion protein, a polypeptide that includes a functional fragment of B7-DC. For example, a useful derivative of B7 is a B7-DC-Ig fusion protein that comprises a polypeptide corresponding to the ECD of B7-DC and an Ig C region. The presence of the fusion partner can alter the solubility, affinity and/or valency (defined here 5 as the number of binding sites available per molecule) of the B7-DC protein. A soluble B7-DC fusion protein, while still binding to a receptor on T cells, may have a different biological effect than of the native protein expressed on an APC, *i.e.*, inhibition of T cell stimulation by competitive binding rather than costimulation.

As used herein an extracellular domain (ECD) of B7-DC is the entire extracellular 0 portion of the protein or any fragment thereof that recognizes and binds to PD-1 or to another receptor on T cells that is not CD28 or CTLA-4. Preferably, an ECD of B7-DC is that portion encoded by amino acid residues from about position 26 to about position 221 of SEQ ID NO:2 or SEQ ID NO:4.

By "soluble B7-DC" is intended a cell-free form of B7-DC that may be shed, secreted or 5 otherwise extracted from the producing cells. Soluble B7-DC includes, but is not limited to, soluble fusion proteins such as B7-DC-Ig, free ECD of B7-DC, or the B7-DC ECD fused (genetically or chemically) to a biologically active molecule.

As indicated earlier, this invention also includes hybrid fusion proteins between a B7-DC 0 domain and a domain or fragment of another B7 family protein, preferably expressed on the cell surface in costimulatory form.

A preferred group of B7-DC variants are those in which at least one amino acid residue and preferably, only one, has been substituted by different residue. For a detailed description of 5 protein chemistry and structure, see Schulz, GE *et al.*, *Principles of Protein Structure*, Springer-Verlag, New York, 1978, and Creighton, T.E., *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, 1983, which are hereby incorporated by reference. The types of substitutions that may be made in the protein molecule may be based on analysis of the frequencies of amino acid changes between a homologous protein of different species, such as those presented in Table 1-2 of Schulz *et al.* (*supra*) and Figure 3-9 of Creighton (*supra*). Based 0 on such an analysis, conservative substitutions are defined herein as exchanges within one of the following five groups:

1	Small aliphatic, nonpolar or slightly polar residues	Ala, Ser, Thr (Pro, Gly);
2	Polar, negatively charged residues and their amides	Asp, Asn, Glu, Gln;
3	Polar, positively charged residues	His, Arg, Lys;
4	Large aliphatic, nonpolar residues	Met, Leu, Ile, Val (Cys)
5	Large aromatic residues	Phe, Tyr, Trp.

The three amino acid residues in parentheses above have special roles in protein architecture. Gly is the only residue lacking a side chain and thus imparts flexibility to the chain. Pro, because of its unusual geometry, tightly constrains the chain. Cys can participate in disulfide bond formation, which is important in protein folding.

More substantial changes in biochemical, functional (or immunological) properties are made by selecting substitutions that are less conservative, such as between, rather than within, the above five groups. Such changes will differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Examples of such substitutions are (i) substitution of Gly and/or Pro by another amino acid or deletion or insertion of Gly or Pro; (ii) substitution of a hydrophilic residue, e.g., Ser or Thr, for (or by) a hydrophobic residue, e.g., Leu, Ile, Phe, Val or Ala; (iii) substitution of a Cys residue for (or by) any other residue; (iv) substitution of a residue having an electropositive side chain, e.g., Lys, Arg or His, for (or by) a residue having an electronegative charge, e.g., Glu or Asp; or (v) substitution of a residue having a bulky side chain, e.g., Phe, for (or by) a residue not having such a side chain, e.g., Gly.

Most acceptable deletions, insertions and substitutions according to the present invention are those that do not produce radical changes in the characteristics of the B7-DC protein in terms of its T cell costimulatory activity. However, when it is difficult to predict the exact effect of the substitution, deletion or insertion in advance of doing so, one skilled in the art will appreciate that the effect can be evaluated by routine screening assays such as those described here, without requiring undue experimentation.

Whereas shorter chain variants can be made by chemical synthesis, for the present invention, the preferred longer chain variants are typically made by site-specific mutagenesis of the nucleic acid encoding the B7-DC polypeptide, expression of the variant nucleic acid in cell culture, and, optionally, purification of the polypeptide from the cell culture, for example, by

immunoaffinity chromatography using specific antibody immobilized to a column (to absorb the variant by binding to at least one epitope).

Chemical Derivatives of B7-DC

“Chemical derivatives” of B7-DC contain additional chemical moieties not normally a part of the protein. Covalent modifications of the polypeptide are included within the scope of this invention. Such derivatized moieties may improve the solubility, absorption, biological half life, and the like. Moieties capable of mediating such effects are disclosed, for example, in *Remington's Pharmaceutical Sciences*, 16th ed., Mack Publishing Co., Easton, PA (1980).

Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Another modification is cyclization of the protein.

Examples of chemical derivatives of the polypeptide follow.

Lysinyl and amino terminal residues are derivatized with succinic or other carboxylic acid anhydrides. Derivatization with a cyclic carboxylic anhydride has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Carboxyl side groups, aspartyl or glutamyl, may be selectively modified by reaction with carbodiimides ($R-N=C=N-R'$) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonia.

Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the amino group of lysine (Creighton, *supra*, pp. 79-86), acetylation of the N-terminal amine, and amidation of the C-terminal carboxyl groups.

Also included are peptides wherein one or more D-amino acids are substituted for one or more L-amino acids.

Multimeric Peptides

The present invention also includes longer polypeptides in which a basic peptidic sequence obtained from the sequence of B7-DC is repeated from about two to about 100 times,

with or without intervening spacers or linkers. It is understood that such multimers may be built from any of the peptide variants defined herein. Moreover, a peptide multimer may comprise different combinations of peptide monomers and the disclosed substitution variants thereof. Such oligomeric or multimeric peptides can be made by chemical synthesis or by recombinant DNA techniques as discussed herein. When produced chemically, the oligomers preferably have from 2-8 repeats of the basic peptide sequence. When produced recombinantly, the multimers may have as many repeats as the expression system permits, for example from two to about 100 repeats.

In tandem multimers, preferably dimers and trimers, of the B7-DC peptide or polypeptide, the chains bonded by interchain disulfide bonds or other "artificial" covalent bonds between the chains such that the chains are "side-by-side" rather than "end to end." Preferred dimers and trimers are those between fusion proteins of B7-DC such as B7-DC-Ig, as described herein.

ANTIBODIES SPECIFIC FOR EPITOPE OF B7-DC

In the following description, reference will be made to various methodologies known to those of skill in the art of immunology, cell biology, and molecular biology. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full. Standard reference works setting forth the general principles of immunology include A.K. Abbas *et al.*, *Cellular and Molecular Immunology* (Fourth Ed.), W.B. Saunders Co., Philadelphia, 2000; C.A. Janeway *et al.*, *Immunobiology. The Immune System in Health and Disease*, Fourth ed., Garland Publishing Co., New York, 1999; Roitt, I. *et al.*, *Immunology*, (current ed.) C.V. Mosby Co., St. Louis, MO (1999); Klein, J., *Immunology*, Blackwell Scientific Publications, Inc., Cambridge, MA, (1990).

Monoclonal antibodies (mAbs) and methods for their production and use are described in Kohler and Milstein, *Nature* 256:495-497 (1975); U.S. Patent No. 4,376,110; Hartlow, E. *et al.*, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988); *Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, New York, NY (1980); H. Zola *et al.*, in *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, 1982)).

Immunoassay methods are also described in Coligan, J.E. *et al.*, eds., *Current Protocols in Immunology*, Wiley-Interscience, New York 1991(or current edition); Butt, W.R. (ed.) *Practical Immunoassay: The State of the Art*, Dekker, New York, 1984; Bizollon, Ch. A., ed., *Monoclonal Antibodies and New Trends in Immunoassays*, Elsevier, New York, 1984; Butler, J.E., ELISA (Chapter 29), In: van Oss, C.J. *et al.*, (eds), *IMMUNOCHEMISTRY*, Marcel Dekker, Inc., New York, 1994, pp. 759-803; Butler, J.E. (ed.), *Immunochemistry of Solid-Phase Immunoassay*, CRC Press, Boca Raton, 1991; Weintraub, B., *Principles of Radioimmunoassays*, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986; Work, T.S. *et al.*, *Laboratory Techniques and Biochemistry in Molecular Biology*, North Holland Publishing Company, NY, (1978) (Chapter by Chard, T., "An Introduction to Radioimmune Assay and Related Techniques").

Anti-idiotypic antibodies are described, for example, in *Idiotypic in Biology and Medicine*, Academic Press, New York, 1984; *Immunological Reviews* Volume 79, 1984; *Immunological Reviews* Volume 90, 1986; *Curr. Top. Microbiol., Immunol.* Volume 119, 1985; Bona, C. *et al.*, *CRC Crit. Rev. Immunol.*, pp. 33-81 (1981); Jerne, NK, *Ann. Immunol. 125C*:373-389 (1974); Jerne, NK, In: *Idiotypes - Antigens on the Inside*, Westen-Schnurr, I., ed., Editiones Roche, Basel, 1982, Urbain, J *et al.*, *Ann. Immunol. 133D*:179- (1982); Rajewsky, K. *et al.*, *Ann. Rev. Immunol.* 1:569-607 (1983)

The present invention provides antibodies, both polyclonal and monoclonal, reactive with novel epitopes of B7-DC that are absent from known B7 family proteins. The antibodies may be xenogeneic, allogeneic, syngeneic, or modified forms thereof, such as humanized or chimeric antibodies. Antiidiotypic antibodies specific for the idiotype of an anti-B7-DC antibody are also included. The term "antibody" is also meant to include both intact molecules as well as fragments thereof that include the antigen-binding site and are capable of binding to a B7-DC epitope. These include , Fab and F(ab')₂ fragments which lack the Fc fragment of an intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl *et al.*, *J. Nucl. Med.* 24:316-325 (1983)). Also included are Fv fragments (Hochman, J. *et al.* (1973) *Biochemistry* 12:1130-1135; Sharon, J. *et al.*(1976) *Biochemistry* 15:1591-1594).). These various fragments are be produced using conventional techniques such as protease cleavage or chemical cleavage (see, e.g., Rousseaux *et al.*, *Meth. Enzymol.*, 121:663-69 (1986))

Polyclonal antibodies are obtained as sera from immunized animals such as rabbits, goats, rodents, *etc.* and may be used directly without further treatment or may be subjected to conventional enrichment or purification methods such as ammonium sulfate precipitation, ion exchange chromatography, and affinity chromatography (see Zola *et al.*, *supra*).

5 The immunogen may comprise the complete B7-D6 protein, or fragments or derivatives thereof. Preferred immunogens comprise all or a part of the ECD of human B7-DC (amino acid residues 26-221), where these residues contain the post-translation modifications, such as glycosylation, found on the native B7-DC. Immunogens comprising the extracellular domain are produced in a variety of ways known in the art, *e.g.*, expression of cloned genes using 0 conventional recombinant methods, isolation from cells of origin, cell populations expressing high levels of B7-DC, *etc.*

The mAbs may be produced using conventional hybridoma technology, such as the procedures introduced by Kohler and Milstein (*Nature*, 256:495-97 (1975)), and modifications thereof (see above references). An animal, preferably a mouse is primed by immunization with 5 an immunogen as above to elicit the desired antibody response in the primed animal.

B lymphocytes from the lymph nodes, spleens or peripheral blood of a primed, animal are fused with myeloma cells, generally in the presence of a fusion promoting agent such as polyethylene glycol (PEG). Any of a number of murine myeloma cell lines are available for such use: the P3-NS1/1-Ag4-1, P3-x63-k0Ag8.653, Sp2/0-Ag14, or HL1-653 myeloma lines 0 (available from the ATCC, Rockville, MD). Subsequent steps include growth in selective medium so that unfused parental myeloma cells and donor lymphocyte cells eventually die while only the hybridoma cells survive. These are cloned and grown and their supernatants screened for the presence of antibody of the desired specificity, *e.g.* by immunoassay techniques using the B7-DC-Ig fusion protein. Positive clones are subcloned, *e.g.*, by limiting dilution, and the mAbs 5 are isolated.

Hybridomas produced according to these methods can be propagated *in vitro* or *in vivo* (in ascites fluid) using techniques known in the art (see generally Fink *et al.*, *Prog. Clin. Pathol.*, 9:121-33 (1984)). Generally, the individual cell line is propagated in culture and the culture medium containing high concentrations of a single mAb can be harvested by decantation, 0 filtration, or centrifugation.

The antibody may be produced as a single chain antibody or scFv instead of the normal multimeric structure. Single chain antibodies include the hypervariable regions from an Ig of

interest and recreate the antigen binding site of the native Ig while being a fraction of the size of the intact Ig (Skerra, A. *et al.* (1988) *Science*, 240: 1038-1041; Pluckthun, A. *et al.* (1989) *Methods Enzymol.* 178: 497-515; Winter, G. *et al.* (1991) *Nature*, 349: 293-299); Bird *et al.*, (1988) *Science* 242:423; Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879; Jost CR *et al.*, 5 *J Biol Chem.* 1994 269:26267-26273; U.S. Patents No. 4,704,692, 4,853,871, 4,94,6778, 5,260,203, 5,455,0Kn contacted with the solution containing an unknown quantity of labeled antibody (which functions as a “reporter molecule”). After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support through the unlabeled antibody, the solid support is washed a second time to remove the unreacted labeled 0 antibody.. This type of forward sandwich assay may be a simple “yes/no” assay to determine whether antigen is present or may be made quantitative by comparing the measure of labeled antibody with that obtained for a standard sample containing known quantities of antigen.

In another type of “sandwich” assay the so-called “simultaneous” and “reverse” assays are used. A simultaneous assay involves a single incubation step as the antibody bound to the 5 solid support and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody associated with the solid support is then determined as it would be in a conventional “forward” sandwich assay.

In the “reverse” assay, stepwise addition first of a solution of labeled antibody to the 0 fluid sample followed by the addition of unlabeled antibody bound to a solid support after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support is then determined as in the “simultaneous” and “forward” assays.

The foregoing antibodies ar useful in method for inhibiting T cell stimulation and 5 treating diseases associated with undesired T cell activation, such as transplant rejection and autoimmunity. This method involves administering a subject in need of such treatment an effective amount of an antibody, preferably a mAb, more preferably a human oor humanized mAb specific for a costimulatory epitope of B7-DC. The administration of antibody must be 0 effective in blocking stimulation of T cells or in eliminating antigen-reactive T cells, thereby inhibiting the targeted T cell response. Relevant dose ranges are described below.

USES OF NUCLEIC ACIDS THAT ENCODE B7-DC PROTEIN

The nucleic acids of this invention are used diagnostically to monitor the progress of a disease, by measuring the expression of B7-DC in cells from biological samples or for assaying the effect of an agent on the expression of B7-DC. This is preferably accomplished by measurement of cellular mRNA levels. For use in such diagnostic methods, the nucleic acid sequence is detectably labeled, *e.g.*, with a radioactive or fluorescent label or biotin and used in a conventional dot blot or Northern hybridization procedure to probe mRNA molecules present in, for example, a preparation of total *kor* poly(A⁺) RNA from a biological sample.

THERAPEUTIC COMPOSITIONS AND THEIR ADMINISTRATION

The B6-DC polypeptide or a cell expressing this polypeptide such as a DC or a tumor cell is administered to a mammalian subject, preferably a human. Cell-associated, immobilized or otherwise aggregated forms of the polypeptide are used to enhance T lymphocyte reactivity and the resultant immunity. The B6-DC-Ig fusion protein assembles as a dimer and, as shown in the examples, co-stimulates T cells. Soluble monomeric forms of the B6-DC polypeptide can bind to the receptor on T cells without stimulating activity and can therefore be considered competitive inhibitors or antagonists of T cell co-stimulation by a stimulatory form of the molecule. Binding of a such a B6-DC antagonist may suppress ongoing T cell reactivity or may interfere with the effect of a costimulatory signal presented by endogenous B6-DC or even by other B7 family members acting via their receptors (*e.g.*, CD28 or CTLA-4).

A composition having the activity of B7-DC as described herein is administered in a pharmaceutically acceptable carrier in a biologically effective or a therapeutically effective amount. The B7-DC polypeptide (or cell expressing the polypeptide) may be given alone or in combination with another protein or peptide such as one having the activity of another member of the B7 family or another immunostimulatory molecule. Treatment may include administration of an adjuvant, used in its broadest sense to include any nonspecific immune stimulating compound such as an interferon. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.

The following doses and amounts also pertain to the antibodies of the invention when administered to a subject.

A therapeutically effective amount is a dosage that, when given for an effective period of time, achieves the desired immunological or clinical effect.

A therapeutically active amount of a polypeptide having B7-DC activity (or an anti-B7-DC antibody) may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the peptide to elicit a desired response in the individual.

Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A therapeutically effective amounts of the protein, in cell associated form may be stated in terms of the protein or cell equivalents.

Thus an effective amount is between about 1 ng and about 1 gram per kilogram of body weight of the recipient, more preferably between about 1 µg and 100 mg/kg, more preferably, between about 100 µg and about 100 mg/kg. Dosage forms suitable for internal administration preferably contain (for the latter dose range) from about 0.1 mg to 500 mg of active ingredient per unit. The active ingredient may vary from 0.5 to 95% by weight based on the total weight of the composition. Alternatively, an effective dose of cells expressing B7-DC, such preferably transduced cells such as DC's or inactivated tumor cells, is between about 10^4 and 10^9 cells, more preferably between about 10^6 and 10^8 cells per subject, preferably in split doses. Those skilled in the art of immunotherapy will be able to adjust these doses without undue experimentation.

The active compound (*e.g.*, B6-DC polypeptide or cell transduced with B6-DC DNA) may be administered in a convenient manner, *e.g.*, injection by a convenient and effective route. Preferred routes include subcutaneous, intradermal, intravenous and intramuscular routes. Other possible routes include oral administration, intrathecal, inhalation, transdermal application, or rectal administration. For the treatment of tumors which have not been completely resected, direct intratumoral injection is also intended.

Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound. Thus, to administer a polypeptide or peptide having B7-DC activity by an enteral route, it may be necessary to coat the composition with, or co-administer the composition with, a material to prevent its inactivation. For example, a peptide may be administered to an individual in an appropriate carrier, diluent or adjuvant, co-administered with enzyme inhibitors (*e.g.*, pancreatic trypsin inhibitor,

diisopropylfluorophosphate (DEP) and trasylol). or in an appropriate carrier such as liposomes (including water-in-oil-in-water emulsions as well as conventional liposomes (Strejan *et al.*, (1984) *J. Neuroimmunol* 7:27).

As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated.

Supplementary active compounds can also be incorporated into the compositions.

Preferred pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. Isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride may be included in the pharmaceutical composition. In all cases, the composition should be sterile and should be fluid. It should be stable under the conditions of manufacture and storage and must include preservatives that prevent contamination with microorganisms such as bacteria and fungi. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.

Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.

Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Parenteral compositions are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units suited as unitary dosages for a mammalian subject; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

For lung instillation, aerosolized solutions are used. In a sprayable aerosol preparations, the active protein may be in combination with a solid or liquid inert carrier material. This may also be packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant. The aerosol preparations can contain solvents, buffers, surfactants, and antioxidants in addition to the protein of the invention.

For topical application, the proteins of the present invention may be incorporated into topically applied vehicles such as salves or ointments, which have both a soothing effect on the skin as well as a means for administering the active ingredient directly to the affected area.

The carrier for the active ingredient may be either in sprayable or nonsprayable form. Non-sprayable forms can be semi-solid or solid forms comprising a carrier indigenous to topical application and having a dynamic viscosity preferably greater than that of water. Suitable formulations include, but are not limited to, solution, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like. If desired, these may be sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, buffers, or salts for influencing osmotic pressure and the like. Examples of preferred vehicles for non-sprayable topical preparations include ointment bases, e.g., polyethylene glycol-1000 (PEG-1000); conventional creams such as HEB cream; gels; as well as petroleum jelly and the like.

Other pharmaceutically acceptable carriers for the B7-DC polypeptide according to the present invention are liposomes, pharmaceutical compositions in which the active protein is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers. The active protein is preferably present in the aqueous layer and in the lipidic layer, inside or outside, or, in any event, in the non-homogeneous system generally known as a liposomal suspension. The hydrophobic layer, or lipidic layer, generally, but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such

as cholesterol, more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid, and/or other materials of a hydrophobic nature.

Modification of Tumor Cells to Express B7-DC and Multiple Costimulatory Molecules

Another aspect of the invention is a cell, preferably a tumor cell, modified to express
5 multiple costimulatory molecules. The temporal expression of costimulatory molecules on activated B cells is different for B7, B7-2 and B7-3. For example, B7-2 is expressed early following B cell activation, whereas B7-3 is expressed later. The different costimulatory molecules may thus serve distinct functions during the course of an immune response. An effective T cell response may require that the T cell receive costimulatory signals from multiple
0 costimulatory molecules.

Accordingly, the invention encompasses a tumor cell which is genetically modified or to express more than one costimulatory molecule. For example, a tumor cell can be modified to express B7-DC and one or more of B7, B7-2 and B7-3.

Before modification, a cell such as a tumor cell may not express any costimulatory
5 molecules, or may express certain costimulatory molecules but not others. As described herein, tumor cells can be modified by transfection with nucleic acid encoding B7-DC alone or with another costimulatory molecule(s). For example, a tumor cell transfected with nucleic acid encoding B7-DC can be further transfected with nucleic acid encoding B7. The sequence of cDNA molecules encoding human or mouse B7-DC proteins are SEQ ID NO:1 and the coding
0 portion of SEQ ID NO:3, respectively. Alternatively, more than one type of modification can be used. For example, a tumor cell transfected with a nucleic acid encoding B7-DC can be stimulated with an agent which induces expression of B7-1, B7-2 or B7-3.

ANTIGENS ASSOCIATED WITH PATHOGENS

A major utility for the present invention is the use of the present compositions in
5 therapeutic vaccine for cancer and for major chronic viral infections that cause morbidity and mortality worldwide. Such vaccines are designed to eliminate infected cells - this requires T cell responses as antibodies are ineffective. The vaccines of the present invention, include, in addition to the antigenic epitope itself:

- (a) a vector such as naked DNA, naked RNA, self replicating RNA replicons and viruses including vaccinia, adenoviruses, adeno-associated virus (AAV), lentiviruses and RNA alphaviruses;

(b) an antigen targeting or processing signal such as HSP70, calreticulin, the extracellular domain of Flt-3 ligand, domain II of Pseudomonas exotoxin ETA, herpes simplex VP22 targeting protein, and the like. (See commonly assigned U.S. patent applications 09//421,608; 09/501,097; 09/693,450; 60/222,9002; 5 60/222,985; 60/268,575 and Chang, W-F *et al.*, *J. Virol.* 75:2368-2376 (2001), which are hereby incorporated by reference in their entirety); and

(c) a costimulatory signal, preferably the B7-DC protein of the present invention or a fusion protein, fragment or functional derivative thereof (alone or in combination with other known costimulatory proteins such as B7.1, B7.2, soluble CD40, etc.).

0 Tumor cells or other types of host cells, including APCs, are transformed, transfected or otherwise transduced with a nucleic encoding an antigen to which an immune response is desired. Such antigens are preferably epitopes of pathogenic microorganisms against which the host is defended by effector T cells responses, including cytotoxic T lymphocyte (CTL) and delayed type hypersensitivity. These typically include viruses, intracellular parasites such as 5 malaria, and bacteria that grow intracellularly such as mycobacteria and listeria. Thus, the types of antigens included in the vaccine compositions of this invention are any of those associated with such pathogens (in addition, of course, to tumor-specific antigens). It is noteworthy that some viral antigens are also tumor antigens in the case where the virus is a causative factor in cancer.

0 In fact, the two most common cancers worldwide, hepatoma and cervical cancer, are associated with viral infection. Hepatitis B virus(HBV) (Beasley, R.P. *et al.*, *Lancet* 2, 1129-1133 (1981) has been implicated as etiologic agent of hepatomas. 80-90% of cervical cancers express the E6 and E7 antigens from one of four "high risk" human papillomavirus types: HPV-16, HPV-18, HPV-31 and HPV-45 (Gissmann, L. *et al.*, *Ciba Found Symp.* 120, 190-207 5 (1986); Beaudenon, S., *et al. Nature* 321, 246-249 (1986). The HPV E6 and E7 antigens are the most promising targets for virus associated cancers in immunocompetent individuals because of their ubiquitous expression in cervical cancer. In addition to their importance as targets for therapeutic cancer vaccines, virus associated tumor antigens are also ideal candidates for prophylactic vaccines. Indeed, introduction of prophylactic HBV vaccines in Asia have 0 decreased the incidence of hepatoma (Chang, M.H., *et al. New Engl. J. Med.* 336, 1855-1859 (1997), representing a great impact on cancer prevention.

Among the most important viruses in chronic human viral infections are human papillomavirus (HPV) hepatitis B virus (HBV), hepatitis C Virus (HCV), human immunodeficiency virus (HIV), Epstein Barr Virus (EBV) and herpes simplex virus (HSV).

In addition to its applicability to human cancer and infectious diseases,, the present invention is also intended for use in treating animal diseases in the veterinary medicine context. Thus, the approaches described herein may be readily applied by one skilled in the art to treatment of veterinary herpesvirus infections including equine herpesviruses, bovine herpesviruses, Marek's disease virus in chickens and other fowl; animal retroviral diseases; pseudorabies and rabies and the like.

The following references set forth principles and current information in the field of basic, medical and veterinary virology and are incorporated by reference: *Fields Virology*, Fields, BN et al., eds., Lippincott Williams & Wilkins, NY, 1996;

Principles of Virology: Molecular Biology, Pathogenesis, and Control, Flint, S.J. et al., eds., Amer Society for Microbiology, Washington, 1999; *Principles and Practice of Clinical Virology*, 4th Edition, Zuckerman. A.J. et al., eds, John Wiley & Sons, NY, 1999; *The Hepatitis C Viruses*, by Hagedorn, CH et al., eds., Springer Verlag, 1999; *Hepatitis B Virus: Molecular Mechanisms in Disease and Novel Strategies for Therapy*, Koshy, R. et al., eds., World Scientific Pub Co, 1998; *Veterinary Virology*, Murphy, F.A. et al., eds., Academic Press, NY, 1999; *Avian Viruses: Function and Control*, Ritchie, B.W., Iowa State University Press, Ames , 2000; *Virus Taxonomy: Classification and Nomenclature of Viruses: Seventh Report of the International Committee on Taxonomy of Viruses*, by M. H. V. Van Regenmortel, MHV et al., eds., Academic Press; NY, 2000.

Targeting Molecules

A number of proteins that have various modes of action have been implicated as "targeting" molecules to be used in conjunction with antigens, preferably as fusion polypeptides, to target the antigen to cells and subcellular compartments that promote presentation of the antigen to T cells in a more potent and effective manner.

Linkage of antigens to heat shock proteins (HSPs) represents a potential approach for increasing the potency of nucleic acid-based (and other) vaccines. HSPs appear to act as natural biologic adjuvants in cancer and viral vaccination. Both the gp96 HSP resident in the endoplasmic reticulum (ER) and the cytosolic Hsp70 act as immunologic adjuvants (Srivastava,

PK *et al.*, *Semin. Immunol.* 3, 57-64 (1991); Udon, H *et al.*, *Proc. Natl. Acad. Sci. USA* 91, 3077-3081 (1994)). These HSPs, or chaperonins, bind a wide array of peptides (Lammert, E., *et al.* *Eur. J. Immunol.* 27, 923-927 (1997)). Hsp70 is a chaperonin that can target associated proteins to the proteosome - the primary cellular protease complex that generates peptides for association with MHC class I molecules. Therefore, antigens directly linked to Hsp70 are more efficiently presented by MHC class I (leading, *inter alia*, to CTL responses). Two features appear to be responsible for HSP adjuvanticity: (1) *in vitro*, peptide loaded gp96 effectively introduce antigens into the MHC class I processing pathway; (2) binding of gp96 to macrophages induces secretion of proinflammatory cytokines, thus augmenting the function of the cells to which the peptide antigen has been targeted.

Immunization with HSP complexes isolated from tumor or from virus-infected cells induces potent antitumor immunity (Srivastava, PK *et al.*, *Int J Cancer.* 33: 417-22, 1984; Srivastava, PK *et al.*, *Proc Natl Acad Sci USA.* 83: 3407-11, 1986; Udon, H *et al.*, *J Immunol.* 152: 5398-5403, 1994; Blachere, NE *et al.*, *J Immunother.* 14: 352-6, 1993; Udon, H *et al.*, *supra*; Tamura, Y *et al.*, *Science.* 278: 117-20, 1997; Janetzki, S *et al.*, *J Immunother.* 21: 269-76, 1998)) or antiviral immunity (Heikema, A *et al.*, *Immunol Lett.* 57: 69-74, 1997; Suto, R *et al.*, *Science.* 269: 1585-8, 1995). Mixing peptides with HSPs *in vitro* generated immunogenic HSP-peptide complexes (Ciupitu, AM *et al.*, *J Exp Med.* 187: 685-91, 1998; Blachere, NE *et al.*, *J Exp Med.* 186: 1315-22, 1997). Some HSP-based protein vaccines involved fusion of the antigen to the HSP (Suzue, K *et al.*, *J Immunol.* 156: 873-9, 1996; Suzue, K. *et al.*, *Proc Natl Acad Sci USA* 94: 13146-51, 1997). More recently, the present inventors and their colleagues (*e.g.*, Chen, C-H *et al.*, *Canc. Res.* 60:1035-1042 (2000)) used HSPs in the form of chimeric DNA or RNA replicon vaccines. They used HPV-16 E7 as antigen fused to *Mycobacterium tuberculosis* HSP70 and showed increased expansion and activation of E7-specific CD8+ T cells which resulted in potent antitumor immunity against established tumors (Lin, K.-Y. *et al.*, *Cancer Res.* 56: 21-26., 1996).

Another useful targeting molecule is the translocation domain of a *Pseudomonas* exotoxin A (ETA), *e.g.*, domain II (dII) of ETA (spanning residues 253-364). A translocation domain is a polypeptide that induces translocation of protein or polypeptide to which it is linked into the cytosol of a cell. For example, similarly applicable polypeptide are derived from a *Diphtheria*, *Clostridia* (*botulinum*, *tetani*), *Anthrax*, *Yersinia*, *Vibrio cholerae*, or *Bordetella*

pertussis toxin. The toxic domain of the DNA encoding the toxin is preferably mutated or deleted in the preparation of such compositions.

Calreticulin (CRT) is an abundant 46 kDa protein located in the endoplasmic reticulum (ER) lumen that displays lectin activity and is known to be involved in the folding and assembly of nascent glycoproteins (Nash (1994) *Mol. Cell. Biochem.* 135:71-78; Hebert (1997) *J. Cell Biol.* 139:613-623; Vassilakos (1998) *Biochemistry* 37:3480-3490; Spiro (1996) *J. Biol. Chem.* 271:11588-11594. CRT associates with peptides transported into the ER by transporters associated with antigen processing, such as TAP-1 and TAP-2 (Spee (1997) *Eur. J. Immunol.* 27:2441-2449). CRT forms complexes *in vitro* with peptides. These complexes, when administered to mice, elicited peptide-specific CD8+ T cell responses (Basu (1999) *J. Exp. Med.* 189:797-802; Nair (1999) *J. Immunol.* 162:6426-6432). CRT purified from mouse tumors elicited immunity specific to the tumor used as the source of CRT, but not to an antigenically distinct tumor (Basu, *supra*). By pulsing DCs *in vitro* with a CRT bound to a peptide, the peptide was re-presented in the context of DC Class I molecules and stimulated peptide-specific CTLs (Nair, *supra*).

The Flt-3 ligand stimulates growth of DC precursors and can promote generation of large numbers of DCs *in vivo* (Maraskovsky, E. *et al.*, *J Exp Med.* 184: 1953-62, 1996; Shurin, MR. *et al.*, *Cell Immunol.* 179: 174-84, 1997). Flt3, a murine tyrosine kinase receptor (Rosnet, O. *et al.*, *Oncogene* 6: 1641-50, 1991) is a member of the III receptor kinase family (for review see Lyman, SD, *Curr Opin Hematol.* 5: 192-6, 1998). In hematopoietic tissues, the expression of Flt3 is restricted to the CD34-positive progenitors. Flt3 was used to identify and subsequently clone the corresponding ligand, Flt3-ligand (Lyman, SD *et al.*, *Cell* 75: 1157-67, 1993; Hannum, C *et al.*, *Nature* 368: 643-8, 1994). The predominant form of Flt3-ligand is synthesized as a transmembrane protein from which the functionally similar soluble ECD is generated by proteolytic cleavage (Lyman *et al.*, *supra*). These proteins bind to and activating unique tyrosine kinase receptors. Among hematopoietic cells, expression of the Flt3 receptor is primarily restricted to the most primitive progenitor cells, including DC precursors. The ECD of Flt3-ligand generated strong anti-tumor effects against several murine model tumors including fibrosarcoma, breast cancer, liver cancer, lung cancer, melanoma and lymphoma (Lynch, DH *et al.*, *Nat Med.* 3: 625-631, 1997; Chen, K *et al.*, *Cancer Res.* 57: 3511-3516, 1997; Braun, SE *et al.*, *Hum Gene Ther.* 10: 2141-2151, 1999; Peron, JM *et al.*, *J Immunol.* 161: 6164-6170, 1998; Chakravarty, PK *et al.*, *Cancer Res.* 59: 6028-6032, 1999; Esche, C *et al.*, *Cancer Res.* 58: 380-

383, 1998.) (19). The present inventors' colleagues linked DNA encoding HPV E6/7 protein to DNA encoding Flt3-ligand ECD. Immunization with this construct dramatically increased expansion and activation of E7 antigen-specific CD8⁺ T cells, resulting in potent anti-tumor immunity against established E7-expressing metastatic tumors.

5 The HSV-1 protein VP22 is a prototype protein that contributes, among other things, to enhanced spread of antigen due to its remarkable property of intercellular transport (Elliott, G., and P. O'Hare. 1997. *Cell* 88:223-33) can be used. For example, VP22 linked to p53 (Phelan, A. et al., 1998, *Nat Biotechnol* 16:440-443) or thymidine kinase (Dilber, MS et al., 1999, *Gene Ther* 6:12-21), facilitated the spread of linked protein to surrounding cells *in vitro* and the treatment of model tumors. VP22 linked to HPV-16 E7 antigen in the context of a DNA vaccine led to a dramatic increase in the number of E7-specific CD8⁺ T cell precursors in vaccinated mice (around 50-fold) and converted a less effective DNA vaccine into one with significant potency against E7-expressing tumors. An non-spreading VP22 mutant failed to enhance vaccine potency. VP22 and proteins that may have a similar mode of action, contribute in several ways 0 to enhanced vaccine potency: (1) facilitate spreading of antigen from transfected cells to surrounding APCs, thereby increasing the number of APCs that present antigen through MHC class I pathway; (2) present antigen more efficiently in transfected cells (3) carryout "cross-priming" whereby release of a VP22/antigen fusion protein leads to uptake and processing by DCs (or other APCs) for presentation via the MHC-I restricted pathway (Huang, A.Y et al., 1994, *Science* 264:961-965)

) Those skilled in the art will know how to identify appropriate epitopes, e.g., CTL epitopes, of the relevant proteins from the pathogens for use in accordance with this invention.

DELIVERY OF B7-DC DNA TO CELLS AND ANIMALS

DNA delivery, for example to effect what is generally known as "gene therapy" involves 5 introduction of a "foreign" DNA into a cell and ultimately, into a live animal. Several general strategies for gene therapy have been studied and have been reviewed extensively (Yang, N-S., *Crit. Rev. Biotechnol.* 12:335-356 (1992); Anderson, W.F., *Science* 256:808-813 (1992); Miller, A.S., *Nature* 357:455-460 (1992); Crystal, R.G., *Amer. J. Med.* 92(suppl 6A):44S-52S (1992); Zwiebel, J.A. et al., *Ann. N.Y. Acad. Sci.* 618:394-404 (1991); McLachlin, J.R. et al., *Prog. Nucl. Acid Res. Molec. Biol.* 38:91-135 (1990); Kohn, D.B. et al., *Cancer Invest.* 7:179-192 0 (1989), which references are herein incorporated by reference in their entirety).

One approach comprises nucleic acid transfer into primary cells in culture followed by autologous transplantation of the *ex vivo* transformed cells into the host, either systemically or into a particular organ or tissue.

For accomplishing the objectives of the present invention, nucleic acid therapy would be
5 accomplished by direct transfer of a the functionally active DNA into mammalian somatic tissue or organ *in vivo*. DNA transfer can be achieved using a number of approaches described below. These systems can be tested for successful expression *in vitro* by use of a selectable marker (e.g., G418 resistance) to select transfected clones expressing the DNA, followed by detection of the presence of the B7-DC expression product (after treatment with the inducer in the case of
0 an inducible system) using an antibody to the product in an appropriate immunoassay. Efficiency of the procedure, including DNA uptake, plasmid integration and stability of integrated plasmids, can be improved by linearizing the plasmid DNA using known methods, and co-transfection using high molecular weight mammalian DNA as a "carrier".

Examples of successful "gene transfer" reported in the art include: (a) direct injection of
5 plasmid DNA into mouse muscle tissues, which led to expression of marker genes for an indefinite period of time (Wolff, J.A. *et al.*, *Science* 247:1465 (1990); Acsadi, G. *et al.*, *The New Biologist* 3:71 (1991)); (b) retroviral vectors are effective for *in vivo* and *in situ* infection of blood vessel tissues; (c) portal vein injection and direct injection of retrovirus preparations into liver effected gene transfer and expression *in vivo* (Horzaglou, M. *et al.*, *J. Biol. Chem.*
0 265:17285 (1990); Koleko, M. *et al.*, *Human Gene Therapy* 2:27 (1991); Ferry, N. *et al.*, *Proc. Natl. Acad. Sci. USA* 88:8387 (1991)); (d) intratracheal infusion of recombinant adenovirus into lung tissues was effective for *in vivo* transfer and prolonged expression of foreign genes in lung respiratory epithelium (Rosenfeld, M.A. *et al.*, *Science* 252:431 (1991)); (e) Herpes simplex virus vectors achieved *in vivo* gene transfer into brain tissue (Ahmad, F. *et al.*, eds, *Miami Short Reports - Advances in Gene Technology: The Molecular Biology of Human Genetic Disease*, Vol 1, Boerringer Manneheim Biochemicals, USA, 1991).

Retroviral-mediated human therapy utilizes amphotrophic, replication-deficient retrovirus systems (Temin, H.M., *Human Gene Therapy* 1:111 (1990); Temin *et al.*, U.S. Patent 4,980,289; Temin *et al.*, U.S. Patent 4,650,764; Temin *et al.*, U.S. Patent No. 5,124,263; Wills,
0 J.W. U.S. Patent 5,175,099; Miller, A.D., U.S. Patent No. 4,861,719). Such vectors have been used to introduce functional DNA into human cells or tissues, for example, the adenosine deaminase gene into lymphocytes, the NPT-II gene and the gene for tumor necrosis factor into

tumor infiltrating lymphocytes. Retrovirus-mediated gene delivery generally requires target cell proliferation for gene transfer (Miller, D.G. *et al.*, *Mol. Cell. Biol.* 10:4239 (1990). This condition is met by certain of the preferred target cells into which the present DNA molecules are to be introduced, *i.e.*, actively growing tumor cells. Gene therapy of cystic fibrosis using transfection by plasmids using any of a number of methods and by retroviral vectors has been described by Collins *et al.*, U.S. Patent 5,240,846.

The DNA molecules encoding the B7-DC sequences may be packaged into retrovirus vectors using packaging cell lines that produce replication-defective retroviruses, as is well-known in the art (see, for example, Cone, R.D. *et al.*, *Proc. Natl. Acad. Sci. USA* 81:6349-6353 (1984); Mann, R.F. *et al.*, *Cell* 33:153-159 (1983); Miller, A.D. *et al.*, *Molec. Cell. Biol.* 5:431-437 (1985); Sorge, J., *et al.*, *Molec. Cell. Biol.* 4:1730-1737 (1984); Hock, R.A. *et al.*, *Nature* 320:257 (1986); Miller, A.D. *et al.*, *Molec. Cell. Biol.* 6:2895-2902 (1986). Newer packaging cell lines which are efficient and safe for gene transfer have also been described (Bank *et al.*, U.S. 5,278,056).

This approach can be utilized in a site specific manner to deliver the retroviral vector to the tissue or organ of choice. Thus, for example, a catheter delivery system can be used (Nabel, EG *et al.*, *Science* 244:1342 (1989)). Such methods, using either a retroviral vector or a liposome vector, are particularly useful to deliver the nucleic acid to be expressed to a blood vessel wall, or into the blood circulation of a tumor.

Other virus vectors may also be used, including recombinant adenoviruses (Horowitz, M.S., In: *Virology*, Fields, BN *et al.*, eds, Raven Press, New York, 1990, p. 1679; Berkner, K.L., *Biotechniques* 6:616 9191988), Strauss, S.E., In: *The Adenoviruses*, Ginsberg, HS, ed., Plenum Press, New York, 1984, chapter 11), herpes simplex virus (HSV) for neuron-specific delivery and persistence. Advantages of adenovirus vectors for human gene therapy include the fact that recombination is rare, no human malignancies are known to be associated with such viruses, the adenovirus genome is double stranded DNA which can be manipulated to accept foreign genes of up to 7.5 kb in size, and live adenovirus is a safe human vaccine organisms. Adeno-associated virus is also useful for human therapy (Samulski, R.J. *et al.*, *EMBO J.* 10:3941 (1991) according to the present invention.

Another vector which can express the DNA molecule of the present invention, and is useful in the present therapeutic setting, particularly in humans, is vaccinia virus, which can be rendered non-replicating (U.S. Patents 5,225,336; 5,204,243; 5,155,020; 4,769,330; Sutter, G *et*

al., *Proc. Natl. Acad. Sci. USA* (1992) 89:10847-10851; Fuerst, T.R. et al., *Proc. Natl. Acad. Sci. USA* (1989) 86:2549-2553; Falkner F.G. et al.; *Nucl. Acids Res* (1987) 15:7192; Chakrabarti, S et al., *Molec. Cell. Biol.* (1985) 5:3403-3409). Descriptions of recombinant vaccinia viruses and other viruses containing heterologous DNA and their uses in immunization and DNA therapy are reviewed in: Moss, B., *Curr. Opin. Genet. Dev.* (1993) 3:86-90; Moss, B. *Biotechnology* (1992) 20: 345-362; Moss, B., *Curr Top Microbiol Immunol* (1992) 158:25-38; Moss, B., *Science* (1991) 252:1662-1667; Piccini, A et al., *Adv. Virus Res.* (1988) 34:43-64; Moss, B. et al., *Gene Amplif Anal* (1983) 3:201-213.

In addition to naked DNA or RNA, or viral vectors, engineered bacteria may be used as vectors. A number of bacterial strains including *Salmonella*, BCG and *Listeria monocytogenes*(LM) (Hoiseth & Stocker, *Nature* 291, 238-239 (1981); Poirier, TP et al. *J. Exp. Med.* 168, 25-32 (1988); (Sadoff, J.C., et al., *Science* 240, 336-338 (1988); Stover, C.K., et al., *Nature* 351, 456-460 (1991); Aldovini, A. et al., *Nature* 351, 479-482 (1991); Schafer, R., et al., *J. Immunol.* 149, 53-59 (1992); Ikonomidis, G. et al., *J. Exp. Med.* 180, 2209-2218 (1994)). These organisms display two promising characteristics for use as vaccine vectors: (1) enteric routes of infection, providing the possibility of oral vaccine delivery; and (2) infection of monocytes/macrophages thereby targeting antigens to professional APCs.

In addition to virus-mediated gene transfer *in vivo*, physical means well-known in the art can be used for direct transfer of DNA, including administration of plasmid DNA (Wolff et al., 1990, *supra*) and particle-bombardment mediated gene transfer (Yang, N.-S., et al., *Proc. Natl. Acad. Sci. USA* 87:9568 (1990); Williams, R.S. et al., *Proc. Natl. Acad. Sci. USA* 88:2726 (1991); Zelenin, A.V. et al., *FEBS Lett.* 280:94 (1991); Zelenin, A.V. et al., *FEBS Lett.* 244:65 (1989); Johnston, S.A. et al., *In Vitro Cell. Dev. Biol.* 27:11 (1991)). Furthermore, electroporation, a well-known means to transfer genes into cell *in vitro*, can be used to transfer DNA molecules according to the present invention to tissues *in vivo* (Titomirov, A.V. et al., *Biochim. Biophys. Acta* 1088:131 ((1991)).

“Carrier mediated gene transfer” has also been described (Wu, C.H. et al., *J. Biol. Chem.* 264:16985 (1989); Wu, G.Y. et al., *J. Biol. Chem.* 263:14621 (1988); Soriano, P. et al., *Proc. Natl. Acad. Sci. USA* 80:7128 (1983); Wang, C-Y. et al., *Proc. Natl. Acad. Sci. USA* 84:7851 (1982); Wilson, J.M. et al., *J. Biol. Chem.* 267:963 (1992)). Preferred carriers are targeted liposomes (Nicolau, C. et al., *Proc. Natl. Acad. Sci. USA* 80:1068 (1983); Soriano et al., *supra*) such as immunoliposomes, which can incorporate acylated mAbs into the lipid bilayer (Wang et

al., supra). Polycations such as asialoglycoprotein/polylysine (Wu *et al.*, 1989, *supra*) may be used, where the conjugate includes a molecule which recognizes the target tissue (e.g., asialoorosomucoid for liver) and a DNA binding compound to bind to the DNA to be transfected. Polylysine is an example of a DNA binding molecule which binds DNA without damaging it. This conjugate is then complexed with plasmid DNA according to the present invention for transfer.

Plasmid DNA used for transfection or microinjection may be prepared using methods well-known in the art, for example using the Quiagen procedure (Quiagen), followed by DNA purification using known methods, such as the methods exemplified herein.

Again, as noted above, for the utility of transduced B7-DC molecules according to this invention may not require stable expression. Rather, transient expression of the polypeptide may be sufficient for transduced cells to perform their immunogenic and/or costimulatory function.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

EXAMPLE I

Materials and Methods

Cell Preparation and Culture

6-12 week old female BALB/c mice were purchased from NCI and used for DC and macrophage preparation.

Bone marrow-derived DCs were cultured in RPMI1640 (Gibco BRL) medium supplemented with 5% fetal calf serum (FCS) (Hyclone), Penicillin/Streptomycin (JRH Biosciences), Gentamycin (Sigma), Nonessential amino acids (JRH Biosciences), L-Glutamate (JRH Biosciences), Sodium Pyruvate (Sigma), 2 mercaptoethanol (Sigma) and 1000 units/ml recombinant murine GM-CSF (Immunex) as previously described(26). Day 8 bone marrow-derived DCs were stained with monoclonal antibodies by conventional methods. Monoclonal antibody against MHC class II, 14-4-4s, was purified from hybridoma supernatant. Dr. William Baldwin, Johns Hopkins University, kindly supplied CTLA4-Ig fusion molecule. Antibodies for MHC class I (28-14-8), F4/80 (C1.A3-1), B7.1 (1G10), B7.2 (GL1), Fc γ RII/III (2.4G2) and

Mac-1 (M1/70) were purchased from PharMingen. For tester cDNA preparation, day 8 cells were purified by cell sorter using 14-4-4s and CTLA4-Ig at the Johns Hopkins University Oncology Center. The purity of MHC class II^{hi} and B7^{hi} population after sorting was 93-98%.

5 Bone marrow-derived macrophages were cultured with RPMI-1640 medium supplemented with 10% FCS, Penicillin/Streptomycin, non-essential amino acids, sodium pyruvate, L glutamine, 2-mercaptoethanol and 250 units/ml recombinant murine M-CSF, and they were treated with 500 units/ml γ -IFN (Pharmingen) and 5 μ g/ml LPS (Sigma) as previously described (27). After stimulation, cell surface expression of MHC class II and B7 were confirmed using flow cytometric analysis on day 10 of culture.

0 Macrophage cell lines WEHI-3, RAW264.7, J774.A.1, PU5-1.8 were kindly provided by Dr. Joshua Farber of the NIAID, National Institutes of Health. They were cultured with ATCC recommended medium.

Allogeneic Mixed Lymphocyte Reaction

5 Day 8 BM-derived DCs characterized as MHC class II^{hi} and B7^{hi} were tested for their ability to stimulate allogeneic T cells in MLC. MLC reactions were performed in 96 well flat bottom microplates by adding increasing number of BALB/c stimulator cells s to 3×10^5 allogeneic C57BL/6 lymphocytes. After 3 days of culture, T cell proliferation was assessed by addition of 1 μ Ci of [³H]-methyl-thymidine (Amersham) to each well for the final 18h of culture. Cells were then harvested, and incorporation of radioactivity was determined using a β counter (Packard 96).

cDNA subtractive hybridization

0 Total RNA from sorted DCs and activated macrophages was extracted with TRIZOL (Gibco BRL). Messenger RNA was purified by Oligotex mRNA purification kit (Qiagen). We used the PCR based SMART cDNA synthesis system (Clonetech) to amplify cDNA followed by the PCR based subtraction system PCR Select (Clonetech). Subtraction was performed following the manufacturer's protocol. After final subtractive PCR, DNA fragments were ligated into plasmid vectors pCR2.1 (Invitrogen) or pCR Blunt (Invitrogen). After transformation, each clone was grown for plasmid DNA amplification and miniprep DNA and then digested with EcoRI to confirm the presence of inserts. Plasmid dot blot was then performed to confirm that the cDNA cloned is dendritic cell specific. Alkaline denatured miniprep DNAs were spotted on Hybond N+ membrane (Amersham) and hybridized with SMART cDNA probe-derived from

sorted DCs or activated macrophages. These cDNA probes were ^{32}P labeled using random primer labeling method (Stratagene Prime-It II). Hybridizations and washing were done as previously described(28). Membranes were exposed to a film (Amersham) for 1-2 days and developed.

5 Plasmid Dot Blot Analysis

Alkaline denatured miniprep DNA samples were spotted on Hybond N+ membrane (Amersham) and hybridized with SMART® cDNA probe-derived from sorted DCs or activated macrophages. These cDNA probes were ^{32}P labeled using a random primer labeling method (Stratagene Prime-It II). Hybridizations and washing were done as previously described 0 [cites??]. For autoradiography, membranes were exposed to a film (Amersham) for 1-2 days and developed.

cDNA library construction and screening - Cloning of B7-DC

Bone marrow-derived DCs were harvested on day 8 without sorting. About 20% to 40% of these cells expressed high MHC class II and B7. Total RNA extraction followed by poly A RNA 5 purification was done as described above. For oligo dT primed DC library construction, we used Lambda ZAP Express cDNA synthesis system (Stratagene). The PCR DNA fragment of B7-DC was probed and used for screening. Membrane transfer, denaturation, renaturation, were performed using Stratagene's protocol. Radiolabeling of probes, hybridization, washing, and autoradiography were done as described above. Positive clones were isolated and 2nd screening 0 was performed. After 2nd screening, plasmids were excised by *in vivo* excision and tested by dot blotting and sequencing. Sequencing was done by the Core Facility at the Johns Hopkins University School of Medicine. BLAST program was used to do homology search of the nucleotide sequence against Genbank (NCBI) for similarity to previously reported genes. The full length B7-DC cDNA clone was pulled out from the DC cDNA library. 5' RACE was 5 performed suing SMART RACE cDNA amplification kit (Clontech). 5'-RACE products were cloned into pCR2.1 vector and sequenced. Two more full length B7-DC clones were obtained by RT-PCR and their sequence were compared to avoid sequence error.

Human B7-DC was cloned as follows: human DCs were obtained from normal peripheral blood mononuclear cells by culture in either GM-CSF + IL-4 or GM-CSF + Flt-3L as described 0 previously(29). RNA was extracted as described above. A BLAST search identified an overlapping EST clone, GenBank accession number AK001879, with homology to mouse B7-

DC. 5' RACE was performed as described above. We sequenced a 5'-RACE PCR fragment and designed a primer corresponding to 5'-UTR of human B7DC. The following primers in the 5'-UTR and 3'-UTR of B7-DC was used to amplify full-length human B7-DC:

5 5'-GGAGCTACTGCATGTTGATTGTTTG-3' [SEQ ID NO:6] and
5'-TGCAAACTGAGGCAC TGAAAAGTC-3' [SEQ ID NO:7]

The full length cDNA sequences of the human and murine B7-DC cDNAs have been deposited with EMBL/GenBank/DDBS under accession number AF329193 and AF142780.

BAC (129SVJ) library screening /Genomic cloning and mapping

0 BAC library screening, followed manufacturer's protocol (Genome Systems, Inc.) Primers used:

5 5'-TTGTTGTCTCCTTCTGTCTCCCAAC-3' [SEQ ID NO:8]and
5'-ACAGTTGCTCCTTGTATCAGGTT-3' [SEQ ID NO:9]

5 BAC library screening obtained 3 positive clones. Chromosome location mapping was done by fluorescence in situ hybridization (Genome Systems Inc.). A total of 80 metaphase cells were analyzed with 79 exhibiting specific labeling. The human B7-DC mapping was done by using available bioinformatic tools, NCBI's BLAST program and the International RH Mapping Consortium. The hB7-DC sequence was searched in htsg and was found to map to two BAC clones RP11-574F11 (AL162253) and Rp11-635N21 (AL354744) localizing on chromosome 9.

Virtual Northern Blotting

0 4-6 weeks old female Balb/c mice were purchased from NCI and used for tissue RNA preparation. RNA extraction and SMART cDNA synthesis for tissues, sorted DCs and activated macrophages were performed as described above. SMART PCR cDNAs were purified by PCR purification kit (Qiagen). 0.5 µg/lane purified DNAs were run on a 1% agarose gel and transferred on a Nytran nylon membrane (Schleier and Schuell). To make radioactive probes, we amplified subtracted library derived plasmid DNAs as templates. We amplified DNA by PCR using primer sets just adjacent to the cloning site of plasmid DNA and used purified PCR DNA of each of the clones for hybridization probes. The nucleotide sequences of these primers are as follows.

5 5'-GTAACGGCCGCCAGTGTGCTG-3' [SEQ ID NO:10] and
5'-CGCCAGTGTGATGGATATCTGCA-3' [SEQ ID NO:11]

Virtual Northern analysis of total RNA of human DCs and control placenta was also performed. The probes used and RNA preparation were described above. Radiolabeling of probes, hybridization, washing and autoradiography were done as described above.

Hamster anti-mB7-DC Ab production

5 Stable transfectants of B7-DC in DC2.4, RAW246.7 and RENCA cell lines were used to immunize Armenian Hamsters. The B7-DC was cloned into the modified pCAGGS vector (30). The hamsters were boosted three times with plasmids containing B7-DC (Rockland). The anti-B7-DC antibody used in this study was from one the sera of one of the three hamsters immunized.

CD28-Ig, CTLA4-Ig and PD-1-Ig binding assay

293T cells were transfected with B7.1-pCAGGS, B7-DC-pCAGG, PD-1-pCAGGS or vector alone using Lipofectamine 2000 (Gibco BRL). After 24hrs, cells were resuspended in FACS buffer (1x HBSS, 2% calf serum, 10mM HEPES and 0.1% NaN₃) and spun at 1000 rpm for 5 min at 4°C. The buffer was then decanted, antibody added to the tubes, incubated at 4°C 5 for 20 min, washed 2X with FACS buffer, and repeated this for secondary antibody. The samples were run on FACScan. B7.1 antibody was used 1:5 dilution, 10 µl / sample (Cal-Tag). Recombinant CD28-Ig, CTLA-4-Ig and PD-1-Ig chimeras were used at 2 µg/ml, 10µl/sample (R&D System, Inc). Goat F(ab')₂ anti-human IgG-PE was used at 1:20 dilution (Southern Biotechnology Associates, Inc.).

B7-DC-Ig Dimer Synthesis

The B7-DC-Ig construct was made by fusing the sequence encoding the N-terminal amino acids of B7-DC without the transmembrane domain in-frame to the sequence encoding the C-terminal amino acids of the human IgG₁ Fc in the pIg-Tail Plus vector(R &D systems). COS-7 cells were transiently transfected with pIg/B7-DC using LipofectAMINE 2000(GIBCO BRL) or 5 GINE JAMMER(Stratagene). The B7-DC-Ig fusion protein was purified from the serum-free supernatants using the saturated ammonium sulfate precipitation. SDS-PAGE and silver staining demonstrated a purity >90%.

T cell Proliferation and Cytokine Assays

For costimulation assays with anti-CD3, 96 well flat bottom plates (Immulon 4 from 0 Dynex) were precoated with anti-CD3 antibodies (2C11, Pharmingen) and B7.1-Ig (R&D

System), B7-DC-Ig or Isotype control (Sigma) at 100 ng/ml were diluted in 1X PBS (Gibco) pH 7.4 for two hours at 37°C. The plates were then washed 3X with 1X PBS and blocked with RPMI1640 medium supplemented with 10% FCS, Penicillin/Streptomycin, non-essential amino acids, sodium pyruvate, L glutamine, 2-mercaptoethanol for one half hour before adding T cells.

5 Spleens and lymph nodes were obtained from 6-10 weeks old BALB/c mice. RBCs were lysed using ACK buffer and T cells were purified using dynabeads M-280 (Dynex), with the indirect method. The beads were washed 2X with PBS pH 7.4 + 1% FCS before adding the cells and an antibody cocktail composed of anti-IE^d and B220/CD45RO or CD8α (Pharmingen) was added to the cells and incubated at 4°C with bi-directional mixing for 30'. The cells were isolated by

0 placing the tube in a Dynal MPC for 5', centrifuged at 1500rpm for 5' and washed 2X with PBS pH 7.4 + 1% FCS to remove unbound Abs. The same procedure was repeated with 15' incubation, and the cells plated at 2×10^5 cells/well. After 72h of incubation, 10 µl of ³H-thymidine (1 µCi/well) was added to each well and incubated for 18hrs. Cells were harvested with a Packard Micromate Cell Harvester, and filters were read on a Packard Matrix 96 direct β counter.

For costimulation assays using the RENCA system to present HA antigen, RENCA cells were cultured with RPMI-1640 medium supplemented with 10% FCS, Penicillin/Streptomycin, non-essential amino acids, sodium pyruvate. It was induced with IFN-γ (75U/ml) for 72 hours for MHC class II expression. They were then irradiated for 13,200 Rad. and plated at 2×10^4 cells/well (96 well flat bottom plates). HA110-120 peptide was then added at 2.5ug/well and various concentrations of the Ig-fusion molecules were added. Transgenic I-E^d + HA specific T cells (kind gift of H. von Boehmer, Harvard University) were isolated as described above and plated at 4×10^5 cells/well. After 48hr of incubation, 10 µl of ³H thymidine (1µCi/well) was added to each well and incubated for 18hrs. Cells were harvested with a Packard Micromate Cell Harvester and filters were read on a Packard Matrix 96 Direct β counter.

For analysis of cytokine production by ELISA, cultures were set up as described above and supernatants were harvested at the indicated times. IL-2, IL-10 and IFN-γ concentrations were determined using commercially available ELISA kits (Endogen), and IL-4 and IL-6 (R&D System).

In Vivo Costimulation

Pooled axillary, inguinal, cervical, and mesenteric LNs from the TCR transgenic mouse line 6.5 that expresses a TCR recognizing an I-E^d restricted HA epitope (¹¹⁰SFERFEIFPKE¹²⁰ [SEQ ID NO:12]) on a B10.D2 genetic background were dissociated in RPMI media (GIBCO

5 BRL), passed over 100µm nylon cell strainer, and washed in sterile Hank's buffer (GIBCO BRL). After FACS® staining to determine the proportion of clonotypic CD4 cells, a cell preparation containing 2.5×10^6 clonotypic cells in 0.2ml sterile Hank's buffer was injected intravenously (i.v.) into the tail vein of recipient B10.D2 mice. Three days after this adoptive transfer, the animals were vaccinated via subcutaneous (s.c.) injection into the hind footpads.

0 Each mouse received bilateral injections of one of three preparations:

(A) 10µg synthetic HA (per footpad) (HA peptide (110-120) combined in a 1:1 v/v ratio with incomplete Freund's Adjuvant (IFA) (Sigma),

(B) the HA -IFA mixture with 25µg of B7-DC-Ig, or

(C) the HA -IFA mixture with 25µg of an isotype control antibody. 7 days later, draining LNs

5 nodes were harvested; 1.5×10^5 LN cells were incubated in round-bottom 96-well tissue culture plates with the indicated concentration of synthetic HA peptide. Proliferation assays were performed by pulsing 48 h cultures with 1 µCi [³H]thymidine and incubating an additional 12 h before harvest and determination of the amount of incorporated radioactivity.

EXAMPLE II

Identification and Characterization Of B7-DC

B7-DC was isolated from a subtracted library between DCs and activated macrophages. The two populations used for cDNA subtraction were bone marrow-derived GM-CSF cultured DCs as the "tester" population and γ-interferon + LPS activated adherent bone marrow-derived

5 M-CSF macrophages as the "driver" population. Day 8 MHC class II^{hi}B7^{hi} "mature" DCs were sorted to >93% purity as the source of tester cDNA. DCs were characterized by flow cytometry as having roughly 50 fold higher MHC class II levels than macrophages. Both populations expressed B7.1 and B7.2 although B7.2 levels were significantly higher in the DCs. F4/80 and CD16 were expressed at higher levels on the macrophage population. Functional comparison of
0 the two populations demonstrated that the DC population was roughly 100 fold more potent than the macrophage population in stimulating an allogeneic mixed lymphocyte reaction.

After RNA extraction from both populations, we used a PCR based cDNA synthesis system followed by the PCR based subtraction procedure, PCR Select. One of the differentially expressed clones encoded a novel immunoglobulin supergene family member, which we name B7-DC. The murine B7-DC cDNA is ~ 1.7kb in length encoding a 247 amino acid (aa) precursor protein with a 23 aa N-terminal signal peptide and a predicted molecular weight of ~ 25kd (Table 1). The putative leader sequence and transmembrane domain were identified using the SOSUI program(31). Two charged aa are found within the 23 aa transmembrane domain of mB7-DC, suggesting a possible binding partner. At the aa level, murine B7-DC is 70% identical to the human B7-DC indicating that they are orthologues (See Tables below). The hB7-DC differs slightly from the murine B7-DC in that it has a longer cytoplasmic tail.

Through a homology search, it was found that B7-DC has significant homology to B7-H1 (34% identity, 48% similarity) (Table 2), to a lesser extent butyrophilin (30% identity, 45% similarity), and <20% identity to B7.1 and B7.2 (Table 3). Phylogenetic studies indicate that butyrophilin is likely related to the B7 family through exon shuffling(32, 33). They each possess the canonical IgV-IgC structure and a transmembrane domain. In contrast to the other B7 family members, murine B7-DC has an extremely short cytoplasmic tail (4 aa).

TABLE 1

Amino acid sequence comparison of murine B7-DC and human B7-DC. The mB7-DC putative leader and transmembrane domain are overlined. The alignment was done using Clustalw-Gonnet Pam250 matrix. The [*] indicates identical amino acids and [:] shows conservative substitutions. Cysteine residues that may be important in the formation of disulfide bonds inside the immunoglobulin V or C domains are italicized..

		<i>Putative leader sequence</i>
0	mB7-DC	MLLLLPILNLSLQLHPVAALFTVTAPKEVYTVDVGSSVSLECDFDRRECTELEGIRASLQ
	hB7-DC	MIFLLLMLSLQLHQIAALFTVTVPKELYIIIEHGSNTLECNFDTGSHVNLAITASLQ *:*** :*.*.**** :*****.***: * : **.*:***:*** . .: * . * ****
5	mB7-DC	KVENDTSLQSERATLLEEQLPLGKALFHIPSVQRDSGQYRCLVICGAAWDYKYLTVKVK
	hB7-DC	KVENDTSPHRERATLLEEQLPLGKASFHIPQVQRDECGQYQCIIIYGVAWDYKYLTLKVK ***** : *****.***** ***.*****.***: *;: * . *****:***
0	mB7-DC	ASYMRIDTRILEVPGTGEVQLTCQARGYPLAEVSWQNVSVPANTSHIRTPEGLYQVTSVL
	hB7-DC	ASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVL *** :*;:***:*** *.*:***** *****.***** ***:***** *****.*****
5	mB7-DC	RLKPQPSRNFSMFWNAHMKELTSAIIDPLSRMEPKVPRTWPLHVFIPACTIALIFLAIV
	hB7-DC	RLKPPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHPTWLLHIFIPSCIIAFIFIATV **** *.*.*****:***:***:*** * * * :***: . ** *;***: * ***:***:*
5	mB7-DC	<i>IIQRKRI-----</i>
	hB7-DC	<i>IALRKQLCQKLYSSKDTTKRPVTTTKREVNSAI</i> * ***:

TABLE 2

Amino acid sequence comparison of mB7-DC and mB7-H1.

0	mB7-DC	MLLLLPILNLSLQLHPVAALFTVTAPKEVYTVDVGSSVSLECDFDRRECTELEGIRASLQ
	mB7-H1	-MRIFAGIIFTACCH-LLRAFTITAPKDLYVVEYGSNTMCRFPVERELDLLALVVYWE : : . : : * : - *:*****:*. : **.*:*** * .. :* .. : . :
5	mB7-DC	K-----VENDTSLQSE---RATLLEEQLPLGKALFHIPSVQRDSGQYRCLVIC
	mB7-H1	KEDEQVIQFVAGEEIDLKPQHSNFRGRASLPKDQLKGNAALQITDVKLQDAGVYCCIISY * :* . * . ***: :*** * :* : :* .. :* :* :* :* :* :* :* :
0	mB7-DC	GAAWDYKYLTVKVKASYMRIDTRILEVPGTGEVQLTCQARGYPLAEVSWQN----VSVP
	mB7-H1	GGA-DYKRITLKVNAPYRKINQRISVDPATSEHELICQAEGYPEAEVIWTNSDHQPVSGK *.* *** :*;***:*. :* : ** * . * :* ***.*** *** * * **
5	mB7-DC	ANTSHIRTPEGLYQVTSVRLKPQPSRNFSMFWNAH--MKELTSAIIDPLSRMEPKVPR
	mB7-H1	RSVTTSRTEGMLLNVTSSSLRVNATANDVFYCTFWRSQPGQNHAAELIPELPATHPPQNR ..: ** * :*** ***: .. * * ***: .. : . :* * . * . *
5	mB7-DC	T-WPLHVFIPACTIALIFLAIVIIQRKRI-----
	mB7-H1	THWVLLGSILLFLIVVSTVLLFLRKQVRMLDVEKCGVEDTSSKNRNDTQFEET * * * * * . : .. : : * :

TABLE 3
Amino acid sequence comparison of B7-DC to the B7 family members.

<u>Reference B7 Protein</u>	<u>Compared to:</u>	<u>% identity¹</u>	<u>% similarity²</u>
mB7-DC	hB7-DC	70	80
	hBT3.1	25	41
mB7-DC	mB7-H1	34	48
	mBT ⁴	30	45
	mB7.1	-	- ³
	mB7.2	-	-
	mB7RP-1/B7h	-	-
MBT	mB7.1	24	48
	mB7.2	24	40
MB7.1	mB7.2	27	45
MB7-H1 ⁵	mB7.1	23	40
	mB7.2	25	49
	mB7RP-1/B7h	24	41
	mBT	24	45

Comparison were done using NCBI blast2 search (matrix BLOSUM62).

1. *Identical amino acids at corresponding positions*
2. *Similar amino acids at corresponding position - grouped as follows: (A, G); (S, T); (E, D); (R, K, H); (Q, N); (V, I, L, M); (Y, F); (W); (C); (P)*
3. *no significant similarity was found using matrix BLOSUM62*
4. *BT=butyrophilin*
5. *=PDL-1*

To determine the genomic structure of mB7-DC, the present inventors isolated a genomic clone by screening a pooled Bacterial Artificial Chromosome (BAC) library using probes from the 5' and 3' UTRs. Chromosome location mapping was performed using the BAC clones. Chromosome localization of B7-DC was done using fluorescent *in situ* hybridization (FISH). Measurements of 10 specifically labeled chromosomes 19 demonstrated that mB7-DC is located at a position which is 47% of the distance from the heterochromatic-euchromatic boundary to the telomere of chromosome 19, an area that corresponds to the interface between bands 19C2 and 19C3. Specific hybridization signals were detected by incubating the hybridized slides in fluoresceinated antidigoxigenin antibodies followed by counter staining with DAPI.

This locus corresponds to a region of human chromosome 9, where hB7-H1 has been mapped.

hB7-DC was found to be located on two chromosome 9 BAC clones. In addition, both hB7-DC and hB7-H1 were found to be located on a single chromosome 9 BAC clone with an insertion size of approximately 164kb (Figure 1). The genomic proximity of B7-DC and B7-H1 is reminiscent of the B7.1/B7.2 pair, which map to within one megabase of each other.

5

EXAMPLE III

B7-DC is selectively expressed in dendritic cells

In order to determine the expression pattern of B7-DC, virtual Northern analysis was performed using RNA extracted from multiple tissues, macrophage cell lines, macrophage cultures and dendritic cells derived from both bone marrow and spleen. While strong hybridization was detected using a B7-DC probe in immature (day 4,6) and mature (day 8 and sorted MHC II^{hi}B7^{hi}) bone marrow derived DC and splenic DC, no signal was detected in any of 4 macrophage cell lines, activated BM macrophages or peritoneal macrophages (Figure 2). Strong expression of hB7-DC was detected in human DCs grown from peripheral blood mononuclear cells with GM-CSF plus either IL-4 or Flt-3L (Figure 3). In order to verify cell surface expression of B7-DC protein, anti-mB7-DC antibodies were used to stain DCs. Staining, blockable with soluble B7-DC-Ig, was observed on DC (Figure 4).

B7-DC does not bind to CD28 or CTLA-4 but does bind to PD-1

Although B7-DC has structural and sequence homology to the B7 family, it does not contain the putative CD28/CTLA-4 binding sequence, SQDXXXELY [SEQ ID NO:13] or XXXYXXRT [SEQ ID NO:14] (34) (where X=any amino acid). To directly assess binding, the ability of dimeric CD28-Ig and CTLA-4-Ig to stain 293T cells transfected with either B7-DC or B7.1 was investigated. Whereas strong binding was observed with B7.1 transfectants, there was no binding to B7-DC transfectants (Figure 5). Based on homology and genomic proximity between B7-DC and B7-H1/PD-L1, experiments were conducted to test PD-1 as a candidate binding partner for B7-DC. Indeed, PD-100IG bound to B7-DC transfectants but not to B7.1 transfectants. The binding of BPD-1-Ig to B7-DC transfectants was lower than that of CTL-4-It and CD28-Ig to B7.1 transfectants, although it was specific. Further confirmation of the binding of PD-1 to B7-DC was obtained from positive staining of stable B7-DC-GFP

transflectants with PD-1-Ig. It was concluded that, as with B7-H1 and B7h/B7RP-1, B7-DC does not use CD28 or CTLA-4 as receptors. Rather, PD-1 appears to be a receptor for B7-DC.

EXAMPLE IV

B7-DC Functions as a Costimulatory Molecule for T Cells

A soluble B7-DC-Ig fusion protein which could be added to T cell stimulation assays was produced for use in testing whether B7-DC possessed costimulatory activity. The proliferative response of T cells was measured to stimulation by increasing amounts of immobilized anti-CD3 in the presence of either B7-DC-Ig, B7.1-Ig or an isotype control. Figure 6 (left) shows that, in the presence of suboptimal anti-CD3 concentration, B7-DC costimulated a greater T cell proliferative response than did B7.1. Furthermore, B7-DC costimulated proliferative responses were higher in CD4 than in CD8 cells (Figure 6, right). B7-DC failed to stimulate T cells in the absence of a TCR-focused stimulus, indicating that B7-DC was providing a true costimulatory signal.

B7-DC also costimulated a proliferative responses when “signal 1” was provided by an MHC-peptide complex. RENCA cells (which express no endogenous B7.1, B7.2 or B7-DC by RT-PCR analysis) were treated with γ -IFN to induce MHC class II expression. These cells were loaded with the I-E^d restricted HA 110-120 peptide (FERFEIFPKE)(35) [SEQ ID NO:15] . Purified splenic T cells from an I-E^d + HA 110-120 specific TCR transgenic mouse line were added and the proliferative response was measured in the presence of either B7-DC-Ig, B7.1-Ig or an isotype control. Figure 7 shows that B7-DC possessed greater costimulatory activity than did B7.1.

Patterns of lymphokine production costimulated by B7-DC

The best characterized T cell responses to costimulation by the B7 family molecules is lymphokine production. These lymphokines are important mediators of T cell effects. Studies were done to analyze production of a number of different lymphokines by T cells that had been stimulated with anti-CD3 or HA antigen (Figure 8) costimulated with either B7-DC-Ig, B7.1-Ig or an isotype control. Patterns of lymphokine costimulation were fairly consistent whether anti-CD3 or an MHC-peptide complex was utilized as “signal 1”. Significantly, B7-DC costimulated greater levels of γ -IFN than did B7.1. B7-DC also costimulated significant amounts of IL-6 production whereas B7.1 costimulated virtually none. While both molecules costimulated IL-2

production, B7.1 did so more efficiently than did B7-DC. Thus, the patterns of costimulation by B7-DC and B7.1 are distinct, with B7-DC being more efficient in costimulating important proinflammatory lymphokines.

5

EXAMPLE V

B7-DC Enhances In Vivo immune Responses

In order to determine whether B7-DC possesses *in vivo* biologic activity, the inventors asked whether B7-DC-Ig enhanced immune responses to peptide vaccines. B7-DC-Ig or an isotype control antibody was added to the immunogenic cocktail of HA 110-120 peptide and IFA. To permit enumeration of HA-specific CD4 T cells *in vivo*, 2.5×10^6 anti-HA 6.5 T cells were transferred into the mice 3 days before immunization. Seven days after immunization, draining LN cells were harvested and the cells stimulated *in vitro* for 2 days with varying amounts of HA110-120 peptide. Figure 9 shows that addition of B7-DC-Ig indeed dramatically enhanced the proliferative response to HA. The total number of HA-specific T cells in draining LN was increased by roughly 2 fold in groups receiving B7-DC-Ig relative to isotype antibody controls.. It was therefore concluded that B7-DC had the ability to enhance antigen-specific responses even on a per cell basis.

5

EXAMPLE VI

Discussion and Conclusions

The present inventors have discovered and characterized a new B7 family member with expression highly restricted to DCs and having unique costimulatory properties for T cells. The human orthologue of B7-DC is also expressed in DCs.

This restricted expression pattern contrasts with the previously described B7 family members, suggesting that B7-DC participates in different immune responses than the known B7.1/2 pathways. While a weak B7-DC signal was detected by RT-PCR in activated macrophages, preliminary realtime RT-PCR analysis indicated that B7-DC mRNA expression in DCs was >15-fold higher than in activated macrophages. Antibody staining likewise detected very low levels of B7-DC on the surface of activated macrophages. It is unclear whether this is sufficient for significant T cell activation.

The unusual pattern of lymphokine production that B7-DC costimulates implies a unique biologic role compared to other B7 family members. The traditional classification of cytokines is as follows: Th1 cytokines include IL-2, γ -IFN and lymphotoxin; Th2 cytokines include IL-4, IL-5, IL-6 and IL-13 (36). B7-DC does not induce either a classic Th1 or Th2 lymphokine profile. B7-DC induces very little IL-4 and no IL-10. However, IL-6 is considered a Th2 cytokine. The lower IL-2 and higher γ -IFN costimulated by B7-DC relative to B7.1 does not conform to a classic Th1 pattern. Nonetheless, the high γ -IFN production suggests that B7-DC evokes important T cell effector function.

B7-DC is noteworthy in its ability to costimulate IL-6. The robust proliferative response of T cells induced by B7-DC is explained in part by its strong costimulation of IL-6 production, which is not observed with B7.1. IL-6 is a potent amplifier of T cell proliferation (in conjunction with other proliferative stimuli) (37, 38). IL-6 is a multifunctional cytokine that regulates not only T cell function but also proinflammatory responses, monocyte differentiation, B cell differentiation, thrombopoiesis, bone resorption, and the growth of certain hematopoietic tumors (39, 40). IL-6 can function in concert with soluble IL6 receptors (sIL-6R) in the induction of chemokines and leukocyte recruitment(41). It can mediate potent antiapoptotic effects via Stat-3 activation. IL-6 dependent Stat-3 activation in T cells has been reported to be an important pathway for the survival of activated T cells (42, 43) although other reports suggest that Stat-3 exerts its effect on resting T cells.

While B7-DC fails to bind CD28 or CTLA-4, it does bind PD-1, a receptor for B7-H1/PD-L1 (22, 47, 48). It has not yet been determined whether it binds ICOS, a receptor for B7h/B7RP-1(23-25, 44-46). The marked homology between B7-DC and B7-H1/PDL-1 (greater than that between B7.1 and B7.2), the close physical linkage of hB7-H1/PD-L1 and hB7-DC and their binding to a common receptor, suggests that they are related by a relatively recent gene duplication event. This is analogous to the relationship between B7.1 and B7.2, which both map to within one megabase on mouse chromosome 16 and on human chromosome 3 (49).

It will be important to discern the relative biologic roles of B7-DC vs B7-H1/PD-L1 as mediated by PD-1 and other putative receptor(s). PD-1 is expressed subsequent to,, and appears to inhibit, T cells activation. PD-1 induces apoptosis under conditions of T cell stimulation with high concentrations of anti-CD3. PD-1 knockout mice develop an autoimmune syndrome (22) characterized by clinical manifestations of hypertrophic cardiomyopathy. In contrast, Dong

et al. (21) reported that B7-H1/PD-L1 co-stimulated T cell proliferation and cytokine release at lower concentrations of anti-CD3. By analogy to the relationship of CD28/CTLA-4, PD-L1 may be a counterreceptor for an as yet unidentified activating receptor. Despite sharing the property of binding to PD-1, B7-DC and B7-H1 are distinct in their lymphokine costimulation patterns; B7-H1 costimulated T cell IL-10 production whereas B7-DC does not. The distinct cellular expression patterns and costimulatory functions of B7-DC suggest a unique role in immune function.

The references cited above and below are all incorporated by reference herein, whether specifically incorporated or not.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

Documents Cited

In addition to documents cited fully in the text, certain documents are cited by number only (parenthetical); the latter are listed below.

1. Hathcock, K.S., G. Laszlo, C. Pucillo, P. Linsley, and R.J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. *J Exp Med* 180, no. 2:631.
2. Razi-Wolf, Z., G.J. Freeman, F. Galvin, B. Benacerraf, L. Nadler, and H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. *Proc Natl Acad Sci USA* 89, no. 9:4210.
3. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol* 9:271.
4. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392, no. 6673:245.
5. Patterson, S. 2000. Flexibility and cooperation among dendritic cells. *Nature Immunol.* 1, no. 4:273.
6. Langenkamp, A., M. Messi, A. Lanzavecchia, and S. Federica. 2000. Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. *Nature Immunol.* 1, no. 4:311.

7. Thompson, C.B., T. Lindsten, J.A. Ledbetter, S.L. Kunkel, H.A. Young, S.G. Emerson, J.M. Leiden, and C.H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. *Proc Natl Acad Sci USA* 86, no. 4:1333.

5 8. Harding, F.A., J.G. McArthur, J.A. Gross, D.H. Raulet, and J.P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. *Nature* 356, no. 6370:607.

0 9. Linsley, P.S., W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, and J.A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. *J Exp Med* 173, no. 3:721.

5 10. Fraser, J.D., B.A. Irving, G.R. Crabtree, and A. Weiss. 1991. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. *Science* 251, no. 4991:313.

0 11. Lindstein, T., C.H. June, J.A. Ledbetter, G. Stella, and C.B. Thompson. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. *Science* 244, no. 4902:339.

5 12. Linsley, P.S., W. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle, and J.A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. *J Exp Med* 174, no. 3:561.

0 13. Waterhouse, P., L.E. Marengere, H.W. Mittrucker, and T.W. Mak. 1996. CTLA-4, a negative regulator of T-lymphocyte activation. *Immunol Rev* 153:183.

5 14. Kuchroo, V.K., M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner, N. Nabavi, and L.H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. *Cell* 80, no. 5:707.

0 15. Lanier, L.L., S. O'Fallon, C. Somoza, J.H. Phillips, P.S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. *J Immunol* 154, no. 1:97.

5 16. Van Parijs, L., M.P. Sethna, A.N. Schweitzer, F. Borriello, A.H. Sharpe, and A.K. Abbas. 1997. Functional consequences of dysregulated B7-1 (CD80) and B7-2 (CD86) expression in B or T lymphocytes of transgenic mice. *J Immunol* 159, no. 11:5336.

0 17. Abbas, A.K., and A.H. Sharpe. 1999. T-cell stimulation: an abundance of B7s [news; comment]. *Nat Med* 5, no. 12:1345.

5 18. Borriello, F., M.P. Sethna, S.D. Boyd, A.N. Schweitzer, E.A. Tivol, D. Jacoby, T.B. Strom, E.M. Simpson, G.J. Freeman, and A.H. Sharpe. 1997. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. *Immunity* 6, no. 3:303.

0 19. Sharpe, A.H. 1995. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. *Curr Opin Immunol* 7, no. 3:389.

5 20. Green, J.M., P.J. Noel, A.I. Sperling, T.L. Walunas, G.S. Gray, J.A. Bluestone, and C.B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. *Immunity* 1, no. 6:501.

0 21. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [see comments]. *Nat Med* 5, no. 12:1365.

5 22. Freeman, G.J., A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. Okazaki, M.C. Byrne, H.F. Horton, L. Fouster, L. Carter, V. Ling, M.R. Bowman, B.M. Carreno, M. Collins, C.R. Wood, and T. Honjo. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 192, no. 7:1027.

0 23. Swallow, M.M., J.J. Wallin, and W.C. Sha. 1999. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. *Immunity* 11, no. 4:423.

5 24. Wang, S., G. Zhu, A.I. Chapoval, H. Dong, K. Tamada, J. Ni, and L. Chen. 2000. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. *Blood* 96, no. 8:2808.

0 25. Yoshinaga, S.K., J.S. Whoriskey, S.D. Khare, U. Sarmiento, J. Guo, T. Horan, G. Shih, M. Zhang, M.A. Coccia, T. Kohno, A. Tafuri-Bladt, D. Brankow, P. Campbell, D. Chang, L. Chiu, T. Dai, G. Duncan, G.S. Elliott, A. Hui, S.M. McCabe, S. Scully, A. Shahinian, C.L. Shaklee, G. Van, T.W. Mak, and et al. 1999. T-cell co-stimulation through B7RP-1 and ICOS. *Nature* 402, no. 6763:827.

5 26. Inaba, K., W.J. Swiggard, R. Steinman, N. Romani, and G. Schuler. 1998. Isolation of dendritic cells. John Wiley & Sons, Inc., New York.

0 27. Fortier, A.H., and L.A. Falk. 1994. Isolation of murine macrophages. John Wiley & Sons, Inc., New York.

28. Orimoto, K., H. Tsuchiya, J. Sakurai, M. Nishizawa, and O. Hino. 1998. Identification of cDNAs induced by the tumor suppressor Tsc2 gene using a conditional expression system in Tsc2 mutant (Eker) rat renal carcinoma cells. *Biochem Biophys Res Commun* 247, no. 3:728.

5 29. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P.O. Fritsch, R.M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. *J Exp Med* 180, no. 1:83.

0 30. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108, no. 2:193.

5 31. Hirolawa, T., S. Boon-Chieng, and S. Mitaku. 1998. SOSUI: Classification and secondary structure prediction system for membrane proteins. *Bioinformatics* 14, no. 4:378.

0 32. Linsley, P.S., R. Peach, P. Gladstone, and J. Bajorath. 1994. Extending the B7 (CD80) gene family. *Protein Sci* 3, no. 8:1341.

5 33. Henry, J., M. Ribouchon, D. Depetris, M. Mattei, C. Offer, R. Tazi-Ahnini, and P. Pontarotti. 1997. Cloning, structural analysis, and mapping of the B30 and B7 multigenic families to the major histocompatibility complex (MHC) and other chromosomal regions. *Immunogenetics* 46, no. 5:383.

0 34. Fargeas, C.A., A. Truneh, M. Reddy, M. Hurle, R. Sweet, and R.P. Sekaly. 1995. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4. *J Exp Med* 182, no. 3:667.

5 35. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. *J Exp Med* 180, no. 1:25.

0 36. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 7:145.

5 37. Suda, T., A. O'Garra, I. MacNeil, M. Fischer, M.W. Bond, and A. Zlotnik. 1990. Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. *Cell Immunol* 129, no. 1:228.

0 38. Suda, T., R. Murray, C. Guidos, and A. Zlotnik. 1990. Growth-promoting activity of IL-1 alpha, IL-6, and tumor necrosis factor-alpha in combination with IL-2, IL-4, or IL-7 on murine thymocytes. Differential effects on CD4/CD8 subsets and on CD3+/CD3- double-negative thymocytes. *J Immunol* 144, no. 8:3039.

5 39. Taga, T., and T. Kishimoto. 1997. Gp130 and the interleukin-6 family of cytokines. *Annu Rev Immunol* 15:797.

0 40. Chomarat, P., J. banchereau, J. Davoust, and A.K. Palucka. 2000. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. *Nature Immunol* 1, no. 6:510.

5 41. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, F. Bussolino, V. Poli, G. Ciliberto, and A. Mantovani. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity* 6, no. 3:315.

0 42. Takeda, K., T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto, and S. Akira. 1998. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. *J Immunol* 161, no. 9:4652.

5 43. Teague, T.K., B.C. Schaefer, D. Hildeman, J. Bender, T. Mitchell, J.W. Kappler, and P. Marrack. 2000. Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. *J Exp Med* 191, no. 6:915.

0 44. Coyle, A.J., S. Lehar, C. Lloyd, J. Tian, T. Delaney, S. Manning, T. Nguyen, T. Burwell, H. Schneider, J.A. Gonzalo, M. Gosselin, L.R. Owen, C.E. Rudd, and J.C. Gutierrez-Ramos. 2000. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. *Immunity* 13, no. 1:95.

5 45. Hutloff, A., A.M. Dittrich, K.C. Beier, B. Eljaschewitsch, R. Kraft, I. Anagnostopoulos, and R.A. Kroczeck. 1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. *Nature* 397, no. 6716:263.

0 46. Yoshinaga, S.K., M. Zhang, J. Pistillo, T. Horan, S.D. Khare, K. Miner, M. Sonnenberg, T. Boone, D. Brankow, T. Dai, J. Delaney, H. Han, A. Hui, T. Kohno, R. Manoukian, J.S. Whoriskey, and M.A. Coccia. 2000. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. *Int Immunol* 12, no. 10:1439.

47. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *Embo J* 11, no. 11:3887.

48. Shinohara, T., M. Taniwaki, Y. Ishida, M. Kawaichi, and T. Honjo. 1994. Structure and chromosomal localization of the human PD-1 gene (PDCD1). *Genomics* 23, no. 3:704.

5 49. Reeves, R.H., D. Patch, A.H. Sharpe, F. Borriello, G.J. Freeman, S. Edelhoff, and C. Distefano. 1997. The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. *Mamm Genome* 8, no. 8:581.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule that encodes a mammalian protein termed B7-DC that is selectively expressed on dendritic cells as compared to activated macrophages.
- 5 2. The nucleic acid molecule of claim 1 that comprises a nucleotide sequence selected from SEQ ID NO:1 or SEQ ID NO:5.
3. An isolated nucleic acid molecule that hybridizes with the nucleic acid molecule of claim 1 or 2 under stringent hybridization conditions.
- 0 4. The nucleic acid molecule of claim 2 that comprises the nucleotide sequence SEQ ID NO:1.
- 5 5. The nucleic acid molecule of any of claims 1-4 that encodes a protein having an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4 or encodes a biologically active fragment, homologue or other functional derivative of said protein.
- 5 6. The nucleic acid molecule of claim 6 that encodes said protein having the sequence SEQ ID NO:2 or encodes said biologically active fragment, homologue or other functional derivative of SEQ ID NO:2.
7. A fragment of the nucleic acid molecule of any of claims 5 or 6 that encodes all or part of the extracellular domain of said B7-DC protein.
- 0 8. The nucleic acid molecule of claim 5 that encodes a B7-DC fusion polypeptide, which molecule comprises:
 - (a) a first nucleic acid sequence encoding a first polypeptide that is all or a part of a B7-DC protein SEQ ID NO: 2 or SEQ ID NO:4;
 - (b) optionally, fused in frame with the first nucleic acid sequence, a linker nucleic acid sequence encoding a linker peptide; and
 - 5 (c) a second nucleic acid sequence that is linked in frame to said first nucleic acid sequence or to said linker nucleic acid sequence and that encodes a second polypeptide.

9. The nucleic acid molecule of claim 8 wherein said second polypeptide consists of one or more domains of an Ig heavy chain constant region.

10. The nucleic acid molecule of claim 11 wherein said second polypeptide consists of two domains of a human IgG constant region.

5 11. An expression vector comprising the nucleic acid of any of claims 1-10 operatively linked to:

- (a) a promoter and
- (b) optionally, additional regulatory sequences that regulate expression of said nucleic acid in a eukaryotic cell.

0 12. The expression vector of claim 11 which is a plasmid.

13. The expression vector of claim 11 which is a viral vector.

14. A vector composition comprising

- (a) a first recombinant expression vector having incorporated in its nucleic acid a nucleotide sequence encoding an antigen of interest against which an immune response is to be induced; and
- (b) a second recombinant expression vector having incorporated in its nucleic acid one or more nucleotide sequences encoding a co-stimulator polypeptide, at least one of which co-stimulator polypeptides is B7-DC, or is a biologically active fragment, homologue or other functional derivative thereof,

5 0 wherein the expression vectors are able to co-infect or co-transfet a host cell resulting in co-expression of the antigen and the costimulator polypeptide, fragment, homologue or derivative.

15. The vector of claim 14 wherein said second vector comprises SEQ ID NO:1 or SEQ ID NO:5.

16. The vector of claim 14 or 15 wherein said second vector comprises SEQ ID NO:1.

5 17. A cell transformed or transfected with the nucleic acid molecule of any of claims 1-

18. A cell transformed or transfected with the expression vector of any of claims
claim 1-16.

19. The cell of claim 19 which is a mammalian cell.
20. The cell of claim 19 which is a human cell.
21. The cell of claim 19 which is a dendritic cell or a progenitor thereof.
22. The cell of claim 19 which is a tumor cell.

5 23. An isolated mammalian tumor cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-DC protein or a biologically active fragment, homologue or other functional derivative thereof, such that when said protein, fragment, homologue or derivative is expressed by said tumor cell, and said tumor cell is contacted with T cells

- (i) said B7-DC protein, fragment, homologue or derivative binds to said T cells; and
- 0 (ii) said tumor cell costimulates said T cells to proliferate and/or to produce and secrete cytokines.

24. The tumor cell of claim 23 wherein said exogenous nucleic acid molecule comprises SEQ ID NO:1, SEQ ID NO:5 or a fragment of said sequence.

5 25. A polypeptide that is selectively expressed on dendritic cells as compared to activated macrophages and has the following functional properties:

- (a) binds to a binding partner on T cells; and
- (b) costimulates T cells to proliferate and/or to produce and secrete cytokines.

26. The polypeptide, fragment, homologue or functional derivative of claim 25 encoded by a nucleic acid molecule having the sequence SEQ ID NO:1 or SEQ ID NO:5, or a fragment, homologue or equivalent of said nucleic acid molecule.

0 27. The polypeptide of claim 26 having the amino acid sequence SEQ ID NO:2 or SEQ ID NO:4, or a fragment, homologue or equivalent of said polypeptide.

5 28. A polypeptide or a biologically active fragment, homologue or other functional derivative of said polypeptide produced by recombinant expression of the nucleic acid of any of claims 1 - 10.

29. The polypeptide of any of claims 25-28 comprising the extracellular domain of the B7-DC protein, which domain comprises amino acid residues 26-221 of SEQ ID NO:2 or SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of said domain.

5 30. The polypeptide of any of claims 25-28 consisting essentially of the extracellular domain of B7-DC which domain includes amino acid residues 26-221 of SEQ ID NO:2 or SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of residues 26-221.

0 31. A B7-DC fusion polypeptide having a first fusion partner comprising all or a part 0 of a B7-DC protein which

- (i) is fused directly to a second polypeptide or,
- (ii) optionally, is fused to a linker peptide sequence that is fused to said second polypeptide.

5 32. A B7-DC fusion polypeptide comprising the polypeptide of any of claims 5 claim 25-30 fused to a second polypeptide.

33. The fusion polypeptide of claim 32, that binds to a binding partner molecule on T cells and co-stimulates said T cells in the presence of an adequate stimulus to the T cell receptor.

34. The fusion polypeptide of claim 33 wherein said binding partner molecule is PD-1.

0 35. The fusion polypeptide of any of claims 31-33 wherein said second polypeptide 0 is one or more domains of an Ig heavy chain constant region.

36. The fusion polypeptide of any of claims 31-35 wherein said first fusion partner comprises amino acids 26-221 of SEQ ID NO:2 or of SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative thereof.

5 37. The fusion polypeptide of claim 36 wherein said first fusion partner comprises amino acids 26-221 of SEQ ID NO:2, or a co-stimulatory fragment, homologue or other functional derivative thereof.

38. The fusion polypeptide of claim 35 wherein said polypeptide has an amino acid sequence corresponding to the hinge, C_H2 and C_H3 regions of a human immunoglobulin Cy1 chain.

39. A dimeric or trimeric fusion polypeptide which is a tandemly linked dimer or 5 trimer of the fusion polypeptide of any of claims 31-38.

40. The fusion polypeptide of any of claims 31 - 38, comprising a linear multimer of two or more repeats of monomers of said first fusion partner linked end to end, directly or with a linker sequences present between said monomer repeats.

41. An antibody that is specific for an epitope of a B7-DC protein, which epitope is 0 not present in a known member of a B7 family protein.

42. The antibody of claim 41 wherein said epitope is a linear or conformational epitope of a polypeptide of SEQ ID NO:2 or SEQ ID NO:4.

43. The antibody of claim 42 wherein said epitope is a linear or conformational epitope of a polypeptide of SEQ ID NO:2.

5 44. The antibody of any of claims 41-42 that is a monoclonal antibody.

45. The antibody of claim 43 that is a human or humanized monoclonal antibody.

46. A method of identifying or quantitating cells expressing a B7-DC polypeptide on their surface in a cell population, comprising

- (a) contacting cells of said population with the antibody of any of claims 41-45, so) that said antibody binds to cells expressing said epitope;
- (b) assessing the presence of, or quantitating the number of, cells to which said antibody is bound.

47. A method of isolating cells expressing a B7-DC polypeptide on their surface from a cell population, comprising

- 5 (a) contacting cells of said population with the antibody of any of claims 41-45, so that said antibody binds to cells expressing said epitope;

(b) positively selecting cells to which said antibody has bound or negatively selecting cells to which said antibody has not bound,
thereby isolating said cells.

48. A method of detecting the presence or quantitating a B7-DC polypeptide, fragment or homologue in a sample, comprising the steps of:

- (a) contacting the sample with the antibody of any of claims 41-45, such that the antibody binds to any polypeptides or fragments bearing said epitope;
- (b) detecting the presence of, or quantitating the polypeptides or fragments bound to said antibody.

49. A method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of said cell to co-stimulate T cells *in vitro* or *in vivo* in the presence of an adequate stimulus to the T cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is induced or increased on said cells.

50. A method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of said cell to co-stimulate T cells *in vitro* or *in vivo* in the presence of an adequate stimulus to the T cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is induced or increased on said cells.

51. The method of claim 49 or 50 wherein said antigen presenting cells are dendritic cells and said progenitors are dendritic cell progenitors.

52. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of cells according to any of claims 17-24, in conjunction with an antigen, wherein said cells are effective to increase the T cell response of said subject to said antigenic stimulation.

53. A method for increasing the T cell response of a mammalian subject to antigenic stimulation with a tumor-associated antigen, comprising administering to said subject an effective amount of tumor cells according to any of claims 22 -24, wherein said tumor cells express said antigen, said administration of said tumor cells being effective to increase the T cell
5 response of said subject to said tumor antigen stimulation.

54. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of a polypeptide, fragment, homologue or functional derivative according to any of claims 25-30 in conjunction with an antigen, wherein the administration of said polypeptide is effective to increase the T cell
0 response of said subject to said antigenic stimulation.

55. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of a fusion polypeptide according to any of claims 31-40, in conjunction with an antigen, wherein the administration of said polypeptide is effective to increase the T cell response of said subject to
5 said antigenic stimulation.

56. A method for inhibiting a T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of an antibody according to any of claims 41-45, wherein the administration of said antibody is effective to block stimulation of T cells or to eliminate antigen-reactive T cells, thereby inhibiting the T cell
0 response.

57. The method of claim 56 wherein said T cell response is directed to a tissue transplant or to an autoantigen such that said method inhibits transplant rejection or an autoimmune reaction.

58. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:

(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;

- (b) contacting said T cells *ex vivo* with an effective amount of cells according to any of claim 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and
- (c) administering said T cells of step (b) to said subject,

5 thereby increasing said immune response of said subject.

59. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:

- (a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
- (b) contacting said T cells *ex vivo* with an effective amount of cells according to any of claims 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and
- (c) administering said T cells of step (b) to said subject,

5 thereby increasing said immune response of said subject.

60. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:

- (a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
- (b) contacting said T cells *ex vivo* with an effective amount of the polypeptide, fragment, homologue or functional derivative of any of claims 25-30, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and
- (c) administering said T cells of step (b) to said subject,

5 thereby increasing said immune response of said subject.

61. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:

- (a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
- (b) contacting said T cells *ex vivo* with an effective amount of a the fusion polypeptide of any of claims 31-40, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and
- (c) administering said T cells of step (b) to said subject,

thereby increasing said immune response of said subject.

5 62. A vaccine composition useful for inducing a protective immune response against
0 an antigen associated with a pathogenic cell or microorganism, comprising

- (a) the transformed or transfected cells of any of claims 17-24 which optionally express said antigen;
- (b) if the cells of (a) do not express said antigen, an additional source of said antigen;
- (c) optionally, a general immunostimulatory agent or adjuvant; and
- 5 (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

63. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising

- (a) a source of antigen to which an immune response is desired;
- 0 (b) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30;
- (c) optionally, a general immunostimulatory agent or adjuvant; and
- (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

5 64. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising

- (a) a source of antigen to which an immune response is desired;
- (b) the fusion polypeptide of any of claims 31-40;
- (c) optionally, a general immunostimulatory agent or adjuvant; and

(d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

65. A co-stimulatory composition for use with an antigen or a vaccine to increase the immunogenicity of the antigen or vaccine, comprising:

5 (a) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30; and
(b) a pharmaceutically and immunologically acceptable excipient or carrier.

66. A co-stimulatory composition for use with an antigen or a vaccine to increase the immunogenicity of the antigen or vaccine, comprising:

0 (a) the fusion polypeptide of any of claims 31-40; and
(b) a pharmaceutically and immunologically acceptable excipient or carrier.

67. A method for inducing or enhancing an immune response to an antigen in a mammalian subject comprising administering to said subject an effective amount of the vaccine composition of any of claims 62-64.

5 68. A method for potentiating an immune response to an antigen or a vaccine in a mammalian subject, comprising administering to said subject, in combination with said antigen or vaccine, the costimulatory composition of claim 65 or 66.




Fig. 1

J774 A1
RAW 264-7
PU 5-18
WEHI
BM
BM DC (day 4)
BM DC (day 6)
BM DC (day 8)
sorted BM -DC
Spleen DC.
act. BM M ϕ
act. peritoneal M ϕ




FIG. 2




Fig. 3




Fig. 4







Fig. 5

Fig. 6**Fig. 7**

**Fig. 8**




Fig. 9

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83750 A3

(51) International Patent Classification⁷: **C12N 15/12, 15/62, 5/10, C07K 14/705, 16/28, A61K 38/17, 39/00, 39/395**

20833 (US). TSUCHIYA, Haruo [JP/US]; 6 Stoneridge Court, Baltimore, MD 21239 (US). GORSKI, Kevin, S. [US/US]; 16 W. Mt. Vernon Place, Baltimore, MD 21201 (US). TSENG, Su-Yi [US/US]; 3032 St. Paul Street, Baltimore, MD 21218 (US).

(21) International Application Number: PCT/US01/13430

(74) Agent: LIVNAT, Shmuel; Venable, Baetjer, Howard & Civiletti, LLP, 1201 New York Avenue, NW, Suite 1000, P.O. Box 34385, Washington, DC 20043-9998 (US).

(22) International Filing Date: 27 April 2001 (27.04.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English


(30) Priority Data:

60/200,580 28 April 2000 (28.04.2000) US
60/240,169 13 October 2000 (13.10.2000) US

(71) Applicant (*for all designated States except US*): **THE JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US)**.

[Continued on next page]

(54) Title: DENDRITIC CELL CO-STIMULATOR MOLECULES



WO 01/83750 A3

(57) Abstract: A costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.



Published:

— *with international search report*

(88) Date of publication of the international search report:

10 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INT'L INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/13430

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/12	C12N15/62	C12N5/10	C07K14/705	C07K16/28
	A61K38/17	A61K39/00	A61K39/395		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>TSENG SU-YI ET AL: "B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 193, no. 7, 2 April 2001 (2001-04-02), pages 839-845, XP002189416 ISSN: 0022-1007 the whole document</p> <p>---</p> <p style="text-align: center;">-/-</p>	1-68

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 February 2002

Date of mailing of the international search report

20.02.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Madruga, J

INT'L NATIONAL SEARCH REPORT

International Application No PCT/US 01/13430

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EM_MUS [Online] EMBL; Accession NO: AF142780, 1 June 1999 (1999-06-01) TSENG S Y ET AL: "Mus musculus Butyrophilin-like protein (Btdc) mRNA, complete cds." XP002189417 cited in the application the whole document	1-3,5-7, 25-28
Y	---	4,8-24, 29-68
X	DATABASE EM_HUM [Online] EMBL; Accession NO: AK001872, 22 February 2000 (2000-02-22) ISOGAI T ET AL: "Homo sapiens cDNA FLJ11010 fis" XP002189418 abstract	3,5,7, 26-28
E	WO 01 34629 A (HUMAN GENOME SCIENCES INC ;BAKER KEVIN P (US); RUBEN STEVEN M (US)) 17 May 2001 (2001-05-17) SEQ ID NO:11, SEQ ID NO: 33 and SEQ ID NO:41 claims	1-7, 11-13, 17-22, 25-28, 41-48
P,X	EP 1 074 617 A (HELIX RES INST) 7 February 2001 (2001-02-07) SEQ ID NO:12622 and SEQ ID NO:4320 & DATABASE GSN [Online] Accession NO:AAH14818, 26 June 2001 (2001-06-26) OTA T. ET AL.: "Human cDNA sequence" the whole document	3,5-7, 26-28
P,X	WO 00 61612 A (CORIXA CORP ;FAN LIQUN (US); WANG TONGTONG (US)) 19 October 2000 (2000-10-19) SEQ ID NO: 264	3,5-7, 26-28
P,X	WO 00 55375 A (ALPHAGENE INC) 21 September 2000 (2000-09-21) SEQ ID NO:81 page 440; claim 90	3,5-7, 26-28
	---	-/-

INT'L NATIONAL SEARCH REPORT

International Application No

PCT/US 01/13430

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEN L ET AL: "COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR OF THE T LYMPHOCYTE MOLECULES CD28 AND CTLA-4" CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 71, 24 December 1992 (1992-12-24), pages 1093-1102, XP000941406 ISSN: 0092-8674 page 1094, left-hand column, paragraph 2 -page 1096, left-hand column, paragraph 1 page 1100, right-hand column, paragraph 2 ---	14-20, 22-24, 52,53, 58,59
A	US 5 861 310 A (GRAY GARY S ET AL) 19 January 1999 (1999-01-19) cited in the application claims; examples ---	14-20, 22-24, 52,53, 58,59
Y	GERSTMAYER BERNHARD ET AL: "Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein." CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 45, no. 3-4, November 1997 (1997-11), pages 156-158, XP002932422 ISSN: 0340-7004 the whole document ---	8-13, 31-40, 55,61, 64,66
Y	HENRY J ET AL: "Structure and evolution of the extended B7 family" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 20, no. 6, June 1999 (1999-06), pages 285-288, XP004169718 ISSN: 0167-5699 the whole document ---	4
Y	WO 92 00092 A (SQUIBB BRISTOL MYERS CO) 9 January 1992 (1992-01-09) claims ---	29,30, 41-48, 54,56, 57,60, 63,65, 67,68
Y	WO 97 24447 A (VIAGENE INC) 10 July 1997 (1997-07-10) page 2, paragraph 2 page 4, line 25 - line 26 page 19, line 23 -page 21, line 18 ---	21, 49-51,62
		-/-

INT'L NATIONAL SEARCH REPORT

International Application No

PCT/US 01/13430

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>YOSHINAGA S K ET AL: "T-cell co-stimulation through B7RP-1 and ICOS" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 402, 16 December 1999 (1999-12-16), pages 827-832, XP002157212 ISSN: 0028-0836 cited in the application the whole document</p> <p>---</p>	31-38
A	<p>WO 95 05464 A (ARCH DEV CORP) 23 February 1995 (1995-02-23) claims; examples</p> <p>---</p>	1-68
A	<p>TOWNSEND S E ET AL: "TUMOR REJECTION AFTER DIRECT COSTIMULATION OF CD8+T CELLS BY B7-TRANSFECTED MELANOMA CELLS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE., US, vol. 259, 15 January 1993 (1993-01-15), pages 368-370, XP000943266 ISSN: 0036-8075 cited in the application the whole document</p> <p>-----</p>	8-24,52, 53,58, 59,62,67

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/13430

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 49-61, 67 and 68 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 4,6,16,37,43 and in part: 1-3, 5, 7-15, 17-36, 38-42 and 44-68

Human B7-DC nucleic acid, polypeptide and uses thereof

2. Claims: In part: 1-3, 5, 7-15, 17-36,38-42 and 44-68

Murine B7-DC nucleic acid, polypeptide and uses thereof

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/13430

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0134629	A	17-05-2001	AU WO	1473501 A 0134629 A1	06-06-2001 17-05-2001
EP 1074617	A	07-02-2001	AU AU AU AU AU AU AU AU AU AU AU AU AU AU AU EP WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO WO	6180800 A 6180900 A 6181000 A 6181100 A 6181200 A 6181300 A 6181400 A 6181500 A 6181600 A 6315800 A 1074617 A2 0109315 A1 0109345 A1 0109316 A1 0109349 A1 0109317 A1 0109318 A1 0109319 A1 0109346 A1 0109320 A1 0109321 A1 0109322 A1 0109323 A1	19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 07-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001
WO 0061612	A	19-10-2000	AU EP WO	4069200 A 1169347 A2 0061612 A2	14-11-2000 09-01-2002 19-10-2000
WO 0055375	A	21-09-2000	AU WO AU EP WO	3899700 A 0055375 A1 2883500 A 1153121 A2 0049134 A1	04-10-2000 21-09-2000 04-09-2000 14-11-2001 24-08-2000
US 5861310	A	19-01-1999	AU AU CA EP JP WO US US	7405294 A 9699198 A 2167091 A1 0711345 A1 9500788 T 9503408 A1 6130316 A 6084067 A	20-02-1995 18-02-1999 02-02-1995 15-05-1996 28-01-1997 02-02-1995 10-10-2000 04-07-2000
WO 9200092	A	09-01-1992	CA EP JP WO US US	2086325 A1 0537293 A1 6508501 T 9200092 A1 5521288 A 5580756 A	03-01-1992 21-04-1993 29-09-1994 09-01-1992 28-05-1996 03-12-1996
WO 9724447	A	10-07-1997	EP WO	0871747 A1 9724447 A1	21-10-1998 10-07-1997
WO 9505464	A	23-02-1995	AU WO	7526894 A 9505464 A1	14-03-1995 23-02-1995

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/083750 A3(51) International Patent Classification⁷: C12N 15/12,
15/62, 5/10, C07K 14/705, 16/28, A61K 38/17, 39/00,
39/395M. [US/US]; 19400 James Creek Court, Brookville, MD
20833 (US). TSUCHIYA, Haruo [JP/US]; 6 Stoneridge
Court, Baltimore, MD 21239 (US). GORSKI, Kevin, S.
[US/US]; 16 W. Mt. Vernon Place, Baltimore, MD 21201
(US). TSENG, Su-Yi [US/US]; 3032 St. Paul Street, Bal-
timore, MD 21218 (US).

(21) International Application Number: PCT/US01/13430

(74) Agent: LIVNAT, Shmuel; Venable, Baetjer, Howard &
Civiletti, LLP, 1201 New York Avenue, NW, Suite 1000,
P.O. Box 34385, Washington, DC 20043-9998 (US).

(22) International Filing Date: 27 April 2001 (27.04.2001)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:

60/200,580 28 April 2000 (28.04.2000) US
60/240,169 13 October 2000 (13.10.2000) US(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European(71) Applicant (for all designated States except US): THE
JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rut-
land Avenue, Baltimore, MD 21205 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): PARDOLL, Drew,

[Continued on next page]

(54) Title: DENDRITIC CELL CO-STIMULATOR MOLECULES



WO 01/083750 A3



(57) Abstract: A costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

3 July 2003

Published:

— *with international search report*

(88) Date of publication of the international search report:

10 May 2002

(15) Information about Correction:

see PCT Gazette No. 27/2003 of 3 July 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DENDRITIC CELL CO-STIMULATOR MOLECULES

BACKGROUND OF THE INVENTION

Field of the Invention

5 The invention in the field of biochemistry and medicine relates to novel proteins that are selectively expressed on the surface of dendritic cells and can be used as cell surface molecules or in soluble form in vaccine compositions to stimulate immune responses.

Description of the Background Art

10 The generation of a T lymphocyte response is a complex process involving cell-cell interactions and production of soluble mediators (cytokines or lymphokines). This response is regulated by several T-cell surface molecules acting as "receptors," including the T-cell receptor (TCR) complex and other "accessory" surface molecules many of which are cell surface "differentiation antigens" that were first defined by monoclonal antibodies ("CD molecules")

15 Optimal activation of all lymphocytes is believed to require two signals: an antigen specific or clonal signal, as well as a second, antigen non-specific signal (Janeway, C., *Cold Spring Harbor Symp. Quant. Biol.* 54:1-14 (1989)). If a lymphocyte encounters an antigen alone, without co-stimulation by so-called co-stimulatory molecules (such as B7 described below), it will respond with either clonal inactivation also called "anergy" (Schwartz, R. *Science* 248:1349 (1990)) or apoptosis (programmed cell death); if the co-stimulatory signal is provided 20 it will respond with clonal expansion specific for the stimulating antigen. No significant amplification of an immune response against a given antigen occurs without co-stimulation (June *et al.* (*Immunology Today* 15:321-331, 1994); Chen *et al.* (*Immunology Today* 14:483-486); Townsend, SE and Allison, JP (1993) *Science* 259:368-370).

25 The quality and potency of an immune response depends in large part on the type of antigen presenting cells (APC) that process and present the antigen to T cells. The density of the peptide antigen/MHC ligand available for engagement of the TCR and the provision of soluble and/or membrane-bound co-stimulatory signals by APCs at the time of T cell engagement and activation is critical. It is for these reasons that immunotherapeutic strategies have begun to focus on providing (a) the target antigen to the appropriate APC types and (b) appropriate co-stimulatory molecules to enhance T cell activation.
30

APCs that provide the signals required for activation of T cells include monocytes/macrophages, B lymphocytes, and, most importantly dendritic cells (DCs). In the past, activated macrophages were believed to be the critical APCs that initiated T cell responses *in vivo*. This notion was based on their ability to phagocytose antigens effectively and process them for surface display and presentation. More recently, attention has shifted to DC as the major initiator *in vivo* of antigen-specific T cell responses. DCs have a distinct phenotype from activated macrophages and are classified into different subtypes capable of initiating distinct immune responses. A functional hallmark of DCs is their approximately 100-fold greater potency than macrophages to activate naïve T cells *in vitro*. To date, the explanation of this potency has been based on quantitative differences in molecules known to be important for antigen presentation. The present invention is based on the discovery of an important qualitative difference.

The first signal in antigen presentation is initiated by interaction of the TCR with antigen presented in the context of class II major histocompatibility complex (MHC) molecules on the APC (Allen, *Immunol. Today* 8:270 (1987)). Co-stimulatory signals come from other molecules, the best characterized of which is the B7 family (namely B7.1, B7.2, and possibly B7.3) which are also present on APCs

Two proteins expressed on the surface of T cells are the best-characterized ligands or counter-receptors for co-stimulatory molecules such as B7. CD28 is a homodimeric glycoprotein of the immunoglobulin (Ig) superfamily (Aruffo and Seed, *Proc. Natl. Acad. Sci.* 84:8573-8577 (1987)) found on most mature human T cells that functions in T cell activation. CD28, is constitutively expressed on resting T cells and increases after activation. After signaling through the T cell receptor, ligation of CD28 induces T cells to proliferate and secrete IL-2 (Linsley, PS, *et al.* (1991) *J. Exp. Med.* 173, 721-730; Gimmi, CD, *et al.* (1991) *Proc. Natl. Acad. Sci. USA.* 88, 6575-6579; Thompson, C. B., *et al.* (1989) *Proc. Natl. Acad. Sci. USA.* 86, 1333-1337; June, C. H., *et al.* (1990) *Immunol. Today.* 11, 211-6; Harding, F. A., *et al.* (1992) *Nature.* 356, 607-609.). CD28 mediates cell-cell contact ("intercellular adhesion"), a form of antigen-independent intercellular interaction that is essential for immune responses (Springer *et al.*, *Ann. Rev. Immunol.* 5:223-252 (1987)). ,

CTLA4 is a T cell surface molecule highly homologous to CD28 but is not expressed on resting T cells and appears following T cell activation (Brunet, J. F., *et al.*, (1987) *Nature* 328,

267-270). CTLA-4 was originally identified by differential screening of a murine cytolytic T cell cDNA library, Brunet *et al. supra*. The role of CTLA-4 as a second receptor for B7 is discussed in Linsley *et al.* (1991) *J. Exp. Med.* 174:561-569, which also noted that B7 has a higher affinity for CTLA4 than for CD28. Freeman *et al.* (1993) *Science* 262:907-909 discussed 5 CTLA-4 in B7 deficient mice. Ligands for CTLA-4 are described in Lenschow *et al.* (1993) *Proc. Nat'l. Acad. Sci.* 90:11054-11058.

Th cells secrete growth and differentiation-inducing cytokines such as IL-2, IL-4 and IL-6 possibly in a focused manner in the area of Th-B cell contact which serves to ensure activation of only B cells presenting antigen to Th cells and avoid activation of bystander B cells.

10 CD28 and CTLA-4 interact with a co-stimulatory molecule generally known as B7. B7 was originally described as a B cell activation antigen because it was found on B cells and was termed B7/BB-1 (Linsley et al, *Proc. Natl. Acad. Sci. USA* 87:5031-5035 (1990). Hereafter, this molecule will be referred to as B7, B7-1 or B7.1). B7 and more recently described B7 homologues are also members of the Ig superfamily. In contrast to CD28 and CTLA-4, B7 15 comprises two extracellular Ig domains, an N-terminal variable (V)-like domain followed by a constant (C)-like domain.

B7 family members are generally expressed on APCs and, as noted, are of critical importance to the activation of naive T cells.. These family members include B7-1 (=B7, also designated CD80) and B7-2 (also designated CD86). References describing B7-1 include 20 Schwartz, R. H. *Cell* 71:1065-1068, 1992; Chen, L. *et al.* *Cell* 71:1093-1102, 1992; Freeman, G. J. *et al.* *J. Immunol* 143:2714-2722, 1989; and Freeman, G. J. *et al.* *J. Exp. Med.* 174:625-631, 1991)). References describing B7-2 include (Freeman, G. J. *et al.* *Science* 262:909-911 813- 960, 1993). To date, both murine B7-1 and B7-2 and human B7-1 and B7-2 have been 25 described (Freeman *et al.*, 1989, *supra*; 1991,, *supra*; and 1993, *supra*). Activated human B lymphocytes express CTLA4/CD28 binding counter-receptors B7-2 and B7-3, both of which can deliver costimulatory signals to T cells via either CD28 or CTLA4.

B7-2 is expressed by B cells at about 24 hours following stimulation with either anti-Ig or anti-MHC class II mAbs. B7-2 induces detectable IL-2 secretion and T cell proliferation. At about 48 to 72 hours post activation, B cells express both B7-1 and a third CTLA4 counter- 30 receptor identified by a mAb BB-1 (Yokochi, T, *et al.* (1982) *J. Immunol.* 128, 823-827), termed B7-3. B7-3 is also expressed on B7-negative activated B cells and can costimulate T cell

proliferation without detectable IL-2 production, indicating that the B7-1 and B7-3 molecules are distinct. B7-3 is expressed on a wide variety of cells including activated B cells, activated monocytes, dendritic cells, Langerhans cells and keratinocytes. At 72 hours post B cell activation, the expression of B7-1 and B7-3 begins to decline. The presence of these 5 CTLA4/CD28 binding counter-receptors on the surface of activated B lymphocytes indicates that T cell costimulation is regulated, in part, by the temporal expression of these molecules following B cell activation.

The importance of the B7:CD28/CTLA4 costimulatory pathway(s) has been demonstrated *in vitro* and *in vivo*. A direct relationship exists between increased T cell activity 10 and increased B7 expression (Razi-Wolf *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:4210-4214 (1992)). T cells are rendered anergic when they, encounter peptides antigens on cells lacking a costimulatory ligand that binds CD28 Blockade of this costimulatory pathway results in the development of antigen specific tolerance in murine and humans systems (Harding *et al.*, *supra*; Lenschow, D. J. *et al.* (1992) *Science*. 257, 789-792; Turka, LA *et al.* (1992) *Proc. Natl. Acad. Sci. USA*. 89, 11102-11105; Gimmi, CD *et al.* (1993) *Proc. Natl. Acad. Sci USA* 90, 6586-6590; Boussiotis, V. *et al.* (1993) *J. Exp. Med.* 178, 1753-1763). Conversely, expression of B7 by B7-negative murine tumor cells induces T-cell mediated specific immunity accompanied by tumor rejection and long lasting protection to tumor challenge (Chen, L, *et al.* (1992) *Cell* 15 71:1093-1102; Townsend *et al.*, *supra*; Baskar, S, *et al.* (1993) *Proc. Natl. Acad. Sci.* 90, 5687-5690.). Therefore, manipulation of the B7:CD28/CTLA4 pathway offers great potential to 20 stimulate or suppress immune responses in humans.

Interactions between CD28 and B7 have been characterized using genetic fusions of the extracellular portions of B7 or CD28 with Ig Cy1 chains (Linsley *et al.*, *J. Exp. Med.* 173:721-730 (1991)). When B7Ig fusion proteins are immobilized, or when B7 is expressed on the 25 surface of a cell, such as a transfected CHO cell, they costimulate T cell proliferation. T cell stimulation with B7+ CHO cells also specifically stimulates increased levels of transcripts for IL-2.

U.S. 5,521,288 describes a method for regulating immune responses by contacting CD28 positive T cells with fragments encoded by parts of DNA encoding B7, primarily corresponding 30 to the extracellular domain (ECD) of B7. Immune responses were also regulated by derivatives of B7 that were are fusion protein constructs including at least a portion of B7 ECD and another

protein, such as the human IgCy1 domain that altered the solubility, binding affinity and/or valency of B7. For example DNA encoding amino acid residues from positions 1-215 of the B7 ECD was joined to DNA encoding amino acid residues of the sequences corresponding to the hinge, CH2 and CH3 regions of human IgCy 1 to form a DNA fusion product which encoded a 5 B7Ig fusion protein. Also disclosed was a method for treating an immune system disease mediated by T cells by administering B7 or B7Ig fusion protein to react with T cells by binding the CD28 receptor. T cell proliferation in graft versus host disease was inhibited by reacting CD28+ T cells with B7 antigen or B7Ig fusion protein in combination with an immunosuppressant.

10 US Patent 5,861,310 discloses tumor cells modified to express one or more T cell costimulatory molecules, including B7-2 and B7-3. One embodiment includes further expression of B7. Modification was by transfection with nucleic acid encoding the B7-2, B7-3 or B7 proteins. Tumor cells could also be genetically modified *in vivo*. Such modified tumor cells said to be useful for treating a patient with a tumor, to prevent or inhibit metastatic spread 15 or inhibit recurrence of the tumor. This document disclosed a method for specifically inducing a CD4+ T cell response against a tumor.

20 U.S. Patent 5,942,607 discloses isolated nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation. In one embodiment, the isolated nucleic acid encoded B7-2. Also disclosed was a nucleic acid comprising at least a portion of the disclosed full length B7-2 sequence. According to this document, the nucleic acid sequences could be integrated into various expression vectors which could direct the synthesis of the corresponding 25 proteins or peptides in a variety of host cells including mammalian and insect cells. Also disclosed were host cells transformed to produce proteins or peptides encoded by these nucleic acid sequences and isolated proteins and peptides which comprise at least a portion of the B7-2 sequence.

Dong H *et al.*, *Nat Med* 1999 5:1365-1399, described a third member of the B7 family, designated B7-H1 that does not bind CD28, CTLA4 or ICOS (inducible co-stimulator). Ligation of B7-H1 co-stimulated T-cell responses to polyclonal stimuli and alloantigens, and preferentially stimulated the production of interleukin-10. IL-2, produced in small amounts, was required for the effect of B7-H1 co-stimulation. This study defined a previously unknown co-stimulatory molecule that may be involved in the negative regulation of cell-mediated immune 30

responses. The same laboratory (Wang S *et al.*, *Blood*. 2000;96:2808-2813) described a new human B7-like gene designated B7-H2, the expression of which was detected on the surface of monocyte-derived immature DCs. Soluble B7-H2 and an Ig fusion protein, B7-H2Ig, bound to activated, but not resting, T cells. This binding was inhibited by a soluble form of ICOS (ICOSIg) but not by CTLA4Ig. ICOSIg stained CHO cells transfected with the B7-H2 gene. Using suboptimal cross-linking of CD3 as a stimulus, costimulation of T-cell proliferation by B7-H2Ig was found to be dose-dependent and correlated with secretion of IL-2, whereas optimal CD3 ligation preferentially stimulated IL-10 production. The authors concluded that B7-H2 is a putative ligand for the ICOS T-cell molecule.

10 Swallow MM *et al.*, *Immunity*, 1999, 11:423-432 reported cloning of a novel gene, *b7h*,
a is a close homolog of B7 molecules that are expressed on APCs. B7h costimulated
proliferation of purified T cells by acting on a receptor distinct from CD28 or CTLA-4.
Surprisingly, although B7h was expressed in unstimulated B cells, its expression was induced in
15 nonlymphoid cells (3T3 cells; embryonic fibroblasts) treated with TNF α and was upregulated in
nonlymphoid tissue of mice treated with LPS, a potent activator of TNF α . These studies defined
a novel costimulatory ligand of T cells and suggested that induction of B7h by TNF α may
directly augment recognition of self during inflammation

20 Yoshinaga SK *et al.*, *Nature*, 1999, 402:827-832, described a new murine costimulatory
receptor-ligand pair. The receptor, related to CD28, was the murine homologue of the human
protein ICOS, and was expressed on activated T cells and resting memory T cells. The ligand,
which was homologous to B7 molecules was designated B7-related protein-1 (B7RP-1). B7RP-
1 is a type 1 transmembrane protein with 20% and 19% amino acid identity to murine B7.1
(CD80) and B7.2 (CD86), respectively. This homology is significant as B7.1 and B7.2 share
only 27% amino acid identity (Freeman, GJ *et al.*, *J. Exp. Med.* 178:2185-2192 (1993)). This
25 homology includes the cysteines that are important for Ig loop formation at conserved locations
(residues 62, 138, 185 and 242 from the initiating methionine). The overall length and relative
position of the transmembrane domain of B7RP-1 are similar to those of the B7 molecules
(Greenfield, EA *et al.*, *Crit. Rev. Immunol.* 18:389-418 (1998)). B7RP-1 was shown to be
expressed on B cells and macrophages. ICOS and B7RP-I did not interact with proteins in the
30 CD28-B7 pathway, and B7RP-1 co-stimulated T cells independently of CD28. Transgenic mice
expressing a fusion protein between B7RP-1 and the Fc portion of Ig ("B7-RP1-Fc") had

lymphoid hyperplasia in spleen, lymph nodes and Peyer's patches. Co stimulatory activity of B7RP-1 *in vivo* was found by demonstrating enhanced delayed-type hypersensitivity in antigen-presensitized mice treated with B7RP-1-Fc at the time of antigen challenge. The authors concluded that ICOS and B7RP-1 define a distinct new receptor-ligand pair that is structurally related to CD28-B7 and is involved in the adaptive immune response.

Yoshinaga SK *et al.*, Int Immunol, 2000 Oct, 12:1439-1447, reported co-stimulation of human T cells through the human B7RP-1 and ICOS interaction. This ligand-receptor pair interacted with a K_D of approximately 33 nM and an off-rate having a $t_{1/2}$ of >10 min. TNF α differentially regulated expression of human B7RP-1 on B cells, monocytes and DC. TNF α enhanced B7RP-1 expression on B cells and monocytes, but inhibits expression on DC. A human B7RP-1-Fc protein, or cells that expressed membrane-bound B7RP-1, co-stimulated T cell proliferation *in vitro*. Specific cytokines, such as IFN γ and IL-10, were induced by B7RP-1 co-stimulation. Although IL-2 levels were not significantly increased, B7RP-1-induced co-stimulation was dependent on IL-2. These studies defined the human ortholog to murine B7RP-1 and characterized its interaction with human ICOS.

PD-1 is an immuno-inhibitory receptor expressed by activated T, B and myeloid cells. Mice deficient in PD-1 showed multiple forms of autoimmunity due to the loss of peripheral tolerance. Freeman, GJ *et al.*, J. Exp. Med. 192:1027- 1034(2000) reported that the ligand of PD-1 (PD-L1) is a member of the B7 gene family. Engagement of PD-1 by PD-L1 resulted in inhibition of TCR-mediated lymphocyte activation (proliferation, cytokine secretion). In addition, PD-1 signaling inhibited suboptimal levels of CD28-mediated costimulation. PD-L1 is expressed by APCs (human monocytes stimulated with IFN γ , activated human DCs). In addition, PD-L1 was shown to be expressed in heart and lung. The authors speculated that relative magnitude of inhibitory PD-L1 signals and costimulatory B7-1/B7-2 signals on APCs may determine the extent of T cell activation and the threshold between tolerance and autoimmunity. The presence of PD-L1 on nonlymphoid tissues may contribute to the magnitude of immune responses at sites of inflammation.

Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents

of these documents is based on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.

SUMMARY OF THE INVENTION

In order to identify genes encoding novel dendritic cell (DC) specific costimulatory molecules for T cell activation, the inventors screened a subtracted cDNA library between DCs and activated macrophages. This cDNA subtraction approach defines genes expressed by DCs but not by activated macrophages. Use of this approach has led to discovery of several novel DC-specific genes that are useful in enhancing the potency of vaccines that depend on activation of T cells. The present application focuses on one such gene.

Based on presence in the DC library and absence from the activated macrophage library, a novel coding sequence, termed "B7-DC" was identified. The B7-DC gene is a member of the B7 family of genes encoding costimulatory molecules. B7-DC is the first B7 family member with DC-specific expression and different receptor specificity. The product of this gene has an important role in mediating the unique ability of DCs to stimulate T cells. Functional analysis indicated that B7-DC is more active than B7-1 in stimulating IFN γ production by T cells. B7-DC DNA and polypeptides are therefore useful in compositions and methods to enhance the efficacy of cellular and molecular vaccine compositions, whether antigen-specific or not.

In one embodiment, the present invention provides an isolated nucleic acid molecule that encodes a mammalian protein termed B7-DC that is selectively expressed on dendritic cells as compared to activated macrophages. The nucleic acid molecule preferably comprises a nucleotide sequence selected from SEQ ID NO:1 (of human origin) or SEQ ID NO:5. (of murine origin). The invention is also directed to an isolated nucleic acid that hybridizes with the above nucleic acid molecule under stringent hybridization conditions. Preferred stringent conditions include incubation in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash in about 0.2X SSC at a temperature of about 50°C. Preferably the above nucleic acid molecule comprises the nucleotide sequence SEQ ID NO:1. A preferred nucleic acid molecule as above encodes a protein having an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4 or encodes a biologically active fragment, homologue or other functional derivative of the protein. Preferably, the nucleic acid molecule encodes the protein having the sequence SEQ ID NO:2 (B7-DC of human origin) or encodes the biologically active fragment, homologue or other functional derivative of SEQ ID NO:2.

In a preferred embodiment, the nucleic acid molecule encodes the extracellular domain of the B7-DC protein, which includes residues 26-221, which encodes a co-stimulatory homologue, fragment or other functional derivative thereof.

In another embodiment, the above nucleic acid molecule encodes a B7-DC fusion protein which comprises:

- (a) a first nucleic acid sequence encoding a first polypeptide that is all or a part of a B7-DC protein (preferably SEQ ID NO:2 or SEQ ID NO:4);
- (b) optionally, fused in frame with the first nucleic acid sequence a linker nucleic acid sequence encoding a linker peptide; and
- 10 (c) a second nucleic acid sequence that is linked in frame to the first nucleic acid sequence or to the linker nucleic acid sequence and that encodes a second polypeptide.

The second polypeptide preferably consists of one or more domains of an Ig heavy chain constant region, preferably the two C domains of human IgG, preferably IgG1.

Also provided is an expression vector comprising any of the above nucleic acid molecules operatively linked to

- (a) a promoter and
- (b) optionally, additional regulatory sequences that regulate expression of the nucleic acid in a eukaryotic cell.

The above expression vector may be a plasmid or a viral vector. These vectors include self replicating RNA replicons (DNA-launched or RNA), suicide RNA vectors DNA viruses (such as adenovirus, vaccina virus, etc.) and RNA virions grown on packaging cell lines.

The vector DNA or RNA may be complexed to gold particles for gene gun -mediated introduction to a host or complexed with other polymers, for example, in controlled release formulations, that enhance delivery to the desired target cells and tissues.

25 Also included is a vector composition which comprises:

- (a) a first recombinant expression vector having incorporated in its sequence a nucleotide sequence encoding an antigen of interest against which an immune response is to be induced; and
- (b) a second recombinant expression vector having incorporated in its nucleic acid sequence 30 or more nucleotide sequences encoding a co-stimulator polypeptide, at least one of which polypeptides is B7-DC, or a biologically active fragment, homologue or other functional derivative thereof,

wherein the expression vectors are able to co-infect or co-transfect a host cell resulting in co-expression of the antigen and the costimulator polypeptide, fragment, homologue or derivative.

In a modification of the above embodiment, the invention provides a third nucleic sequence encoding a targeting protein that (i) promotes spread of the expressed product (antigen) between cells, preferably APCs, (ii) increases the display of the antigen on APCs in which the nucleic acid is expressed., and/or (iii) promotes the re-presentation (cross--priming) and display of the antigen in APCs of a host into which the vector is introduced. The targeting protein-encoding nucleic acid may be fused to the nucleic acid encoding the antigen or the co-stimulator or both. acid the first or the second vector includes nucleic acid. In one embodiment, the vector composition combines thee antigen-encoding nucleic acid, the co-stimulator-encoding nucleic acid (preferably B7-DC) and a “targeting” protein-encoding nucleic acid into a single fused construct.

This invention includes a cell transformed or transfected with any of the above nucleic acid molecules or expression vectors. The cell is preferably a eukaryotic cell, more preferably a mammalian cell, most preferably a human cell. The cell may be a dendritic cell or a progenitor thereof. In another embodiment, the cell is a tumor cell, preferably a tumor cell that bears an antigen that is the same as, or cross-reactive with,, an antigen on a tumor in the host against which an immune response is desired.

A preferred embodiment is an isolated mammalian tumor cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-DC protein (preferably SEQ ID NO:2 or SEQ ID NO:4) or a biologically active fragment, homologue or other functional derivative thereof, such that when the protein, fragment, homologue or derivative is expressed by the tumor cell, and the tumor cell is contacted with T cells

- (i) the B7-DC protein, fragment,, homologue or derivative binds to the T cells; and
- (ii) the tumor cell costimulates the T cells to proliferate and/or to produce and secrete cytokines.

The present invention is also directed to a polypeptide that is selectively expressed on dendritic cells as compared to activated macrophages and has the following functional properties:

- (a) binds to a binding partner on T cells; and
- (b) costimulates T cells to proliferate and/or to produce and secrete cytokines.

Also included are biologically active fragments, homologues or other functional derivatives of the polypeptide.

The polypeptide, fragment, homologues or functional derivative is preferably encoded by a nucleic acid molecule having the sequence SEQ ID NO:1 or SEQ ID NO:5, or a fragment, 5 homologue or equivalent of the nucleic acid molecule. A preferred polypeptide has the amino acid sequence SEQ ID NO:2 or SEQ ID NO:4.

The polypeptide or a biologically active fragment, homologues or other functional derivative of the polypeptide may be produced by recombinant expression of one of the above nucleic acids.

10 A preferred polypeptide comprises the extracellular domain of the B7-DC protein, preferably

- (a) amino acid residues 26-221 of SEQ ID NO:2 (*human*) or
- (b) amino acid residues 26-221 of SEQ ID NO:4 (*mouse*).

The above polypeptide may consist essentially of the extracellular domain of B7-DC

15 Also provided is a B7-DC fusion polypeptide having a first fusion partner comprising all or a part of a B7-DC protein fused

- (i) directly to a second polypeptide or,
- (ii) optionally, fused to a linker peptide sequence that is fused to the second polypeptide.

20 The above A B7-DC fusion protein may also be fused to a second polypeptide, preferably one or more domains of an Ig heavy chain constant region, preferably having an amino acid sequence corresponding to the hinge, C_H2 and C_H3 regions of a human immunoglobulin C_y1 chain.

25 In one embodiment of the above fusion protein, the first fusion partner is the extracellular domain of a B7-DC protein, the full length sequence of which is SEQ ID NO:2 or SEQ ID NO:4.

The fusion protein preferably binds to a binding partner on T cells and co-stimulates T cells in the presence of an adequate stimulus to the T cell receptor.

30 Also provided is a dimeric or trimeric fusion protein which is a **dimer** or trimer of the above fusion proteins. Preferably, the chains are tandemly linked via disulfide bonds or other interchain covalent bonds.

In a preferred dimeric fusion protein, the dimer results from the covalent bonding of Cys residue in the C_H regions of two of the Ig heavy chains that are the same Cys residues that are disulfide linked in dimerized normal Ig H chains.

The fusion protein of the invention may comprise a multimer of two or more repeats of the first fusion partner linked end to end, directly or with a linker sequence between one or more monomers.

The present invention also provides an antibody that is specific for an epitope of a B7-DC protein, which epitope is not present in a known member of a B7 family protein. The epitope may be a linear or conformational epitope of a polypeptide of SEQ ID NO:2 or SEQ ID NO:4. The antibody is preferably a monoclonal antibody, more preferably a human or humanized (via engineering) monoclonal antibody.

Also provided is a method of using the above antibody to identify or quantitate cells expressing a B7-DC polypeptide on their surface in a cell population, comprising

- (a) contacting cells of the population with the above antibody so that the antibody binds to cells expressing the epitope;
- (b) assessing the presence of or quantitating the number of cells to which the antibody is bound.

Another method is provided for isolating cells expressing a B7-DC polypeptide on their surface from a cell population, comprising

- (a) contacting the population with the above antibody so that the antibody binds to cells expressing the epitope;
- (b) positively selecting cells to which the antibody has bound or negatively selecting cells to which the antibody has not bound.

Also provided is a method of detecting the presence or quantitating a B7-DC polypeptide, fragment or homologue in a sample, comprising the steps of:

- (a) contacting the sample with the antibody of claim 43 such that the antibody binds to any polypeptides or fragments bearing the epitope;
- (b) detecting the presence of, or quantitating the polypeptides or fragments bound to the antibody.

The present invention is also directed to a method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of the cell to co-stimulate T cells *in vitro* or *in vivo* in the presence of an

adequate stimulus to the T cell receptor, comprising transforming or transfecting the antigen presenting cell or progenitor cell with the expression vector as described above, such that the expression of the B7-DC polypeptide is induced or increased on the cells. The antigen presenting cells are preferably dendritic cells and the progenitors are dendritic cell progenitors.

5 The present invention provides method for stimulating immune responses using cellular co-stimulatory compositions as well as polypeptide co-stimulators. One method for increasing the T cell response of a mammalian subject to antigenic stimulation comprises administering to the subject an effective amount of cells as described above, preferably tumor cells, in conjunction with an antigenic stimulus, wherein the cells are effective to increase the T cell 10 response of the subject to the antigenic stimulation. The foregoing is preferably accomplished by co-injection of the antigen and the co-stimulatory composition.

15 A method for increasing the T cell response of a mammalian subject to antigenic stimulation with a tumor-associated antigen, comprises administering to the subject an effective amount of tumor cells as described above, , wherein the tumor cells express the antigen, the administration of the tumor cells being effective to increase the T cell response of the subject to the tumor antigen stimulation.

20 A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to the subject an effective amount of a polypeptide, fragment, homologue or functional derivative as above, or a fusion polypeptide or protein as above, in conjunction with an antigenic stimulus, wherein the administration of the polypeptide is effective to increase the T cell response of the subject to the antigenic stimulation.

25 This invention also provides a method for inhibiting a T cell response of a mammalian subject to antigenic stimulation, comprising administering to the subject an effective amount of an antibody as described, wherein the administration of the antibody is effective to block stimulation of T cells or to eliminate antigen-reactive T cells, thereby inhibiting the T cell response. These methods are particularly useful for treating a subject with a tissue or organ transplant to inhibit transplant rejection and/or to promote engraftment. In the case of an autoantigen, the method blocks or diminishes autoimmune reactions and their pathologic sequelae.

30 The present invention provides therapeutic methods using T cells that have undergone *ex vivo* stimulation with the compositions of this invention. One method for increasing the immune response of a mammalian subject to antigenic stimulation comprises:

- (a) obtaining T cells from the subject, from an immunologically compatible donor for said subject, or from an immunologically acceptable cultured cell line;
- (b) contacting the T cells *ex vivo* with an effective amount of cells as described above, wherein the contacting is effective to increase the response of the T cells to antigenic stimulation; and
- (c) administering the T cells of step (b) to the subject, thereby increasing the immune response of the subject.

In another embodiment, the method for increasing the immune response of a mammalian subject to antigenic stimulation comprises:

- (a) obtaining T cells from obtaining T cells from the subject, from an immunologically compatible donor for said subject, or from an immunologically acceptable cultured cell line;
- (b) contacting the T cells *ex vivo* with an effective amount of (i) a polypeptide, fragment, homologue or functional derivative as described above, or (ii) a fusion polypeptide as above, wherein the contacting is effective to increase the response of the T cells to antigenic stimulation; and
- (c) administering the T cells of step (b) to the subject, thereby increasing (or generating) an immune response of the subject.

Also provided herein is a vaccine composition comprising

- (a) (i) cells as described above that express a B7-DC construct, (ii) a B7-DC polypeptide, fragment, homologue or functional derivative , (iii) a B7-DC fusion polypeptide or protein
- (b) generally, an additional source of antigen to which an immune response is desired -- though this may not be required in the case of the cell-based vaccine wherein the cells themselves expresses the antigen (as in the case of tumor antigen-bearing tumor cells);
- (c) optionally, a general immunostimulatory agent or adjuvant; and
- (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

A method for inducing or enhancing an immune response to an antigen in a mammalian subject comprises administering to the subject an effective amount of the above vaccine composition.

Also provided is a co-stimulatory composition for use with an antigen or a vaccine, comprising:

- (a) a B7-DC polypeptide (preferably SEQ ID NO:2 or SEQ ID NO:4), a fragment, a homologue or a functional derivative thereof, or a B7-DC fusion polypeptide, and
- 5 (b) a pharmaceutically and immunologically acceptable excipient or carrier.

A method for potentiating an immune response to an antigen or a vaccine in a mammalian subject, comprises administering to the subject, in combination with the antigen or vaccine, the above costimulatory composition.

A method of stimulating a systemic immune response to a tumor in a subject, comprises 10 administering to the subject genetically altered tumor cells which cells

- (a) are derived from a tumor in the subject, and
- (b) are genetically altered by introduction *ex vivo* of a B7-DC nucleic acid as described above, the expression of which provides a costimulatory signal in the subject, wherein the administering results in stimulation of the systemic immune response directed to the 15 tumor.

The tumor cells are preferably treated, preferably by irradiation, to prevent their growth after they have been administered.

The subject may be subjected to a tumor-reducing regimen of chemotherapy, irradiation or surgical resection prior to the administering of the above therapeutic compositions.

20 Also provided is a method of inducing an antitumor response in a mammal having an antigen-positive tumor, comprising:

- (a) providing cells of the tumor or of a tumor cell line that
 - (i) express antigens shared with the tumor of the mammal;
 - (ii) are transfected with a B7-DC-encoding nucleic acid vector as above, that when expressed, a B7-DC molecule causes the cells to co-stimulate a T cell response to antigens of the tumor;
 - (iii) optionally, are irradiated prior to step (b);
- (b) administering an effective number of the cells to the mammal, which cells express the antigens and the B7-DC molecule;

25 30 thereby inducing an antitumor response

In the above method, the antitumor response is characterized by:

- (A) at least a 50% decrease in the sum of the products of maximal perpendicular diameters of all measurable lesions;
- (B) no evidence of new lesions, and
- 5 (C) no progression of any preexisting lesions.

Also provided is a method of inducing regression or attenuation of primary growth or regrowth of a tumor in a mammal bearing the tumor, comprising:

- (a) providing cells of the tumor or of a tumor cell line that
 - (i) express antigens shared with the tumor of the mammal;
 - 10 (ii) are transfected with a B7-DC-encoding nucleic acid vector as above, that, when expressed, as a B7-DC molecule causes the cells to co-stimulate a T cell response to antigens of the tumor;
 - (iii) optionally, are irradiated prior to step (b);
- (b) administering an effective number of the cells to the mammal, which cells express the 15 antigens and the B7-DC molecule;

thereby inducing a systemic immune response specific to the tumor antigens of the melanoma, thereby inducing the regression or the attenuation

A method of inhibiting recurrent growth of an antigen-positive tumor in a mammal, comprises:

- 20 (a) providing cells of the tumor or of a tumor cell line that
 - (i) express antigens shared with the tumor of the mammal;
 - (ii) are transfected with a B7-DC-encoding nucleic acid vector as above, that, when expressed, causes the cells to co-stimulate a T cell response to antigens of the tumor;
- (iii) optionally, are irradiated prior to step (b);

- (b) administering an effective number of the cells to the mammal, which cells express the antigens and the B7-DC molecule;

thereby inducing a systemic immune response specific to the tumor antigens in the mammal, which immune response inhibits the recurrent growth of the tumor.

30 Another embodiment is directed to a method of providing a co-stimulatory signal in the vicinity of locally-administered antigen in a mammalian subject to promote the local generation

of an inflammatory and immune response that results in a state of systemic immunity to the antigen, the method comprising administering to a local site in the subject

(a) cells that express a costimulation-effective amount of B7-DC polypeptide, fragment, homologue or functional derivative as above, and

5 (b) the antigen

such that costimulation in physical proximity with the antigen promotes the local generation of the response and results in the state of systemic immunity.

In the above method, the antigen is preferably a tumor antigen that is administered in (b) in the form of tumor cells or subcellular antigenic material. The tumor cells may also be the 10 cells that express the B7-DC polypeptide, fragment, homologue or derivative in (a).

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram showing shows the map of hB7-DC which is localized on human chromosome 9p24. hB7-DC maps to BAC clone RPCI-11.2.

15 **Figure 2** shows that B7-DC is differentially expressed between DCs and macrophages. Distribution of B7-DC mRNA in bone marrow DCs, splenic DCs, macrophages, macrophage lines and tissues was assessed by virtual Northern blot analysis using 0.5 µg/lane purified DNA run on a 1% agarose gel. G3PDH was used as control. J774A1, Raw264.7, Pu5-1.8 and WEHI cells are macrophage cell lines. BM: bone marrow.

20 **Figure 3** shows a virtual Northern blot of B7-DC expression on human DCs. Lane 1 shows human DCs cultured with GM-CSF + Flt-3L, lane 2 shows human placenta and lane 3 shows human DCs cultured with GM-CSF + IL4. Oligonucleotides from the 5'and 3' UTR of human B7-DC were used to make PCR DNA probe for virtual Northern analysis of total RNA of human DCs. β-actin was used as control to ensure the quality of mRNA.

25 **Figure 4** represents is a flow cytometric analysis showing surface expression of B7-DC on mature BM-DCs. Day 9 murine BM-DCs were Fc-blocked and stained with control antibody or B7-DC antisera. Specificity of binding was demonstrated by adding B7-DC-Ig to compete for the binding of anti-B7-DC to the surface of DCs.

30 **Figure 5** shows the binding of B7-DC to PD-1 but not CTLA-4 or CD28. 293T cells were transiently transfected with pCAGGS-B7.1 o pCAGGS-B7-DC. Transfectants were

stained with PD-1-Ig, 28-Ig and CTLA-4-Ig fusion molecules followed by PE-labeled secondary antibody. Staining of pCAGGS (empty vector) transfectants was negative (not shown)

Figure 6 (left and right panel) shows the costimulation of T cell proliferation by anti-CD3 and B7-DC-Ig. Left graph: purified T cells (CD4 + CD8) were cultured in wells pre-coated with increasing concentrations of anti-CD3 (mAb 2C11) and a fixed concentration (0.1 µg/ml) of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲). Results depict one representative experiment of three. Cells were incubated for 72h and labeled with ³H-thymidine. CPM, counts per minute. Right Graph: purified CD8 T cells were cultured in wells pre-coated with increasing concentrations of anti-CD3 and fixed concentration of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲) as in (a). Results are of one representative experiment of two. Cells were incubated for 72h and labeled with ³H-thymidine. CPM, counts per minute.

Figure 7 shows the costimulation of antigen-specific T cell proliferative responses RENCA cells were treated with IFN γ for 72hrs to induce MHC class II expression and incubated with 12.5 µg/ml of HA110-120 peptide. Purified HA + I-E^d specific transgenic T cells were added together with increasing concentrations of either B7.1-Ig (◆), B7-DC-Ig (●) or Isotype control (▲) in soluble form. Cells were incubated for 48h and labeled with ³H-thymidine. CPM, counts per minute. Results are one representative experiment of three.

Figure 8 shows cytokine secretion of T cells costimulated by B7-DC.

Upper panels: purified T cells were cultured in wells pre-coated with anti-CD3 (0.12 µg/ml) and 0.1 µg/ml of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲) as in Fig. 6 (left). Results depict one representative experiment of three.

Lower panels: γ -IFN treated RENCA cells loaded with 12.5 µg/ml HA(110-120) peptide were incubated with purified HA + I-E^d specific transgenic T cells together with 2 µg/ml of soluble B7.1-Ig, B7-DC-Ig or isotype control (symbols as above). Results depict one representative experiment of two. Supernatants were collected after 24h and 48h culture and assayed for the indicated lymphokines using ELISA.

Figure 9 shows that B7-DC-Ig greatly enhances antigen specific proliferation after *in vivo* co-stimulation. After adoptive transfer of 2.5×10^6 TCR transgenic cells specific for HA, three groups of mice were immunized s.c., in their hind footpads with either HA peptide (110-120), incomplete Freund's adjuvant (IFA) alone or in combination with either B7-DC-Ig + IFA

stained with PD-1-Ig, 28-Ig and CTLA-4-Ig fusion molecules followed by PE-labeled secondary antibody. Staining of pCAGGS (empty vector) transfectants was negative (not shown)

Figure 6 (left and right panel) shows the costimulation of T cell proliferation by anti-CD3 and B7-DC-Ig. Left graph: purified T cells (CD4 + CD8) were cultured in wells pre-coated with increasing concentrations of anti-CD3 (mAb 2C11) and a fixed concentration (0.1 µg/ml) of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲). Results depict one representative experiment of three. Cells were incubated for 72h and labeled with ³H-thymidine. CPM, counts per minute. Right Graph: purified CD8 T cells were cultured in wells pre-coated with increasing concentrations of anti-CD3 and fixed concentration of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲) as in (a). Results are of one representative experiment of two. Cells were incubated for 72h and labeled with ³H-thymidine. CPM, counts per minute.

Figure 7 shows the costimulation of antigen-specific T cell proliferative responses RENCA cells were treated with IFN γ for 72hrs to induce MHC class II expression and incubated with 12.5 µg/ml of HA110-120 peptide. Purified HA + I-E^d specific transgenic T cells were added together with increasing concentrations of either B7.1-Ig (◆), B7-DC-Ig (●) or Isotype control (▲) in soluble form. Cells were incubated for 48h and labeled with ³H-thymidine. CPM, counts per minute. Results are one representative experiment of three.

Figure 8 shows cytokine secretion of T cells costimulated by B7-DC.
Upper panels: purified T cells were cultured in wells pre-coated with anti-CD3 (0.12 µg/ml) and 0.1 µg/ml of immobilized B7.1-Ig (◆), B7-DC-Ig (●) or isotype control (▲) as in Fig. 6 (left). Results depict one representative experiment of three.
Lower panels: γ -IFN treated RENCA cells loaded with 12.5 µg/ml HA(110-120) peptide were incubated with purified HA + I-E^d specific transgenic T cells together with 2 µg/ml of soluble B7.1-Ig, B7-DC-Ig or isotype control (symbols as above). Results depict one representative experiment of two. Supernatants were collected after 24h and 48h culture and assayed for the indicated lymphokines using ELISA.

Figure 9 shows that B7-DC-Ig greatly enhances antigen specific proliferation after *in vivo* co-stimulation. After adoptive transfer of 2.5×10^6 TCR transgenic cells specific for HA, three groups of mice were immunized s.c., in their hind footpads with either HA peptide (110-120), incomplete Freund's adjuvant (IFA) alone or in combination with either B7-DC-Ig + IFA

or an isotype control antibody with IFA. Draining lymph nodes were harvested on day 7. 1.5×10^5 LN cells were incubated with the HA peptide for 48h, pulsed with $1\mu\text{Ci}$ [^3H]thymidine and the radioactivity incorporated after 12h was determined.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present inventors have now identified new proteins and nucleic acids that serve as the basis for improved immunotherapeutic compositions and methods. Human and murine forms of a novel costimulatory protein named B7-DC have been discovered and are disclosed herein.

DNA encoding human B7-DC has the nucleotide sequence SEQ ID NO:1, show below.

```
1  atgatcttcctcgtaatgttggcattgcagttcaccagatagcagctta  
61 ttcacagtgcacgtccctaaggaaactgtacataatagagcatggcagaatgtgaccctg  
121 gaatgcacattgacacttggaaagtcatgtgaacctggagcaataacagccagttgcaa  
181 aagggtggaaaatgatacatccccacccgtgaaagagccacttgcggaggagcagctg  
241 ccccttagggaaaggcctcgttccacatacctcaagtccaagtgagggacgaaggacagtc  
301 caatgcataatcatctatgggtcgccctggactacaagtgactctgaaagtcaaa  
361 gtttcctacagggaaaataaacactcacatctaaagggttcagaaacagatgaggtagag  
421 ctccacctgcaggctacaggttatcctctggcagaagtatcctggccaaacgtcagcgtt  
481 cctgccaacaccagccactccaggccccctgaaggccttaccaggtcaccagtgttctg  
541 cgccctaaagccacccctggcagaaacttcagctgtgttctggaaataactcacgtgagg  
601 gaacttacttggccagacattgacattcaaaagtcaagatggaaaccaggacccatccaact  
661 tggctgcttacatttcatccccctctgcatattgcttcatttcatagccacagtg  
721 atagccctaagaaaacaactctgtcaaaagctgttattcttcaaaagacacaacaaaaga  
781 cctgtcaccacaacaaagagggaaagtgaacagtgctatc 819
```

The human B7-DC protein has the amino acid sequence SEQ ID NO:2, shown below (with leader sequence, transmembrane domain and cytoplasmic tail annotated):

<i>putative leader sequence</i>		
1	MIFLLLMLSL	ELQLHQIAAL FTVTVPKELY IIEHGSNVTL ECNFDTGSHV
51	NLGAITASLQ	KVENDTSPHR ERATLLEEQQL PLGKASFHIP QVQVRDEGQY
101	QCIIIIYGVAW	DYKYLTLLKVK ASYRKINTHI LKVPETDEVE LTCQATGYPL
151	AEVSWPNVSV	PANTSHSRTP EGLYQVTSVL RLKPPPGRNF SCVFWNTHVR
<i>putative TM domain</i>		
201	ELTLASIDLQ	SQMEPRTHPT WLLHIFIPSC II A FIFIATV IALRKQLCQKL
251	LYSSKDTTKR	PVTTTKREVN SAI
	<i>cytoplasmic tail</i>	
		273

The extracellular domain of this protein is from residue P²⁶ through residue W²²¹.

A DNA clone that includes the coding sequence encoding murine B7-DC has the nucleotide sequence SEQ ID NO:3, show below. The coding sequence (underscored, set off in triplets) begins from the methionine codon **a**t**g** (bolded) beginning at nucleotide 210 and terminates with the **t**a**g** stop codon (bolded) (nucleotides 951-953)

	gaattcggcacgaggtaaatgtggcatatcttggatcccttcgtctcccaactag	60
	agagaacacacttacggctccgtcccccggcagggttggtgtcggtgtattggctcc	120
	agggAACCTGATACAAGGAGAACACTGTGTGCTGCCTTCTGTCTTGCTTGGAGAC	180
	tgtgctgggtgctgatattgacacagacc	209
5	<u>atg ctg ctc ctg ctg ccg ata ctg aac ctg agc tta caa ctt cat cct</u>	257
	gta gca gct tta ttc acc gtg aca gcc cct aaa gaa <u>gtg tac acc gta</u>	305
	gac gtc ggc agc agt <u>gtg agc ctg gag tgc gat ttt gac cgc aga gaa</u>	353
	tgc act gaa ctg gaa ggg ata aga gcc agt ttg cag aag gta gaa aat	401
	<u>gat acg tct ctg caa agt gaa aga gcc acc ctg ctg gag gag cag ctg</u>	449
10	<u>ccc ctg gga aag gct ttg ttc cac atc cct agt gtc caa gtg aga gat</u>	497
	<u>tcc ggg cag tac cgt tgc ctg gtc atc tgc ggg gcc gcc tgg gac tac</u>	545
	aag tac ctg acg <u>gtg aaa gtc aaa gct tct tac atg agg ata gac act</u>	593
	agg atc ctg gag gtt cca ggt aca ggg gag <u>gtg ctt acc tgc cag</u>	641
	<u>gct aga ggt tat ccc cta gca gaa gtg tcc tgg caa aat gtc agt gtt</u>	689
15	<u>cct gcc aac acc agc cac atc agg acc ccc gaa ggc ctc tac cag gtc</u>	737
	<u>acc agt gtt ctg cgc ctc aag cct cag cct agc aga aac ttc agc tgc</u>	785
	atg ttc tgg aat gct cac atg aag gag <u>ctg act tca gcc atc att gac</u>	833
	<u>cct ctg agt cgg atg gaa ccc aaa gtc ccc aga acg tgg cca ctt cat</u>	881
	<u>gtt ttc atc ccc gcc tgc acc atc gct ttg atc ttc ctg gcc ata gtg</u>	929
20	<u>ata atc cag aga aag agg atc tag</u>	953
	gggaagctgtattacggaaaggatgggtcttcttccagatctggacctggcggtcttgg	1013
	gagtttggaaaggatctgtatggaaaccctcaagagacttctggactcaaagtgagaatctt	1073
	gcaggacacctgcatttgactttgaaccctttggacgggtgaccccagggtccgaagagg	1133
	agctttaagactgacaatcttccctgtctcaagactctctgtcaacagccaagaccCAA	1193
25	tggcacttagacttacccctgggatctggaccccaggactgaggccctaaggctctaatg	1253
	actttcagggtgagaacaaaaggaaattgtctccggccccccccccactctgtcttccg	1313
	caggagacatggaaattcccaagttactaaaatagattgtcaatagagtatttatagcc	1373
	ctcatttcctccgggacttggagcttcagacagggttttctataaacaagtcataaac	1433
	tgatgtgtttacagcatctagaatcttggcagccctgtcaagttctaaactactggaaag	1493
30	catttaagcaacacgtcaagtggccctgtgtggatattttctactttctgtttta	1553
	aagtgtgagtcacaaggtaattttgttaacctgtgtatcactgtttctgtctttca	1613
	tttcaactacattttaaaaaaaaaaaaaaaaaaaaaaaaaaaa	1655

SEQ ID NO:5 is the coding sequence part of SEQ ID NO:3.

The murine B7-DC protein, encoded by the coding region of SEQ ID NO:3, (i.e., by
 35 SEQ ID NO:5) has the amino acid sequence SEQ ID NO:4 shown below (with leader sequence,
 transmembrane domain and cytoplasmic tail annotated):

	<i>putative leader sequence</i>	
1	MLLLPIILNL SLQLHPVAAL FTVTAPKEVY TVDVGVSSVSL ECDFDRRECT	50
51	ELEGIRASLQ KVENDTSLSQ ERATLLEEQL PLGKALFHIP SVQVRDSGQY	100
101	RCLVICGAAW DYKYLTVKVVK ASYMRIDTRI LEVPGTGEVQ LTCQARGYPL	150
151	AEVSWQNVS PANTSHIRTP EGLYQVTSVL RLKPQPSRNF SCMFVNAMHK	200
	<i>putative TM domain</i>	
201	ELTSAIIDPL SRMEPKVPRT WPLHVFIPAC TIALIFLAIV IIQRKRI	247
	<i>cyto. tail</i>	

45 The extracellular domain of this protein is from residue P²⁶ through residue W²²¹

The complete DNA sequence of murine B7-DC (originally termed “butyrophilin-like protein” or
 “Btdc”) has the Genbank accession number AF142780.2

Basic Molecular Approach

This approach is described in more detail in the Examples. The inventors utilized the PCR Select approach which incorporate two important features. First, the initial PCR reaction prior to the hybridization steps requires only small quantity of RNA. This technique allows the
5 use of highly purified mature DCs that have been rendered substantially free of contaminating macrophages, progenitor cells or other potential contaminating cells. Such highly purified DCs are known to be difficult to obtain in very large numbers. Second, the PCR Select procedure enabled cloning of low copy number, differentially expressed genes.

To identify genes differentially expressed by DCs relative to their cellular counterpart,
10 the activated macrophage, and to identify genes associated with DC-specific functions, the present inventors applied a cDNA subtraction approach. They used a modified PCR-based “representative differential analysis” (RDA) combined with suppression PCR (PCR SelectTM) (Diatchenko, L. et al., *Proc. Natl. Acad. Sci USA* 93:66025-6030 (1996)).

GENERAL RECOMBINANT DNA METHODS

15 Basic texts disclosing general methods of molecular biology, all of which are incorporated by reference, include: Sambrook, J et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989; Ausubel, FM et al. *Current Protocols in Molecular Biology*, Vol. 2, Wiley-Interscience, New York, (current edition); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); Glover, DM, ed, *DNA Cloning: A Practical Approach*, vol. I & II, IRL Press, 1985; Albers, B. et al., *Molecular Biology of the Cell*, 2nd Ed., Garland Publishing, Inc., New York, NY (1989); Watson, JD et al., *Recombinant DNA*, 2nd Ed., Scientific American Books, New York, 1992; and Old, RW et al., *Principles of Gene Manipulation: An Introduction to Genetic Engineering*, 2nd Ed., University of California Press, Berkeley, CA (1981).

25 Unless otherwise indicated, a particular nucleic acid sequence is intended to encompasses conservative substitution variants thereof (e.g., degenerate codon substitutions) and a complementary sequence. The term “nucleic acid” is synonymous with “polynucleotide” and is intended to include a gene, a cDNA molecule, an mRNA molecule, as well as a fragment of any of these such as an oligonucleotide, and further, equivalents thereof (explained more fully below). Sizes of nucleic acids are stated either as kilobases (kb) or base pairs (bp). These are estimates derived from agarose or polyacrylamide gel electrophoresis (PAGE), from nucleic acid

sequences which are determined by the user or published. Protein size is stated as molecular mass in kilodaltons (kDa) or as length (number of amino acid residues). Protein size is estimated from PAGE, from sequencing, from presumptive amino acid sequences based on the coding nucleic acid sequence or from published amino acid sequences.

5 Specifically, cDNA molecules encoding the amino acid sequence corresponding to B7-DC or fragments or derivatives thereof can be synthesized by the polymerase chain reaction (PCR) (see, for example, U.S. 4,683,202) using primers derived the sequence of the protein disclosed herein. These cDNA sequences can then be assembled into a eukaryotic or prokaryotic expression vector and the resulting vector can be used to direct the synthesis of 10 B7-DC, or its fragment or derivative by appropriate host cells, for example COS or CHO cells.

This invention includes isolated nucleic acids having a nucleotide sequence encoding the novel B7-DC, fragments thereof or equivalents thereof. The term nucleic acid as used herein is intended to include such fragments or equivalents. The nucleic acid sequences of this invention can be DNA or RNA. A preferred nucleic acid is cDNA encoding human B7-DC having the 15 sequence SEQ ID NO:1 or equivalents thereof.

Preferably, the nucleic acid of the present invention is a cDNA molecule encoding at least a portion of B7-DC. This cDNA can be made from mRNA extracted from mature DCs or other cells naturally expressing this protein. A nucleic acid sequence encoding B7-DC is obtainable from DC genomic DNA. Thus, DNA encoding B7-DC can be cloned from a cDNA 20 or a genomic library in accordance with known protocols.

A cDNA nucleotide sequence encoding B7-DC can be obtained by isolating total mRNA from an appropriate cell line. Double stranded cDNA is prepared from total mRNA. cDNA can be inserted into a suitable plasmid, bacteriophage or viral vector using any one of a number of known techniques.

25 In reference to a nucleotide sequence, the term "equivalent" is intended to include sequences encoding structurally homologous and/or a functionally equivalent proteins. For example, a natural polymorphism of the B7-DC nucleotide sequence (especially at the third base of a codon) may be manifest as "silent" mutations which do not change the amino acid sequence. However, polymorphisms that involve amino acid sequence changes in B7-DC may 30 exist in a human (or other mammalian) population. Those of skill in the art will appreciate that these allelic variants that have changes in one or more nucleotides (up to about 3-4% of the total coding sequence) will likely be found in a human population due to natural allelic variation. Any

and all such allelic variations and resulting nucleic acid and polypeptide polymorphisms in the DNA encoding B7-DC are within the scope of the invention.

Furthermore, there may be one or more naturally occurring isoforms or related, immunologically cross-reactive family members of the B7-DC protein described herein. Such 5 isoforms or family members are defined as proteins that share function amino acid sequence similarity to B7-DC, even if they are encoded by genes at different loci.

Fragment of Nucleic Acid

A fragment of the nucleic acid sequence is defined as a nucleotide sequence having fewer nucleotides than the nucleotide sequence encoding the full length B7-DC protein. This 10 invention includes such nucleic acid fragments that encode polypeptides which retain (1) the ability of B7-DC to bind to its natural ligand(s) on T cells and (2) to enhance or inhibit (depending on how they are presented) activated T cell mediated immune responses (measured as cytokine production and/or T cell proliferation by T cells that have received a primary activation signal).

15 For example, a nucleic acid fragment as intended herein encodes a B7-DC polypeptide that retains the ability to bind to the surface of T cells to a receptor that has not yet been identified (but is does not appear to be CD28 or CTLA-4) and deliver a costimulatory signal to T lymphocytes. By another criterion, the present nucleic acid fragment is one that hybridizes with a nucleic acid from another animal species and is therefore useful in screening assays to 20 detect novel proteins that are “cross-reactive” with B7-DC.

Generally, the nucleic acid sequence encoding a fragment of the B7-DC polypeptide comprises of nucleotides from the sequence encoding the mature protein. However, in some instances it may be desirable to include all or part of the leader sequence portion of the nucleic acid. Nucleic acid sequences of this invention may also include linker sequences, natural or modified restriction endonuclease sites and other sequences that are useful for manipulations 25 related to cloning, expression or purification of encoded protein or fragments. These and other modifications of nucleic acid sequences are described herein or are well-known in the art.

In one embodiment, DNA encoding the amino acid sequence corresponding to the ECD of B7-DC, containing amino acids from about position 26-221, is joined to DNA encoding the amino acid sequences corresponding to the hinge, C_H2 and C_H3 regions of human Ig Cy1, using 30 PCR, to form a construct that is expressed as B7-DC-Ig fusion protein.

An analogous DNA molecule encoding a B7-Ig fusion protein was disclosed in U.S. 5,521,288 and deposited with the American Type Culture Collection in Rockville, Md., under accession number 68627.

The techniques for assembling and expressing DNA encoding B7-DC and soluble B7-DC fusion proteins such as synthesis of oligonucleotides, PCR, transforming cells, constructing vectors, expression systems, and the like are well-established in the art. Those of ordinary skill are familiar with the standard resource materials for specific conditions and procedures.

In other embodiments, the DNA encoding a domain or fragment of B7-DC is fused with a nucleic acid encoding most or all of the remaining portion of another B7 family protein, such as B7.1, B7.2 or B7.3. The complete DNA sequence of human B7.1 (CD80) has the Genbank accession number X60958; the accession number for the mouse sequence is X60958; the accession number for the rat sequence is U05593. The complete cDNA sequence of human B7.2 (CD86) has the Genbank accession number L25259; the accession number for the mouse sequence is L25606.

EXPRESSION VECTORS AND HOST CELLS

This invention includes an expression vector comprising a nucleic acid sequence encoding a B7-DC polypeptide operably linked to at least one regulatory sequence. "Operably linked" means that the coding sequence is linked to a regulatory sequence in a manner that allows expression of the coding sequence. Known regulatory sequences are selected to direct expression of the desired protein in an appropriate host cell. Accordingly, the term "regulatory sequence" includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in, for example, Goeddel, *Gene Expression Technology. Methods in Enzymology*, vol. 185, Academic Press, San Diego, Calif. (1990)).

Those skilled in the art appreciate that the particular design of an expression vector of this invention depends on considerations such as the host cell to be transfected and/or the type of protein to be expressed.

The present expression vectors comprise the full range of nucleic acid molecules encoding the various embodiments of B7-DC: full length protein and its functional derivatives (defined herein) including polypeptide fragments, variants, fusion proteins, etc. Thus, in one embodiment, the expression vector comprises a nucleic acid encoding at least a portion of the B7-DC protein such as the ECD, alone or fused to another protein.

Such expression vectors are used to transfect host cells for expression of the DNA and production of the encoded proteins which include fusion proteins or peptides. It will be understood that a genetically modified cell expressing the B7-DC polypeptide may transiently express the exogenous DNA for a time sufficient for the cell to be useful for its stated purpose.

5 Thus, if the cell is to serve as an immunogen having an augmented costimulatory capacity *in vivo* or *ex vivo*,, the length of time that expression is required, or that the cell remain alive, is the time necessary for the cell to exert its immunogenic and/or costimulatory function. For example, in the case of a transduced tumor cell expressing the B7-DC of the present invention, expression of B7-DC may be for as little as 6 hours, preferably 24 hours, more preferably for at 10 least 2-4 days. Of course, expression may also be stable (*i.e.*, for the life of the cell).

Appropriate expression vectors and regulatory elements (*e.g.*, *e.g.*, inducible or constitutive promoters) discussed below are selected in accordance with the desired or required stability of expression.

The present invention provides methods for producing the B7-DC protein, fragments and derivatives. For example, a host cell transfected with a nucleic acid vector that encodes at 15 least a portion of the B7-DC protein is cultured under appropriate conditions to allow expression of B7-DC polypeptide.

Host cells may also be transfected with one or more expression vectors that singly or in combination comprise DNA encoding at least a portion of the B7-DC protein and DNA 20 encoding at least a portion of a second protein, so that the host cells produce fusion polypeptides that include both the portions.

When the recombinant expression vector comprises DNA encoding a portion of B7-DC and DNA encoding another protein, such as human IgCy1, the resulting fusion protein may have altered solubility, binding affinity and/or valency. A B7-DC Ig fusion protein, for example, is 25 preferably secreted by transfected host cells in cultures and is therefore isolated from the culture medium. Alternatively, if protein is retained in the cytoplasm, the cells are harvested and lysed and the protein isolated from this lysate.

A culture typically includes host cells, appropriate growth media and other byproducts. Suitable culture media are well known in the art. B7-DC protein can be isolated from medium 30 or cell lysates using conventional techniques for purifying proteins and peptides, including ammonium sulfate precipitation, fractionation column chromatography (*e.g.* ion exchange, gel filtration, affinity chromatography, etc.) and/or electrophoresis (see generally, "Enzyme

Purification and Related Techniques", *Methods in Enzymology*, 22: 233-577 (1971)). Once purified, partially or to homogeneity, the recombinant B7-DC proteins of the invention can be utilized in pharmaceutical compositions as described in more detail herein.

Prokaryotic or eukaryotic host cells transformed or transfected to express B7-DC or a homologue or functional derivative thereof are within the scope of the invention. For example, B7-DC may be expressed in bacterial cells such as *E. coli*, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO) or human cells. Other suitable host cells may be found in Goeddel, (1990) *supra* or are otherwise known to those skilled in the art.

Expression in eukaryotic cells leads to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of the recombinant protein.

Examples of vectors for expression in yeast *S. cerevisiae* include pYEpSec1 (Baldari *et al.*, (1987) *EMBO J.* 6:229-234), pMFA (Kurjan *et al.* (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith *et al.*, (1983) *Mol. Cell Biol.* 3: 2156-2165,) and the pVL series (Lucklow, V. A., and Summers, M. D., (1989) *Virology* 170: 31-39). Generally, COS cells (Gluzman, Y., (1981) *Cell* 23: 175-182) are used in conjunction with such vectors as pCDM 8 (Aruffo A. and Seed, B., *supra*, for transient amplification/expression in mammalian cells, while CHO (*dhfr*-negative CHO) cells are used with vectors such as pMT2PC (Kaufman *et al.* (1987), *EMBO J.* 6: 187-195) for stable amplification/expression in mammalian cells. The NS0 myeloma cell line (a glutamine synthetase expression system.) is available from Celltech Ltd.

Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the reporter group and the target protein to enable separation of the target protein from the reporter group subsequent to purification of the fusion protein. Proteolytic enzymes for such cleavage and their recognition sequences include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Inducible non-fusion expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69: 301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 60-89). While target gene expression relies on

host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pET 11d relies on transcription from the T7 gn10-lacO fusion promoter mediated by coexpressed viral RNA polymerase (T7gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7gn1 under the transcriptional control of the lacUV 5 promoter.

One embodiment of this invention is a transfected cell which expresses novel B7-DC *de novo*. In the case of a cell already expressing B7-DC, such as a mature DC, the transfected cell expresses increased amounts of B7-DC proteins or fragments thereof on the cell surface.

For example, a tumor cell such as a sarcoma, melanoma, leukemia, lymphoma, carcinoma or neuroblastoma is transfected with an expression vector directing the expression of B7-DC on the tumor cell surface. Such transfected tumor cells can be used as immunogens to induce therapeutic antitumor immunity as described herein.

Vector Construction

Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction techniques which are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and re-ligated in the form desired.

The DNA sequences which form the vectors are available from a number of sources. Backbone vectors and control systems are generally found on available "host" vectors which are used for the bulk of the sequences in construction. For the pertinent coding sequence, initial construction may be, and usually is, a matter of retrieving the appropriate sequences from cDNA or genomic DNA libraries. However, once the sequence is disclosed it is possible to synthesize the entire gene sequence *in vitro* starting from the individual nucleotide derivatives. The entire gene sequence for genes of sizeable length, e.g., 500-1000 bp may be prepared by synthesizing individual overlapping complementary oligonucleotides and filling in single stranded nonoverlapping portions using DNA polymerase in the presence of the deoxyribonucleotide triphosphates. This approach has been used successfully in the construction of several genes of known sequence. See, for example, Edge, M. D., *Nature* (1981) 292:756; Nambair, K. P., *et al.*, *Science* (1984) 223:1299; and Jay, E., *J Biol Chem* (1984) 259:6311.

Synthetic oligonucleotides are prepared by either the phosphotriester method as described by references cited above or the phosphoramidite method as described by Beaucage,

S. L., and Caruthers, M. H., *Tet Lett* (1981) 22:1859; and Matteucci, M. D., and Caruthers, M. H., *J Am Chem Soc* (1981) 103:3185 and can be prepared using commercially available automated oligonucleotide synthesizers. Kinase treatment of single strands prior to annealing or for labeling is achieved using an excess, e.g., about 10 units of polynucleotide kinase to 1 nmole substrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl₂, 5 mM dithiothreitol, 1-2 mM ATP, 1.7 pmoles γ -³²P-ATP (2.9 mCi/mmole), 0.1 mM spermidine, 0.1 mM EDTA.

Once the components of the desired vectors are thus available, they can be excised and ligated using standard restriction and ligation procedures. Site-specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 mg of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 ml of buffer solution; in the examples herein, typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37°C. are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in *Methods in Enzymology* (1980) 65:499-560.

Restriction cleaved fragments may be blunt ended by treating with the large fragment of *E. coli* DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20° to 25° C. in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl₂, 6 mM DTT and 0.1-1.0 mM dNTPs. The Klenow fragment fills in at 5' single-stranded overhangs but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the, or selected, dNTPs within the limitations dictated by the nature of the overhang. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or BAL-31 results in hydrolysis of any single-stranded portion.

Ligations are typically performed in 15-50 ml volumes under the following standard conditions and temperatures: for example, 20 mM Tris-HCl pH 7.5, 10mM MgCl₂ , 10 mM

5 DTT, 33 µg/ml BSA, 10-50mM NaCl, and either 40 µM ATP, 0.01-0.02 (Weiss) units T4 DNA ligase at 0° C. (for “sticky end” ligation) or 1mM ATP, 0.3-0.6 (Weiss) units T4 DNA ligase at 14° C. (for “blunt end” ligation). Intermolecular “sticky end” ligations are usually performed at 33-100 µg/ml total DNA concentrations (5-100 nM total end concentration). Intermolecular blunt end ligations are performed at 1 mM total ends concentration.

10 In vector construction employing “vector fragments”, the fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase (CIAP) in order to remove the 5' phosphate and prevent self-ligation. Digestions are conducted at pH 8 in approximately 10 mM Tris-HCl, 1 mM EDTA using BAP or CIAP at about 1 unit/mg vector at 60° for about one hour. The preparation is extracted with phenol/chloroform and ethanol precipitated. Alternatively, re-ligation can be prevented in vectors which have been double digested by additional restriction enzyme and separation of the unwanted fragments.

15 Any of a number of methods are used to introduce mutations into the coding sequence to generate the variants of the invention. These mutations include simple deletions or insertions, systematic deletions, insertions or substitutions of clusters of bases or substitutions of single bases.

20 For example, modifications of B7-DC DNA sequence (cDNA or genomic DNA) are created by site-directed mutagenesis, a well-known technique for which protocols and reagents are commercially available (Zoller, MJ *et al.*, *Nucleic Acids Res* (1982) 10:6487-6500 and Adelman, JP *et al.*, *DNA* (1983) 2:183-193)). Correct ligations for plasmid construction are confirmed, for example, by first transforming *E. coli* strain MC1061 (Casadaban, M., *et al.*, *J Mol Biol* (1980) 138:179-207) or other suitable host with the ligation mixture. Using conventional methods, transformants are selected based on the presence of the ampicillin-, tetracycline- or other antibiotic resistance gene (or other selectable marker) depending on the mode of plasmid construction. Plasmids are then prepared from the transformants with optional chloramphenicol amplification optionally following chloramphenicol amplification ((Clewell, DB *et al.* , *Proc Natl Acad Sci USA* (1969) 62:1159; Clewell, D. B., *J Bacteriol* (1972) 110:667). Several mini DNA preps are commonly used. See, e.g., Holmes, DS, *et al.*, *Anal Biochem* (1981) 114:193-197; Birnboim, HC *et al.* , *Nucleic Acids Res* (1979) 7:1513-1523. The isolated DNA is analyzed by restriction and/or sequenced by the dideoxy nucleotide method of Sanger (*Proc Natl Acad Sci USA* (1977) 74:5463) as further described by Messing, *et al.*,

Nucleic Acids Res (1981) 9:309, or by the method of Maxam *et al.* *Methods in Enzymology* (1980) 65:499.

5 Vector DNA can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming host cells can be found in Sambrook *et al. supra* and other standard texts.

10 Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the reporter group and the target protein to enable separation of the target protein from the reporter group subsequent to purification of the fusion protein. Proteolytic enzymes for such cleavage and their recognition sequences include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein.

15 Inducible non-fusion expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69: 301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of target genes inserted into pET 11d relies on transcription from the T7 gn10-lacO fusion promoter mediated by coexpressed viral RNA polymerase (T7gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7gn1 under the transcriptional control of the lacUV 5 promoter.

Promoters and Enhancers

25 A promoter region of a DNA or RNA molecule binds RNA polymerase and promotes the transcription of an "operably linked" nucleic acid sequence. As used herein, a "promoter sequence" is the nucleotide sequence of the promoter which is found on that strand of the DNA or RNA which is transcribed by the RNA polymerase. Two sequences of a nucleic acid molecule, such as a promoter and a coding sequence, are "operably linked" when they are linked to each other in a manner which permits both sequences to be transcribed onto the same RNA transcript or permits an RNA transcript begun in one sequence to be extended into the second sequence. Thus, two sequences, such as a promoter sequence and a coding sequence of DNA or

RNA are operably linked if transcription commencing in the promoter sequence will produce an RNA transcript of the operably linked coding sequence. In order to be "operably linked" it is not necessary that two sequences be immediately adjacent to one another in the linear sequence.

The preferred promoter sequences of the present invention must be operable in
5 mammalian cells and may be either eukaryotic or viral promoters. Suitable promoters may be inducible, repressible or constitutive. An example of a constitutive promoter is the viral promoter MSV-LTR, which is efficient and active in a variety of cell types, and, in contrast to most other promoters, has the same enhancing activity in arrested and growing cells. Other preferred viral promoters include that present in the CMV-LTR (from cytomegalovirus)
10 (Bashart, M. et al., *Cell* 41:521 (1985)) or in the RSV-LTR (from Rous sarcoma virus) (Gorman, C.M., *Proc. Natl. Acad. Sci. USA* 79:6777 (1982)). Also useful are the promoter of the mouse metallothionein I gene (Hamer, D., et al., *J. Mol. Appl. Gen.* 1:273-288 (1982)); the TK promoter of Herpes virus (McKnight, S., *Cell* 31:355-365 (1982)); the SV40 early promoter (Benoist, C., et al., *Nature* 290:304-310 (1981)); and the yeast *gal4* gene promoter (Johnston, 15 S.A., et al., *Proc. Natl. Acad. Sci. (USA)* 79:6971-6975 (1982); Silver, P.A., et al., *Proc. Natl. Acad. Sci. (USA)* 81:5951-5955 (1984)). Other illustrative descriptions of transcriptional factor association with promoter regions and the separate activation and DNA binding of transcription factors include: Keegan et al., *Nature* (1986) 231:699; Fields et al., *Nature* (1989) 340:245; Jones, *Cell* (1990) 61:9; Lewin, *Cell* (1990) 61:1161; Ptashne et al., *Nature* (1990) 346:329;
20 Adams et al., *Cell* (1993) 72:306. The relevant disclosure of all of these above-listed references is hereby incorporated by reference.

The promoter region may further include an octamer region which may also function as a tissue specific enhancer, by interacting with certain proteins found in the specific tissue. The enhancer domain of the DNA construct of the present invention is one which is specific for the target cells to be transfected, or is highly activated by cellular factors of such target cells.
25

Examples of vectors (plasmid or retrovirus) are disclosed in (Roy-Burman et al., U.S. Patent No. 5,112,767). For a general discussion of enhancers and their actions in transcription, see, Lewin, B.M., *Genes IV*, Oxford University Press, Oxford, (1990), pp. 552-576. Particularly useful are retroviral enhancers (e.g., viral LTR). The enhancer is preferably placed upstream from the promoter with which it interacts to stimulate gene expression. For use with retroviral vectors, the endogenous viral LTR may be rendered enhancer-less and substituted with other desired

enhancer sequences which confer tissue specificity or other desirable properties such as transcriptional efficiency on the B7-DC-encoding DNA molecule of the present invention.

The nucleic acid sequences of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated with commercially available DNA synthesizers (See, e.g., Itakura *et al.* U.S. Pat. No. 4,598,049; Caruthers *et al.* U.S. Pat. No. 4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071, incorporated by reference herein).

PROTEINS AND POLYPEPTIDES

10 The present invention includes an "isolated" B7-DC protein having the sequence SEQ ID NO:2 or SEQ ID NO:4. While the present disclosure exemplifies the full length human and murine B7-DC protein (and DNA), it is to be understood that homologues of B7-DC from other mammalian species and mutants thereof that possess the characteristics disclosed herein are intended within the scope of this invention.

15 Also included is a "functional derivative" of B7-DC which means an amino acid substitution variant, a "fragment," or a "chemical derivative" of B7-DC, which terms are defined below. A functional derivative retains measurable B7-DC activity, preferably that of binding to a receptor on T cells and costimulating T cell activity, which permits its utility in accordance with the present invention. "Functional derivatives" encompass "variants" and "fragments" regardless of whether the terms are used in the conjunctive or the alternative herein.

20 A functional homologue must possess the above biochemical and biological activity. In view of this functional characterization, use of homologous proteins B7-DC from other species, including proteins not yet discovered, fall within the scope of the invention if these proteins have sequence similarity and the recited biochemical and biological activity.

25 To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred method of alignment, Cys residues are aligned.

30 In a preferred embodiment, the length of a sequence being compared is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and

even more preferably at least 70%, 80%, or 90% of the length of the reference sequence. For example, when aligning a second sequence to the human B7-DC protein amino acid sequence (SEQ ID NO:2) having 276 amino acid residues, at least 83, preferably at least 110, more preferably at least 138, even more preferably at least 166, and even more preferably at least 193, 5 221 or 248 amino acid residues are aligned). The amino acid residues (or nucleotides) at corresponding amino acid positions (or nucleotide) positions are then compared. When a position in the first sequence is occupied by the same amino acid residue (or nucleotide) as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid 10 "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the 15 percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity 20 between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated 25 into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases, for example, to identify other family members or related sequences. Such searches can be performed using the NBLAST and 30 XBLAST programs (version 2.0) of Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to human or murine B7-DC nucleic acid molecules.

BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to human or murine B7-DC protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing
5 BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

Thus, a homologue of the B7-DC protein described above is characterized as having (a) functional activity of native B7-DC, and (b) sequence similarity to a native B7-DC protein (such as SEQ ID NO:2 or SEQ ID NO:4, when determined above, of at least about 30% (at the amino
10 acid level), preferably at least about 50%, more preferably at least about 70%, even more preferably at least about 90%).

It is within the skill in the art to obtain and express such a protein using DNA probes based on the disclosed sequences of B7-DC. Then, the protein's biochemical and biological activity can be tested readily using art-recognized methods such as those described herein, for
15 example, a standard T cell proliferation or cytokine secretion assay. A biological assay of T cell co-stimulation will indicate whether the homologue has the requisite activity to qualify as a "functional" homologue.

Preferred assays measure the functional characteristics of B7-DC such as stimulating T cells synthesis of cytokines, which depends on binding or cross-linking of the TCR ("primary activation signal"), as well as delivery of a costimulatory signal. The binding of B7-DC to its natural ligand(s) on T cells transmits a signal that induces increased cytokine production, such as IL-2, which in turn stimulates proliferation which can also be measured routinely.

A "variant" of B6-DC refers to a molecule substantially identical to either the full protein or to a fragment thereof in which one or more amino acid residues have been replaced
25 (substitution variant) or which has one or several residues deleted (deletion variant) or added (addition variant). A "fragment" of B6-DC refers to any subset of the molecule, preferably one that includes the ECD, that is, a shorter polypeptide of the full-length protein.

A number of processes can be used to generate fragments, mutants and variants of the isolated DNA sequence. Small subregions or fragments of the nucleic acid encoding the B7-DC
30 protein, for example 1-30 bases in length, can be prepared by standard, chemical synthesis. Antisense oligonucleotides and primers for use in the generation of larger synthetic fragment.

A preferred functional derivative is a fusion protein, a polypeptide that includes a functional fragment of B7-DC. For example, a useful derivative of B7 is a B7-DC-Ig fusion protein that comprises a polypeptide corresponding to the ECD of B7-DC and an Ig C region. The presence of the fusion partner can alter the solubility, affinity and/or valency (defined here as the number of binding sites available per molecule) of the B7-DC protein. A soluble B7-DC fusion protein, while still binding to a receptor on T cells, may have a different biological effect than of the native protein expressed on an APC, *i.e.*, inhibition of T cell stimulation by competitive binding rather than costimulation.

As used herein an extracellular domain (ECD) of B7-DC is the entire extracellular portion of the protein or any fragment thereof that recognizes and binds to PD-1 or to another receptor on T cells that is not CD28 or CTLA-4. Preferably, an ECD of B7-DC is that portion encoded by amino acid residues from about position 26 to about position 221 of SEQ ID NO:2 or SEQ ID NO:4.

By "soluble B7-DC" is intended a cell-free form of B7-DC that may be shed, secreted or otherwise extracted from the producing cells. Soluble B7-DC includes, but is not limited to, soluble fusion proteins such as B7-DC-Ig, free ECD of B7-DC, or the B7-DC ECD fused (genetically or chemically) to a biologically active molecule.

As indicated earlier, this invention also includes hybrid fusion proteins between a B7-DC domain and a domain or fragment of another B7 family protein, preferably expressed on the cell surface in costimulatory form.

A preferred group of B7-DC variants are those in which at least one amino acid residue and preferably, only one, has been substituted by different residue. For a detailed description of protein chemistry and structure, see Schulz, GE *et al.*, *Principles of Protein Structure*, Springer-Verlag, New York, 1978, and Creighton, T.E., *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, 1983, which are hereby incorporated by reference. The types of substitutions that may be made in the protein molecule may be based on analysis of the frequencies of amino acid changes between a homologous protein of different species, such as those presented in Table 1-2 of Schulz *et al.* (*supra*) and Figure 3-9 of Creighton (*supra*). Based on such an analysis, conservative substitutions are defined herein as exchanges within one of the following five groups:

1	Small aliphatic, nonpolar or slightly polar residues	Ala, Ser, Thr (Pro, Gly);
2	Polar, negatively charged residues and their amides	Asp, Asn, Glu, Gln;
3	Polar, positively charged residues	His, Arg, Lys;
4	Large aliphatic, nonpolar residues	Met, Leu, Ile, Val (Cys)
5	Large aromatic residues	Phe, Tyr, Trp.

The three amino acid residues in parentheses above have special roles in protein architecture. Gly is the only residue lacking a side chain and thus imparts flexibility to the chain. Pro, because of its unusual geometry, tightly constrains the chain. Cys can participate in disulfide bond formation, which is important in protein folding.

More substantial changes in biochemical, functional (or immunological) properties are made by selecting substitutions that are less conservative, such as between, rather than within, the above five groups. Such changes will differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Examples of such substitutions are (i) substitution of Gly and/or Pro by another amino acid or deletion or insertion of Gly or Pro; (ii) substitution of a hydrophilic residue, *e.g.*, Ser or Thr, for (or by) a hydrophobic residue, *e.g.*, Leu, Ile, Phe, Val or Ala; (iii) substitution of a Cys residue for (or by) any other residue; (iv) substitution of a residue having an electropositive side chain, *e.g.*, Lys, Arg or His, for (or by) a residue having an electronegative charge, *e.g.*, Glu or Asp; or (v) substitution of a residue having a bulky side chain, *e.g.*, Phe, for (or by) a residue not having such a side chain, *e.g.*, Gly.

Most acceptable deletions, insertions and substitutions according to the present invention are those that do not produce radical changes in the characteristics of the B7-DC protein in terms of its T cell costimulatory activity. However, when it is difficult to predict the exact effect of the substitution, deletion or insertion in advance of doing so, one skilled in the art will appreciate that the effect can be evaluated by routine screening assays such as those described here, without requiring undue experimentation.

Whereas shorter chain variants can be made by chemical synthesis, for the present invention, the preferred longer chain variants are typically made by site-specific mutagenesis of the nucleic acid encoding the B7-DC polypeptide, expression of the variant nucleic acid in cell culture, and, optionally, purification of the polypeptide from the cell culture, for example, by

immunoaffinity chromatography using specific antibody immobilized to a column (to absorb the variant by binding to at least one epitope).

Chemical Derivatives of B7-DC

“Chemical derivatives” of B7-DC contain additional chemical moieties not normally a part of the protein. Covalent modifications of the polypeptide are included within the scope of this invention. Such derivatized moieties may improve the solubility, absorption, biological half life, and the like. Moieties capable of mediating such effects are disclosed, for example, in *Remington’s Pharmaceutical Sciences*, 16th ed., Mack Publishing Co., Easton, PA (1980).

Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Another modification is cyclization of the protein.

Examples of chemical derivatives of the polypeptide follow.

Lysinyl and amino terminal residues are derivatized with succinic or other carboxylic acid anhydrides. Derivatization with a cyclic carboxylic anhydride has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Carboxyl side groups, aspartyl or glutamyl, may be selectively modified by reaction with carbodiimides ($R-N=C=N-R'$) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonia.

Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the amino group of lysine (Creighton, *supra*, pp. 79-86), acetylation of the N-terminal amine, and amidation of the C-terminal carboxyl groups.

Also included are peptides wherein one or more D-amino acids are substituted for one or more L-amino acids.

Multimeric Peptides

The present invention also includes longer polypeptides in which a basic peptidic sequence obtained from the sequence of B7-DC is repeated from about two to about 100 times,

with or without intervening spacers or linkers. It is understood that such multimers may be built from any of the peptide variants defined herein. Moreover, a peptide multimer may comprise different combinations of peptide monomers and the disclosed substitution variants thereof. Such oligomeric or multimeric peptides can be made by chemical synthesis or by recombinant DNA techniques as discussed herein. When produced chemically, the oligomers preferably have from 2-8 repeats of the basic peptide sequence. When produced recombinantly, the multimers may have as many repeats as the expression system permits, for example from two to about 100 repeats.

In tandem multimers, preferably dimers and trimers, of the B7-DC peptide or polypeptide, the chains bonded by interchain disulfide bonds or other "artificial" covalent bonds between the chains such that the chains are "side-by-side" rather than "end to end." Preferred dimers and trimers are those between fusion proteins of B7-DC such as B7-DC-Ig, as described herein.

ANTIBODIES SPECIFIC FOR EPITOPEs OF B7-DC

In the following description, reference will be made to various methodologies known to those of skill in the art of immunology, cell biology, and molecular biology. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full. Standard reference works setting forth the general principles of immunology include A.K. Abbas *et al.*, *Cellular and Molecular Immunology* (Fourth Ed.), W.B. Saunders Co., Philadelphia, 2000; C.A. Janeway *et al.*, *Immunobiology. The Immune System in Health and Disease*, Fourth ed., Garland Publishing Co., New York, 1999; Roitt, I. *et al.*, *Immunology*, (current ed.) C.V. Mosby Co., St. Louis, MO (1999); Klein, J., *Immunology*, Blackwell Scientific Publications, Inc., Cambridge, MA, (1990).

Monoclonal antibodies (mAbs) and methods for their production and use are described in Kohler and Milstein, *Nature* 256:495-497 (1975); U.S. Patent No. 4,376,110; Hartlow, E. *et al.*, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988); *Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, New York, NY (1980); H. Zola *et al.*, in *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, 1982)).

Immunoassay methods are also described in Coligan, J.E. *et al.*, eds., *Current Protocols in Immunology*, Wiley-Interscience, New York 1991(or current edition); Butt, W.R. (ed.) *Practical Immunoassay: The State of the Art*, Dekker, New York, 1984; Bizollon, Ch. A., ed., *Monoclonal Antibodies and New Trends in Immunoassays*, Elsevier, New York, 1984; Butler, J.E., ELISA (Chapter 29), In: van Oss, C.J. *et al.*, (eds), *IMMUNOCHEMISTRY*, Marcel Dekker, Inc., New York, 1994, pp. 759-803; Butler, J.E. (ed.), *Immunochemistry of Solid-Phase Immunoassay*, CRC Press, Boca Raton, 1991; Weintraub, B., *Principles of Radioimmunoassays*, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986; Work, T.S. *et al.*, *Laboratory Techniques and Biochemistry in Molecular Biology*, North Holland Publishing Company, NY, (1978) (Chapter by Chard, T., "An Introduction to Radioimmune Assay and Related Techniques").

Anti-idiotypic antibodies are described, for example, in *Idiotypic in Biology and Medicine*, Academic Press, New York, 1984; *Immunological Reviews* Volume 79, 1984; *Immunological Reviews* Volume 90, 1986; *Curr. Top. Microbiol. Immunol.* Volume 119, 1985; Bona, C. *et al.*, *CRC Crit. Rev. Immunol.*, pp. 33-81 (1981); Jerne, NK, *Ann. Immunol. 125C*:373-389 (1974); Jerne, NK, In: *Idiotypes - Antigens on the Inside*, Westen-Schnurr, I., ed., Editiones Roche, Basel, 1982, Urbain, J *et al.*, *Ann. Immunol. 133D*:179- (1982); Rajewsky, K. *et al.*, *Ann. Rev. Immunol. 1*:569-607 (1983)

The present invention provides antibodies, both polyclonal and monoclonal, reactive with novel epitopes of B7-DC that are absent from known B7 family proteins. The antibodies may be xenogeneic, allogeneic, syngeneic, or modified forms thereof, such as humanized or chimeric antibodies. Antiidiotypic antibodies specific for the idiotype of an anti-B7-DC antibody are also included. The term "antibody" is also meant to include both intact molecules as well as fragments thereof that include the antigen-binding site and are capable of binding to a B7-DC epitope. These include , Fab and F(ab')₂ fragments which lack the Fc fragment of an intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl *et al.*, *J. Nucl. Med.* 24:316-325 (1983)). Also included are Fv fragments (Hochman, J. *et al.* (1973) *Biochemistry* 12:1130-1135; Sharon, J. *et al.* (1976) *Biochemistry* 15:1591-1594).). These various fragments are be produced using conventional techniques such as protease cleavage or chemical cleavage (see, e.g., Rousseaux *et al.*, *Meth. Enzymol.*, 121:663-69 (1986))

Polyclonal antibodies are obtained as sera from immunized animals such as rabbits, goats, rodents, *etc.* and may be used directly without further treatment or may be subjected to conventional enrichment or purification methods such as ammonium sulfate precipitation, ion exchange chromatography, and affinity chromatography (see Zola *et al.*, *supra*).

5 The immunogen may comprise the complete B7-D6 protein, or fragments or derivatives thereof. Preferred immunogens comprise all or a part of the ECD of human B7-DC (amino acid residues 26-221), where these residues contain the post-translation modifications, such as glycosylation, found on the native B7-DC. Immunogens comprising the extracellular domain are produced in a variety of ways known in the art, *e.g.*, expression of cloned genes using
10 conventional recombinant methods, isolation from cells of origin, cell populations expressing high levels of B7-DC, *etc.*

15 The mAbs may be produced using conventional hybridoma technology, such as the procedures introduced by Kohler and Milstein (*Nature*, 256:495-97 (1975)), and modifications thereof (see above references). An animal, preferably a mouse is primed by immunization with an immunogen as above to elicit the desired antibody response in the primed animal.

20 B lymphocytes from the lymph nodes, spleens or peripheral blood of a primed, animal are fused with myeloma cells, generally in the presence of a fusion promoting agent such as polyethylene glycol (PEG). Any of a number of murine myeloma cell lines are available for such use: the P3-NS1/1-Ag4-1, P3-x63-k0Ag8.653, Sp2/0-Ag14, or HL1-653 myeloma lines (available from the ATCC, Rockville, MD). Subsequent steps include growth in selective medium so that unfused parental myeloma cells and donor lymphocyte cells eventually die while only the hybridoma cells survive. These are cloned and grown and their supernatants screened for the presence of antibody of the desired specificity, *e.g.* by immunoassay techniques using the B7-DC-Ig fusion protein. Positive clones are subcloned, *e.g.*, by limiting dilution, and the mAbs
25 are isolated.

30 Hybridomas produced according to these methods can be propagated *in vitro* or *in vivo* (in ascites fluid) using techniques known in the art (see generally Fink *et al.*, *Prog. Clin. Pathol.*, 9:121-33 (1984)). Generally, the individual cell line is propagated in culture and the culture medium containing high concentrations of a single mAb can be harvested by decantation, filtration, or centrifugation.

The antibody may be produced as a single chain antibody or scFv instead of the normal multimeric structure. Single chain antibodies include the hypervariable regions from an Ig of

interest and recreate the antigen binding site of the native Ig while being a fraction of the size of the intact Ig (Skerra, A. *et al.* (1988) *Science*, 240: 1038-1041; Pluckthun, A. *et al.* (1989) *Methods Enzymol.* 178: 497-515; Winter, G. *et al.* (1991) *Nature*, 349: 293-299); Bird *et al.*, (1988) *Science* 242:423; Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879; Jost CR *et al.*, 5 *J Biol Chem.* 1994 269:26267-26273; U.S. Patents No. 4,704,692, 4,853,871, 4,94,6778, 5,260,203, 5,455,0Kn contacted with the solution containing an unknown quantity of labeled antibody (which functions as a “reporter molecule”). After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support through the unlabeled antibody, the solid support is washed a second time to remove the unreacted labeled 10 antibody. This type of forward sandwich assay may be a simple “yes/no” assay to determine whether antigen is present or may be made quantitative by comparing the measure of labeled antibody with that obtained for a standard sample containing known quantities of antigen.

In another type of “sandwich” assay the so-called “simultaneous” and “reverse” assays are used. A simultaneous assay involves a single incubation step as the antibody bound to the 15 solid support and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody associated with the solid support is then determined as it would be in a conventional “forward” sandwich assay.

In the “reverse” assay, stepwise addition first of a solution of labeled antibody to the 20 fluid sample followed by the addition of unlabeled antibody bound to a solid support after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support is then determined as in the “simultaneous” and “forward” assays.

25 The foregoing antibodies ar useful in method for inhibiting T cell stimulation and treating diseases associated with undesired T cell activation, such as transplant rejection and autoimmunity. This method involves administering a subject in need of such treatment an effective amount of an antibody, preferably a mAb, more preferably a human oor humanized mAb specific for a costimulatory epitope of B7-DC. The administration of antibody must be 30 effective in blocking stimulation of T cells or in eliminating antigen-reactive T cells, thereby inhibiting the targeted T cell response. Relevant dose ranges are described below.

USES OF NUCLEIC ACIDS THAT ENCODE B7-DC PROTEIN

The nucleic acids of this invention are used diagnostically to monitor the progress of a disease, by measuring the expression of B7-DC in cells from biological samples or for assaying the effect of an agent on the expression of B7-DC. This is preferably accomplished by measurement of cellular mRNA levels. For use in such diagnostic methods, the nucleic acid sequence is detectably labeled, *e.g.*, with a radioactive or fluorescent label or biotin and used in a conventional dot blot or Northern hybridization procedure to probe mRNA molecules present in, for example, a preparation of total *kor* poly(A+) RNA from a biological sample.

THERAPEUTIC COMPOSITIONS AND THEIR ADMINISTRATION

The B6-DC polypeptide or a cell expressing this polypeptide such as a DC or a tumor cell is administered to a mammalian subject, preferably a human. Cell-associated, immobilized or otherwise aggregated forms of the polypeptide are used to enhance T lymphocyte reactivity and the resultant immunity. The B6-DC-Ig fusion protein assembles as a dimer and, as shown in the examples, co-stimulates T cells. Soluble monomeric forms of the B6-DC polypeptide can bind to the receptor on T cells without stimulating activity and can therefore be considered competitive inhibitors or antagonists of T cell co-stimulation by a stimulatory form of the molecule. Binding of a such a B6-DC antagonist may suppress ongoing T cell reactivity or may interfere with the effect of a costimulatory signal presented by endogenous B6-DC or even by other B7 family members acting via their receptors (*e.g.*, CD28 or CTLA-4)).

A composition having the activity of B7-DC as described herein is administered in a pharmaceutically acceptable carrier in a biologically effective or a therapeutically effective amount. The B7-DC polypeptide (or cell expressing the polypeptide) may be given alone or in combination with another protein or peptide such as one having the activity of another member of the B7 family or another immunostimulatory molecule. Treatment may include administration of an adjuvant, used in its broadest sense to include any nonspecific immune stimulating compound such as an interferon. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.

The following doses and amounts also pertain to the antibodies of the invention when administered to a subject.

A therapeutically effective amount is a dosage that, when given for an effective period of time, achieves the desired immunological or clinical effect.

A therapeutically active amount of a polypeptide having B7-DC activity (or an anti-B7-DC antibody) may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the peptide to elicit a desired response in the individual.

Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A therapeutically effective amounts of the protein, in cell associated form may be stated in terms of the protein or cell equivalents.

Thus an effective amount is between about 1 ng and about 1 gram per kilogram of body weight of the recipient, more preferably between about 1 µg and 100 mg/kg, more preferably, between about 100 µg and about 100 mg/kg. Dosage forms suitable for internal administration preferably contain (for the latter dose range) from about 0.1 mg to 500 mg of active ingredient per unit. The active ingredient may vary from 0.5 to 95% by weight based on the total weight of the composition. Alternatively, an effective dose of cells expressing B7-DC, such preferably transduced cells such as DC's or inactivated tumor cells, is between about 10^4 and 10^9 cells, more preferably between about 10^6 and 10^8 cells per subject, preferably in split doses. Those skilled in the art of immunotherapy will be able to adjust these doses without undue experimentation.

The active compound (*e.g.*, B6-DC polypeptide or cell transduced with B6-DC DNA) may be administered in a convenient manner, *e.g.*, injection by a convenient and effective route. Preferred routes include subcutaneous, intradermal, intravenous and intramuscular routes. Other possible routes include oral administration, intrathecal, inhalation, transdermal application, or rectal administration. For the treatment of tumors which have not been completely resected, direct intratumoral injection is also intended.

Depending on the route of administration, the active compound may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound. Thus, to administer a polypeptide or peptide having B7-DC activity by an enteral route, it may be necessary to coat the composition with, or co-administer the composition with, a material to prevent its inactivation. For example, a peptide may be administered to an individual in an appropriate carrier, diluent or adjuvant, co-administered with enzyme inhibitors (*e.g.*, pancreatic trypsin inhibitor,

diisopropylfluorophosphate (DEP) and trasylool). or in an appropriate carrier such as liposomes (including water-in-oil-in-water emulsions as well as conventional liposomes (Strejan *et al.*, (1984) *J. Neuroimmunol* 7:27).

As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated.

Supplementary active compounds can also be incorporated into the compositions.

Preferred pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. Isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride may be included in the pharmaceutical composition. In all cases, the composition should be sterile and should be fluid. It should be stable under the conditions of manufacture and storage and must include preservatives that prevent contamination with microorganisms such as bacteria and fungi. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.

Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.

Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Parenteral compositions are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units suited as unitary dosages for a mammalian subject; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

For lung instillation, aerosolized solutions are used. In a sprayable aerosol preparations, the active protein may be in combination with a solid or liquid inert carrier material. This may also be packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant. The aerosol preparations can contain solvents, buffers, surfactants, and antioxidants in addition to the protein of the invention.

For topical application, the proteins of the present invention may be incorporated into topically applied vehicles such as salves or ointments, which have both a soothing effect on the skin as well as a means for administering the active ingredient directly to the affected area.

The carrier for the active ingredient may be either in sprayable or nonsprayable form. Non-sprayable forms can be semi-solid or solid forms comprising a carrier indigenous to topical application and having a dynamic viscosity preferably greater than that of water. Suitable formulations include, but are not limited to, solution, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like. If desired, these may be sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, buffers, or salts for influencing osmotic pressure and the like. Examples of preferred vehicles for non-sprayable topical preparations include ointment bases, e.g., polyethylene glycol-1000 (PEG-1000); conventional creams such as HEB cream; gels; as well as petroleum jelly and the like.

Other pharmaceutically acceptable carriers for the B7-DC polypeptide according to the present invention are liposomes, pharmaceutical compositions in which the active protein is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers. The active protein is preferably present in the aqueous layer and in the lipidic layer, inside or outside, or, in any event, in the non-homogeneous system generally known as a liposomal suspension. The hydrophobic layer, or lipidic layer, generally, but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such

as cholesterol, more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid, and/or other materials of a hydrophobic nature.

Modification of Tumor Cells to Express B7-DC and Multiple Costimulatory Molecules

Another aspect of the invention is a cell, preferably a tumor cell, modified to express multiple costimulatory molecules. The temporal expression of costimulatory molecules on activated B cells is different for B7, B7-2 and B7-3. For example, B7-2 is expressed early following B cell activation, whereas B7-3 is expressed later. The different costimulatory molecules may thus serve distinct functions during the course of an immune response. An effective T cell response may require that the T cell receive costimulatory signals from multiple costimulatory molecules.

Accordingly, the invention encompasses a tumor cell which is genetically modified or to express more than one costimulatory molecule. For example, a tumor cell can be modified to express B7-DC and one or more of B7, B7-2 and B7-3.

Before modification, a cell such as a tumor cell may not express any costimulatory molecules, or may express certain costimulatory molecules but not others. As described herein, tumor cells can be modified by transfection with nucleic acid encoding B7-DC alone or with another costimulatory molecule(s). For example, a tumor cell transfected with nucleic acid encoding B7-DC can be further transfected with nucleic acid encoding B7. The sequence of cDNA molecules encoding human or mouse B7-DC proteins are SEQ ID NO:1 and the coding portion of SEQ ID NO:3, respectively. Alternatively, more than one type of modification can be used. For example, a tumor cell transfected with a nucleic acid encoding B7-DC can be stimulated with an agent which induces expression of B7-1, B7-2 or B7-3.

ANTIGENS ASSOCIATED WITH PATHOGENS

A major utility for the present invention is the use of the present compositions in therapeutic vaccine for cancer and for major chronic viral infections that cause morbidity and mortality worldwide. Such vaccines are designed to eliminate infected cells - this requires T cell responses as antibodies are ineffective. The vaccines of the present invention, include, in addition to the antigenic epitope itself:

- (a) a vector such as naked DNA, naked RNA, self replicating RNA replicons and viruses including vaccinia, adenoviruses, adeno-associated virus (AAV), lentiviruses and RNA alphaviruses;

(b) an antigen targeting or processing signal such as HSP70, calreticulin, the extracellular domain of Flt-3 ligand, domain II of Pseudomonas exotoxin ETA, herpes simplex VP22 targeting protein, and the like. (See commonly assigned U.S. patent applications 09//421,608; 09/501,097; 09/693,450; 60/222,9002; 5 60/222,985; 60/268,575 and Chang, W-F *et al.*, *J. Virol.* 75:2368-2376 (2001), which are hereby incorporated by reference in their entirety); and

(c) a costimulatory signal, preferably the B7-DC protein of the present invention or a fusion protein, fragment or functional derivative thereof (alone or in combination with other known costimulatory proteins such as B7.1, B7.2, soluble CD40, etc.).

10 Tumor cells or other types of host cells, including APCs, are transformed, transfected or otherwise transduced with a nucleic encoding an antigen to which an immune response is desired. Such antigens are preferably epitopes of pathogenic microorganisms against which the host is defended by effector T cells responses, including cytotoxic T lymphocyte (CTL) and delayed type hypersensitivity. These typically include viruses, intracellular parasites such as 15 malaria, and bacteria that grow intracellularly such as mycobacteria and listeria. Thus, the types of antigens included in the vaccine compositions of this invention are any of those associated with such pathogens (in addition, of course, to tumor-specific antigens). It is noteworthy that some viral antigens are also tumor antigens in the case where the virus is a causative factor in cancer.

20 In fact, the two most common cancers worldwide, hepatoma and cervical cancer, are associated with viral infection. Hepatitis B virus(HBV) (Beasley, R.P. *et al.*, *Lancet* 2, 1129-1133 (1981) has been implicated as etiologic agent of hepatomas. 80-90% of cervical cancers express the E6 and E7 antigens from one of four "high risk" human papillomavirus types: HPV-16, HPV-18, HPV-31 and HPV-45 (Gissmann, L. *et al.*, *Ciba Found Symp.* 120, 190-207 25 (1986); Beaudenon, S., *et al. Nature* 321, 246-249 (1986). The HPV E6 and E7 antigens are the most promising targets for virus associated cancers in immunocompetent individuals because of their ubiquitous expression in cervical cancer. In addition to their importance as targets for therapeutic cancer vaccines, virus associated tumor antigens are also ideal candidates for prophylactic vaccines. Indeed, introduction of prophylactic HBV vaccines in Asia have 30 decreased the incidence of hepatoma (Chang, M.H., *et al. New Engl. J. Med.* 336, 1855-1859 (1997), representing a great impact on cancer prevention.

Among the most important viruses in chronic human viral infections are human papillomavirus (HPV) hepatitis B virus (HBV), hepatitis C Virus (HCV), human immunodeficiency virus (HIV), Epstein Barr Virus (EBV) and herpes simplex virus (HSV).

In addition to its applicability to human cancer and infectious diseases,, the present invention is also intended for use in treating animal diseases in the veterinary medicine context. Thus, the approaches described herein may be readily applied by one skilled in the art to treatment of veterinary herpesvirus infections including equine herpesviruses, bovine herpesviruses, Marek's disease virus in chickens and other fowl; animal retroviral diseases; pseudorabies and rabies and the like.

The following references set forth principles and current information in the field of basic, medical and veterinary virology and are incorporated by reference: *Fields Virology*, Fields, BN et al., eds., Lippincott Williams & Wilkins, NY, 1996;

Principles of Virology: Molecular Biology, Pathogenesis, and Control, Flint, S.J. et al., eds., Amer Society for Microbiology, Washington, 1999; *Principles and Practice of Clinical Virology*, 4th Edition, Zuckerman. A.J. et al., eds, John Wiley & Sons, NY, 1999; *The Hepatitis C Viruses*, by Hagedorn, CH et al., eds., Springer Verlag, 1999; *Hepatitis B Virus: Molecular Mechanisms in Disease and Novel Strategies for Therapy*,

Koshy, R. et al., eds., World Scientific Pub Co, 1998; *Veterinary Virology*, Murphy, F.A. et al., eds., Academic Press, NY, 1999; *Avian Viruses: Function and Control*, Ritchie, B.W., Iowa

State University Press, Ames , 2000; *Virus Taxonomy: Classification and Nomenclature of Viruses: Seventh Report of the International Committee on Taxonomy of Viruses*, by M. H. V. Van Regenmortel, MHV et al., eds., Academic Press; NY, 2000.

Targeting Molecules

A number of proteins that have various modes of action have been implicated as "targeting" molecules to be used in conjunction with antigens, preferably as fusion polypeptides, to target the antigen to cells and subcellular compartments that promote presentation of the antigen to T cells in a more potent and effective manner.

Linkage of antigens to heat shock proteins (HSPs) represents a potential approach for increasing the potency of nucleic acid-based (and other) vaccines. HSPs appear to act as natural biologic adjuvants in cancer and viral vaccination. Both the gp96 HSP resident in the endoplasmic reticulum (ER) and the cytosolic Hsp70 act as immunologic adjuvants (Srivastava,

PK *et al.*, *Semin. Immunol.* 3, 57-64 (1991); Udono, H *et al.*, *Proc. Natl. Acad. Sci. USA* 91, 3077-3081 (1994)). These HSPs, or chaperonins, bind a wide array of peptides (Lammert, E., *et al.* *Eur. J. Immunol.* 27, 923-927 (1997)). Hsp70 is a chaperonin that can target associated proteins to the proteosome - the primary cellular protease complex that generates peptides for association with MHC class I molecules. Therefore, antigens directly linked to Hsp70 are more efficiently presented by MHC class I (leading, *inter alia*, to CTL responses). Two features appear to be responsible for HSP adjuvanticity: (1) *in vitro*, peptide loaded gp96 effectively introduce antigens into the MHC class I processing pathway; (2) binding of gp96 to macrophages induces secretion of proinflammatory cytokines, thus augmenting the function of the cells to which the peptide antigen has been targeted.

Immunization with HSP complexes isolated from tumor or from virus-infected cells induces potent antitumor immunity (Srivastava, PK *et al.*, *Int J Cancer.* 33: 417-22, 1984; Srivastava, PK *et al.*, *Proc Natl Acad Sci USA.* 83: 3407-11, 1986; Udono, H *et al.*, *J Immunol.* 152: 5398-5403, 1994; Blachere, NE *et al.*, *J Immunother.* 14: 352-6, 1993; Udono, H *et al.*, *supra*; Tamura, Y *et al.*, *Science.* 278: 117-20, 1997; Janetzki, S *et al.*, *J Immunother.* 21: 269-76, 1998)) or antiviral immunity (Heikema, A *et al.*, *Immunol Lett.* 57: 69-74, 1997; Suto, R *et al.*, *Science.* 269: 1585-8, 1995). Mixing peptides with HSPs *in vitro* generated immunogenic HSP-peptide complexes (Ciupitu, AM *et al.*, *J Exp Med.* 187: 685-91, 1998; Blachere, NE *et al.*, *J Exp Med.* 186: 1315-22, 1997). Some HSP-based protein vaccines involved fusion of the antigen to the HSP (Suzue, K *et al.*, *J Immunol.* 156: 873-9, 1996; Suzue, K. *et al.*, *Proc Natl Acad Sci USA* 94: 13146-51, 1997). More recently, the present inventors and their colleagues (e.g., Chen, C-H *et al.*, *Canc. Res.* 60:1035-1042 (2000)) used HSPs in the form of chimeric DNA or RNA replicon vaccines. They used HPV-16 E7 as antigen fused to *Mycobacterium tuberculosis* HSP70 and showed increased expansion and activation of E7-specific CD8+ T cells which resulted in potent antitumor immunity against established tumors (Lin, K.-Y. *et al.*, *Cancer Res.* 56: 21-26., 1996).

Another useful targeting molecule is the translocation domain of a *Pseudomonas* exotoxin A (ETA), e.g., domain II (dII) of ETA (spanning residues 253-364). A translocation domain is a polypeptide that induces translocation of protein or polypeptide to which it is linked into the cytosol of a cell. For example, similarly applicable polypeptide are derived from a *Diphtheria*, *Clostridia* (*botulinum*, *tetani*), *Anthrax*, *Yersinia*, *Vibrio cholerae*, or *Bordetella*

pertussis toxin. The toxic domain of the DNA encoding the toxin is preferably mutated or deleted in the preparation of such compositions.

Calreticulin (CRT) is an abundant 46 kDa protein located in the endoplasmic reticulum (ER) lumen that displays lectin activity and is known to be involved in the folding and assembly of nascent glycoproteins (Nash (1994) *Mol. Cell. Biochem.* 135:71-78; Hebert (1997) *J. Cell Biol.* 139:613-623; Vassilakos (1998) *Biochemistry* 37:3480-3490; Spiro (1996) *J. Biol. Chem.* 271:11588-11594. CRT associates with peptides transported into the ER by transporters associated with antigen processing, such as TAP-1 and TAP-2 (Spee (1997) *Eur. J. Immunol.* 27:2441-2449). CRT forms complexes *in vitro* with peptides. These complexes, when administered to mice, elicited peptide-specific CD8+ T cell responses (Basu (1999) *J. Exp. Med.* 189:797-802; Nair (1999) *J. Immunol.* 162:6426-6432). CRT purified from mouse tumors elicited immunity specific to the tumor used as the source of CRT, but not to an antigenically distinct tumor (Basu, *supra*). By pulsing DCs *in vitro* with a CRT bound to a peptide, the peptide was re-presented in the context of DC Class I molecules and stimulated peptide-specific CTLs (Nair, *supra*).

The Flt-3 ligand stimulates growth of DC precursors and can promote generation of large numbers of DCs *in vivo* (Maraskovsky, E. *et al.*, *J Exp Med.* 184: 1953-62, 1996; Shurin, MR. *et al.*, *Cell Immunol.* 179: 174-84, 1997). Flt3, a murine tyrosine kinase receptor (Rosnet, O. *et al.*, *Oncogene* 6: 1641-50, 1991) is a member of the III receptor kinase family (for review see Lyman, SD, *Curr Opin Hematol.* 5: 192-6, 1998). In hematopoietic tissues, the expression of Flt3 is restricted to the CD34-positive progenitors. Flt3 was used to identify and subsequently clone the corresponding ligand, Flt3-ligand (Lyman, SD *et al.*, *Cell* 75: 1157-67, 1993; Hannum, C *et al.*, *Nature* 368: 643-8, 1994). The predominant form of Flt3-ligand is synthesized as a transmembrane protein from which the functionally similar soluble ECD is generated by proteolytic cleavage (Lyman *et al.*, *supra*). These proteins bind to and activating unique tyrosine kinase receptors. Among hematopoietic cells, expression of the Flt3 receptor is primarily restricted to the most primitive progenitor cells, including DC precursors. The ECD of Flt3-ligand generated strong anti-tumor effects against several murine model tumors including fibrosarcoma, breast cancer, liver cancer, lung cancer, melanoma and lymphoma (Lynch, DH *et al.*, *Nat Med.* 3: 625-631, 1997; Chen, K *et al.*, *Cancer Res.* 57: 3511-3516, 1997; Braun, SE *et al.*, *Hum Gene Ther.* 10: 2141-2151, 1999; Peron, JM *et al.*, *J Immunol.* 161: 6164-6170, 1998; Chakravarty, PK *et al.*, *Cancer Res.* 59: 6028-6032, 1999; Esche, C *et al.*, *Cancer Res.* 58: 380-

383, 1998.) (19). The present inventors' colleagues linked DNA encoding HPV E1 protein to DNA encoding Flt3-ligand ECD. Immunization with this construct dramatically increased expansion and activation of E1 antigen-specific CD8⁺ T cells, resulting in potent anti-tumor immunity against established E1-expressing metastatic tumors.

5 The HSV-1 protein VP22 is a prototype protein that contributes, among other things, to enhanced spread of antigen due to its remarkable property of intercellular transport (Elliott, G., and P. O'Hare. 1997. *Cell* 88:223-33) can be used. For example, VP22 linked to p53 (Phelan, A. et al., 1998, *Nat Biotechnol.* 16:440-443) or thymidine kinase (Dilber, MS et al., 1999, *Gene Ther.* 6:12-21), facilitated the spread of linked protein to surrounding cells *in vitro* and the treatment of model tumors. VP22 linked to HPV-16 E1 antigen in the context of a DNA vaccine led to a dramatic increase in the number of E1-specific CD8⁺ T cell precursors in vaccinated mice (around 50-fold) and converted a less effective DNA vaccine into one with significant potency against E1-expressing tumors. A non-spreading VP22 mutant failed to enhance vaccine potency. VP22 and proteins that may have a similar mode of action, contribute in several ways to enhanced vaccine potency: (1) facilitate spreading of antigen from transfected cells to surrounding APCs, thereby increasing the number of APCs that present antigen through MHC class I pathway; (2) present antigen more efficiently in transfected cells (3) carryout "cross-priming" whereby release of a VP22/antigen fusion protein leads to uptake and processing by DCs (or other APCs) for presentation via the MHC-I restricted pathway (Huang, A.Y et al., 1994, *Science* 264:961-965)

10

15

20

Those skilled in the art will know how to identify appropriate epitopes, e.g., CTL epitopes, of the relevant proteins from the pathogens for use in accordance with this invention.

DELIVERY OF B7-DC DNA TO CELLS AND ANIMALS

DNA delivery, for example to effect what is generally known as "gene therapy" involves introduction of a "foreign" DNA into a cell and ultimately, into a live animal. Several general strategies for gene therapy have been studied and have been reviewed extensively (Yang, N-S., *Crit. Rev. Biotechnol.* 12:335-356 (1992); Anderson, W.F., *Science* 256:808-813 (1992); Miller, A.S., *Nature* 357:455-460 (1992); Crystal, R.G., *Amer. J. Med.* 92(suppl 6A):44S-52S (1992); Zwiebel, J.A. et al., *Ann. N.Y. Acad. Sci.* 618:394-404 (1991); McLachlin, J.R. et al., *Prog. Nucl. Acid Res. Molec. Biol.* 38:91-135 (1990); Kohn, D.B. et al., *Cancer Invest.* 7:179-192 (1989), which references are herein incorporated by reference in their entirety).

25

30

One approach comprises nucleic acid transfer into primary cells in culture followed by autologous transplantation of the *ex vivo* transformed cells into the host, either systemically or into a particular organ or tissue.

For accomplishing the objectives of the present invention, nucleic acid therapy would be accomplished by direct transfer of a functionally active DNA into mammalian somatic tissue or organ *in vivo*. DNA transfer can be achieved using a number of approaches described below. These systems can be tested for successful expression *in vitro* by use of a selectable marker (e.g., G418 resistance) to select transfected clones expressing the DNA, followed by detection of the presence of the B7-DC expression product (after treatment with the inducer in the case of an inducible system) using an antibody to the product in an appropriate immunoassay.

Efficiency of the procedure, including DNA uptake, plasmid integration and stability of integrated plasmids, can be improved by linearizing the plasmid DNA using known methods, and co-transfection using high molecular weight mammalian DNA as a "carrier".

Examples of successful "gene transfer" reported in the art include: (a) direct injection of plasmid DNA into mouse muscle tissues, which led to expression of marker genes for an indefinite period of time (Wolff, J.A. *et al.*, *Science* 247:1465 (1990); Acsadi, G. *et al.*, *The New Biologist* 3:71 (1991)); (b) retroviral vectors are effective for *in vivo* and *in situ* infection of blood vessel tissues; (c) portal vein injection and direct injection of retrovirus preparations into liver effected gene transfer and expression *in vivo* (Horzaglou, M. *et al.*, *J. Biol. Chem.* 265:17285 (1990); Koleko, M. *et al.*, *Human Gene Therapy* 2:27 (1991); Ferry, N. *et al.*, *Proc. Natl. Acad. Sci. USA* 88:8387 (1991)); (d) intratracheal infusion of recombinant adenovirus into lung tissues was effective for *in vivo* transfer and prolonged expression of foreign genes in lung respiratory epithelium (Rosenfeld, M.A. *et al.*, *Science* 252:431 (1991)); (e) Herpes simplex virus vectors achieved *in vivo* gene transfer into brain tissue (Ahmad, F. *et al.*, eds, *Miami Short Reports - Advances in Gene Technology: The Molecular Biology of Human Genetic Disease*, Vol 1, Boerringer Manneheim Biochemicals, USA, 1991).

Retroviral-mediated human therapy utilizes amphotrophic, replication-deficient retrovirus systems (Temin, H.M., *Human Gene Therapy* 1:111 (1990); Temin *et al.*, U.S. Patent 4,980,289; Temin *et al.*, U.S. Patent 4,650,764; Temin *et al.*, U.S. Patent No. 5,124,263; Wills, J.W. U.S. Patent 5,175,099; Miller, A.D., U.S. Patent No. 4,861,719). Such vectors have been used to introduce functional DNA into human cells or tissues, for example, the adenosine deaminase gene into lymphocytes, the NPT-II gene and the gene for tumor necrosis factor into

tumor infiltrating lymphocytes. Retrovirus-mediated gene delivery generally requires target cell proliferation for gene transfer (Miller, D.G. *et al.*, *Mol. Cell. Biol.* 10:4239 (1990). This condition is met by certain of the preferred target cells into which the present DNA molecules are to be introduced, *i.e.*, actively growing tumor cells. Gene therapy of cystic fibrosis using transfection by plasmids using any of a number of methods and by retroviral vectors has been described by Collins *et al.*, U.S. Patent 5,240,846.

The DNA molecules encoding the B7-DC sequences may be packaged into retrovirus vectors using packaging cell lines that produce replication-defective retroviruses, as is well-known in the art (see, for example, Cone, R.D. *et al.*, *Proc. Natl. Acad. Sci. USA* 81:6349-6353 (1984); Mann, R.F. *et al.*, *Cell* 33:153-159 (1983); Miller, A.D. *et al.*, *Molec. Cell. Biol.* 5:431-437 (1985); Sorge, J., *et al.*, *Molec. Cell. Biol.* 4:1730-1737 (1984); Hock, R.A. *et al.*, *Nature* 320:257 (1986); Miller, A.D. *et al.*, *Molec. Cell. Biol.* 6:2895-2902 (1986). Newer packaging cell lines which are efficient and safe for gene transfer have also been described (Bank *et al.*, U.S. 5,278,056).

This approach can be utilized in a site specific manner to deliver the retroviral vector to the tissue or organ of choice. Thus, for example, a catheter delivery system can be used (Nabel, EG *et al.*, *Science* 244:1342 (1989)). Such methods, using either a retroviral vector or a liposome vector, are particularly useful to deliver the nucleic acid to be expressed to a blood vessel wall, or into the blood circulation of a tumor.

Other virus vectors may also be used, including recombinant adenoviruses (Horowitz, M.S., In: *Virology*, Fields, BN *et al.*, eds, Raven Press, New York, 1990, p. 1679; Berkner, K.L., *Biotechniques* 6:616 9191988), Strauss, S.E., In: *The Adenoviruses*, Ginsberg, HS, ed., Plenum Press, New York, 1984, chapter 11), herpes simplex virus (HSV) for neuron-specific delivery and persistence. Advantages of adenovirus vectors for human gene therapy include the fact that recombination is rare, no human malignancies are known to be associated with such viruses, the adenovirus genome is double stranded DNA which can be manipulated to accept foreign genes of up to 7.5 kb in size, and live adenovirus is a safe human vaccine organisms. Adeno-associated virus is also useful for human therapy (Samulski, R.J. *et al.*, *EMBO J.* 10:3941 (1991) according to the present invention.

Another vector which can express the DNA molecule of the present invention, and is useful in the present therapeutic setting, particularly in humans, is vaccinia virus, which can be rendered non-replicating (U.S. Patents 5,225,336; 5,204,243; 5,155,020; 4,769,330; Sutter, G *et*

al., *Proc. Natl. Acad. Sci. USA* (1992) 89:10847-10851; Fuerst, T.R. et al., *Proc. Natl. Acad. Sci. USA* (1989) 86:2549-2553; Falkner F.G. et al.; *Nucl. Acids Res* (1987) 15:7192; Chakrabarti, S et al., *Molec. Cell. Biol.* (1985) 5:3403-3409). Descriptions of recombinant vaccinia viruses and other viruses containing heterologous DNA and their uses in immunization and DNA therapy are reviewed in: Moss, B., *Curr. Opin. Genet. Dev.* (1993) 3:86-90; Moss, B. *Biotechnology* (1992) 20: 345-362; Moss, B., *Curr Top Microbiol Immunol* (1992) 158:25-38; Moss, B., *Science* (1991) 252:1662-1667; Piccini, A et al., *Adv. Virus Res.* (1988) 34:43-64; Moss, B. et al., *Gene Amplif Anal* (1983) 3:201-213.

In addition to naked DNA or RNA, or viral vectors, engineered bacteria may be used as vectors. A number of bacterial strains including *Salmonella*, BCG and *Listeria monocytogenes*(LM) (Hoiseth & Stocker, *Nature* 291, 238-239 (1981); Poirier, TP et al. *J. Exp. Med.* 168, 25-32 (1988); (Sadoff, J.C., et al., *Science* 240, 336-338 (1988); Stover, C.K., et al., *Nature* 351, 456-460 (1991); Aldovini, A. et al., *Nature* 351, 479-482 (1991); Schafer, R., et al., *J. Immunol.* 149, 53-59 (1992); Ikonomidis, G. et al., *J. Exp. Med.* 180, 2209-2218 (1994)). These organisms display two promising characteristics for use as vaccine vectors: (1) enteric routes of infection, providing the possibility of oral vaccine delivery; and (2) infection of monocytes/macrophages thereby targeting antigens to professional APCs.

In addition to virus-mediated gene transfer *in vivo*, physical means well-known in the art can be used for direct transfer of DNA, including administration of plasmid DNA (Wolff et al., 1990, *supra*) and particle-bombardment mediated gene transfer (Yang, N.-S., et al., *Proc. Natl. Acad. Sci. USA* 87:9568 (1990); Williams, R.S. et al., *Proc. Natl. Acad. Sci. USA* 88:2726 (1991); Zelenin, A.V. et al., *FEBS Lett.* 280:94 (1991); Zelenin, A.V. et al., *FEBS Lett.* 244:65 (1989); Johnston, S.A. et al., *In Vitro Cell. Dev. Biol.* 27:11 (1991)). Furthermore, electroporation, a well-known means to transfer genes into cell *in vitro*, can be used to transfer DNA molecules according to the present invention to tissues *in vivo* (Titomirov, A.V. et al., *Biochim. Biophys. Acta* 1088:131 ((1991))).

“Carrier mediated gene transfer” has also been described (Wu, C.H. et al., *J. Biol. Chem.* 264:16985 (1989); Wu, G.Y. et al., *J. Biol. Chem.* 263:14621 (1988); Soriano, P. et al., *Proc. Natl. Acad. Sci. USA* 80:7128 (1983); Wang, C-Y. et al., *Proc. Natl. Acad. Sci. USA* 84:7851 (1982); Wilson, J.M. et al., *J. Biol. Chem.* 267:963 (1992)). Preferred carriers are targeted liposomes (Nicolau, C. et al., *Proc. Natl. Acad. Sci. USA* 80:1068 (1983); Soriano et al., *supra*) such as immunoliposomes, which can incorporate acylated mAbs into the lipid bilayer (Wang et

al., supra). Polycations such as asialoglycoprotein/polylysine (Wu *et al.*, 1989, *supra*) may be used, where the conjugate includes a molecule which recognizes the target tissue (e.g., asialoorosomucoid for liver) and a DNA binding compound to bind to the DNA to be transfected. Polylysine is an example of a DNA binding molecule which binds DNA without damaging it. This conjugate is then complexed with plasmid DNA according to the present invention for transfer.

Plasmid DNA used for transfection or microinjection may be prepared using methods well-known in the art, for example using the Quiagen procedure (Quiagen), followed by DNA purification using known methods, such as the methods exemplified herein.

Again, as noted above, for the utility of transduced B7-DC molecules according to this invention may not require stable expression. Rather, transient expression of the polypeptide may be sufficient for transduced cells to perform their immunogenic and/or costimulatory function.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

EXAMPLE I

Materials and Methods

Cell Preparation and Culture

6-12 week old female BALB/c mice were purchased from NCI and used for DC and macrophage preparation.

Bone marrow-derived DCs were cultured in RPMI1640 (Gibco BRL) medium supplemented with 5% fetal calf serum (FCS) (Hyclone), Penicillin/Streptomycin (JRH Biosciences), Gentamycin (Sigma), Nonessential amino acids (JRH Biosciences), L-Glutamate (JRH Biosciences), Sodium Pyruvate (Sigma), 2 mercaptoethanol (Sigma) and 1000 units/ml recombinant murine GM-CSF (Immunex) as previously described(26). Day 8 bone marrow-derived DCs were stained with monoclonal antibodies by conventional methods. Monoclonal antibody against MHC class II, 14-4-4s, was purified from hybridoma supernatant. Dr. William Baldwin, Johns Hopkins University, kindly supplied CTLA4-Ig fusion molecule. Antibodies for MHC class I (28-14-8), F4/80 (C1.A3-1), B7.1 (1G10), B7.2 (GL1), Fc γ RII/III (2.4G2) and

Mac-1 (M1/70) were purchased from PharMingen. For tester cDNA preparation, day 8 cells were purified by cell sorter using 14-4-4s and CTLA4-Ig at the Johns Hopkins University Oncology Center. The purity of MHC class II^{hi} and B7^{hi} population after sorting was 93-98%.

5 Bone marrow-derived macrophages were cultured with RPMI-1640 medium supplemented with 10% FCS, Penicillin/Streptomycin, non-essential amino acids, sodium pyruvate, L glutamine, 2-mercaptoethanol and 250 units/ml recombinant murine M-CSF, and they were treated with 500 units/ml γ -IFN (Pharmingen) and 5 μ g/ml LPS (Sigma) as previously described (27). After stimulation, cell surface expression of MHC class II and B7 were confirmed using flow cytometric analysis on day 10 of culture.

10 Macrophage cell lines WEHI-3, RAW264.7, J774.A.1, PU5-1.8 were kindly provided by Dr. Joshua Farber of the NIAID, National Institutes of Health. They were cultured with ATCC recommended medium.

Allogeneic Mixed Lymphocyte Reaction

15 Day 8 BM-derived DCs characterized as MHC class II^{hi} and B7^{hi} were tested for their ability to stimulate allogeneic T cells in MLC. MLC reactions were performed in 96 well flat bottom microplates by adding increasing number of BALB/c stimulator cells s to 3×10^5 allogeneic C57BL/6 lymphocytes. After 3 days of culture, T cell proliferation was assessed by addition of 1 μ Ci of [³H]-methyl-thymidine (Amersham) to each well for the final 18h of culture. Cells were then harvested, and incorporation of radioactivity was determined using a β counter (Packard 96).

cDNA subtractive hybridization

20 Total RNA from sorted DCs and activated macrophages was extracted with TRIZOL (Gibco BRL). Messenger RNA was purified by Oligotex mRNA purification kit (Qiagen). We used the PCR based SMART cDNA synthesis system (Clonetech) to amplify cDNA followed by the PCR based subtraction system PCR Select (Clonetech). Subtraction was performed following the manufacturer's protocol. After final subtractive PCR, DNA fragments were ligated into plasmid vectors pCR2.1 (Invitrogen) or pCR Blunt (Invitrogen). After transformation, each clone was grown for plasmid DNA amplification and miniprep DNA and then digested with EcoRI to confirm the presence of inserts. Plasmid dot blot was then performed to confirm that the cDNA cloned is dendritic cell specific. Alkaline denatured miniprep DNAs were spotted on Hybond N+ membrane (Amersham) and hybridized with SMART cDNA probe-derived from

sorted DCs or activated macrophages. These cDNA probes were ^{32}P labeled using random primer labeling method (Stratagene Prime-It II). Hybridizations and washing were done as previously described(28). Membranes were exposed to a film (Amersham) for 1-2 days and developed.

5 Plasmid Dot Blot Analysis

Alkaline denatured miniprep DNA samples were spotted on Hybond N+ membrane (Amersham) and hybridized with SMART® cDNA probe-derived from sorted DCs or activated macrophages. These cDNA probes were ^{32}P labeled using a random primer labeling method (Stratagene Prime-It II). Hybridizations and washing were done as previously described [cites??]. For autoradiography, membranes were exposed to a film (Amersham) for 1-2 days and developed.

10 cDNA library construction and screening - Cloning of B7-DC

Bone marrow-derived DCs were harvested on day 8 without sorting. About 20% to 40% of these cells expressed high MHC class II and B7. Total RNA extraction followed by poly A RNA purification was done as described above. For oligo dT primed DC library construction, we used Lambda ZAP Express cDNA synthesis system (Stratagene). The PCR DNA fragment of B7-DC was probed and used for screening. Membrane transfer, denaturation, renaturation, were performed using Stratagene's protocol. Radiolabeling of probes, hybridization, washing, and autoradiography were done as described above. Positive clones were isolated and 2nd screening was performed. After 2nd screening, plasmids were excised by *in vivo* excision and tested by dot blotting and sequencing. Sequencing was done by the Core Facility at the Johns Hopkins University School of Medicine. BLAST program was used to do homology search of the nucleotide sequence against Genbank (NCBI) for similarity to previously reported genes. The full length B7-DC cDNA clone was pulled out from the DC cDNA library. 5' RACE was performed suing SMART RACE cDNA amplification kit (Clontech). 5'-RACE products were cloned into pCR2.1 vector and sequenced. Two more full length B7-DC clones were obtained by RT-PCR and their sequence were compared to avoid sequence error.

Human B7-DC was cloned as follows: human DCs were obtained from normal peripheral blood mononuclear cells by culture in either GM-CSF + IL-4 or GM-CSF + Flt-3L as described previously(29). RNA was extracted as described above. A BLAST search identified an overlapping EST clone, GenBank accession number AK001879, with homology to mouse B7-

DC. 5' RACE was performed as described above. We sequenced a 5'-RACE PCR fragment and designed a primer corresponding to 5'-UTR of human B7DC. The following primers in the 5'-UTR and 3'-UTR of B7-DC was used to amplify full-length human B7-DC:

5 5'-GGAGCTACTGCATGTTGATTGTTTG-3' [SEQ ID NO:6] and
5'-TGCAAACTGAGGCACTGAAAAGTC-3' [SEQ ID NO:7]

The full length cDNA sequences of the human and murine B7-DC cDNAs have been deposited with EMBL/GenBank/DDBS under accession number AF329193 and AF142780.

BAC (129SVJ) library screening /Genomic cloning and mapping

10 BAC library screening, followed manufacturer's protocol (Genome Systems, Inc.) Primers used:

5'-TTGTTGTCTCCTCTGTCTCCAAC-3' [SEQ ID NO:8]and
5'-ACAGTTGCTCCTGTATCAGGTT-3' [SEQ ID NO:9]

15 BAC library screening obtained 3 positive clones. Chromosome location mapping was done by fluorescence in situ hybridization (Genome Systems Inc.). A total of 80 metaphase cells were analyzed with 79 exhibiting specific labeling. The human B7-DC mapping was done by using available bioinformatic tools, NCBI's BLAST program and the International RH Mapping Consortium. The hB7-DC sequence was searched in htsg and was found to map to two BAC clones RP11-574F11 (AL162253) and Rp11-635N21 (AL354744) localizing on chromosome 9.

20 Virtual Northern Blotting

4-6 weeks old female Balb/c mice were purchased from NCI and used for tissue RNA preparation. RNA extraction and SMART cDNA synthesis for tissues, sorted DCs and activated macrophages were performed as described above. SMART PCR cDNAs were purified by PCR purification kit (Qiagen). 0.5 µg/lane purified DNAs were run on a 1% agarose gel and transferred on a Nytran nylon membrane (Schleier and Schuell). To make radioactive probes, we amplified subtracted library derived plasmid DNAs as templates. We amplified DNA by PCR using primer sets just adjacent to the cloning site of plasmid DNA and used purified PCR DNA of each of the clones for hybridization probes. The nucleotide sequences of these primers are as follows.

30 5'-GTAACGGCCGCCAGTGTGCTG-3' [SEQ ID NO:10] and
5'-CGCCAGTGTGATGGATATCTGCA-3' [SEQ ID NO:11]

Virtual Northern analysis of total RNA of human DCs and control placenta was also performed. The probes used and RNA preparation were described above. Radiolabeling of probes, hybridization, washing and autoradiography were done as described above.

Hamster anti-mB7-DC Ab production

5 Stable transfectants of B7-DC in DC2.4, RAW246.7 and RENCA cell lines were used to immunize Armenian Hamsters. The B7-DC was cloned into the modified pCAGGS vector (30). The hamsters were boosted three times with plasmids containing B7-DC (Rockland). The anti-B7-DC antibody used in this study was from one the sera of one of the three hamsters immunized.

10 **CD28-Ig, CTLA4-Ig and PD-1-Ig binding assay**

293T cells were transfected with B7.1-pCAGGS, B7-DC-pCAGG, PD-1-pCAGGS or vector alone using Lipofectamine 2000 (Gibco BRL). After 24hrs, cells were resuspended in FACS buffer (1x HBSS, 2% calf serum, 10mM HEPES and 0.1% NaN₃) and spun at 1000 rpm for 5 min at 4°C. The buffer was then decanted, antibody added to the tubes, incubated at 4°C for 20 min, washed 2X with FACS buffer, and repeated this for secondary antibody. The samples were run on FACScan. B7.1 antibody was used 1:5 dilution, 10 µl / sample (Cal-Tag). Recombinant CD28-Ig, CTLA-4-Ig and PD-1-Ig chimeras were used at 2 µg/ml, 10µl/sample (R&D System, Inc). Goat F(ab')₂ anti-human IgG-PE was used at 1:20 dilution (Southern Biotechnology Associates, Inc.).

15 **B7-DC-Ig Dimer Synthesis**

The B7-DC-Ig construct was made by fusing the sequence encoding the N-terminal amino acids of B7-DC without the transmembrane domain in-frame to the sequence encoding the C-terminal amino acids of the human IgG₁ Fc in the pIg-Tail Plus vector(R &D systems). COS-7 cells were transiently transfected with pIg/B7-DC using LipofectAMINE 2000(GIBCO BRL) or GINE JAMMER(Stratagene). The B7-DC-Ig fusion protein was purified from the serum-free supernatants using the saturated ammonium sulfate precipitation. SDS-PAGE and silver staining demonstrated a purity >90%.

20 **T cell Proliferation and Cytokine Assays**

For costimulation assays with anti-CD3, 96 well flat bottom plates (Immulon 4 from Dynex) were precoated with anti-CD3 antibodies (2C11, Pharmingen) and B7.1-Ig (R&D

System), B7-DC-Ig or Isotype control (Sigma) at 100 ng/ml were diluted in 1X PBS (Gibco) pH 7.4 for two hours at 37°C. The plates were then washed 3X with 1X PBS and blocked with RPMI1640 medium supplemented with 10% FCS, Penicillin/Streptomycin, non-essential amino acids, sodium pyruvate, L glutamine, 2-mercaptoethanol for one half hour before adding T cells.

5 Spleens and lymph nodes were obtained from 6-10 weeks old BALB/c mice. RBCs were lysed using ACK buffer and T cells were purified using dynabeads M-280 (Dynex), with the indirect method. The beads were washed 2X with PBS pH 7.4 + 1% FCS before adding the cells and an antibody cocktail composed of anti-IE^d and B220/CD45RO or CD8α (Pharmingen) was added to the cells and incubated at 4°C with bi-directional mixing for 30'. The cells were isolated by

10 placing the tube in a Dynal MPC for 5', centrifuged at 1500rpm for 5' and washed 2X with PBS pH 7.4 + 1% FCS to remove unbound Abs. The same procedure was repeated with 15' incubation, and the cells plated at 2×10^5 cells/well. After 72h of incubation, 10 μl of ^3H -thymidine (1 μCi/well) was added to each well and incubated for 18hrs. Cells were harvested with a Packard Micromate Cell Harvester, and filters were read on a Packard Matrix 96 direct β counter.

15

For costimulation assays using the RENCA system to present HA antigen, RENCA cells were cultured with RPMI-1640 medium supplemented with 10% FCS, Penicillin/Streptomycin, non-essential amino acids, sodium pyruvate. It was induced with IFN-γ (75U/ml) for 72 hours for MHC class II expression. They were then irradiated for 13,200 Rad. and plated at 2×10^4 cells/well (96 well flat bottom plates). HA110-120 peptide was then added at 2.5ug/well and various concentrations of the Ig-fusion molecules were added. Transgenic I-E^d + HA specific T cells (kind gift of H. von Boehmer, Harvard University) were isolated as described above and plated at 4×10^5 cells/well. After 48hr of incubation, 10 μl of ^3H thymidine (1μCi/well) was added to each well and incubated for 18hrs. Cells were harvested with a Packard Micromate Cell Harvester and filters were read on a Packard Matrix 96 Direct β counter.

20

25

For analysis of cytokine production by ELISA, cultures were set up as described above and supernatants were harvested at the indicated times. IL-2, IL-10 and IFN-γ concentrations were determined using commercially available ELISA kits (Endogen), and IL-4 and IL-6 (R&D System).

In Vivo Costimulation

Pooled axillary, inguinal, cervical, and mesenteric LNs from the TCR transgenic mouse line 6.5 that expresses a TCR recognizing an I-E^d restricted HA epitope (¹¹⁰SFERFEIFPKE¹²⁰ [SEQ ID NO:12]) on a B10.D2 genetic background were dissociated in RPMI media (GIBCO

5 BRL), passed over 100µm nylon cell strainer, and washed in sterile Hank's buffer (GIBCO

BRL). After FACS® staining to determine the proportion of clonotypic CD4 cells, a cell

preparation containing 2.5 x 10⁶ clonotypic cells in 0.2ml sterile Hank's buffer was injected intravenously (i.v.) into the tail vein of recipient B10.D2 mice. Three days after this adoptive transfer, the animals were vaccinated via subcutaneous (s.c.) injection into the hind footpads.

10 Each mouse received bilateral injections of one of three preparations:

(A) 10µg synthetic HA (per footpad) (HA peptide (110-120) combined in a 1:1 v/v ratio with incomplete Freund's Adjuvant (IFA) (Sigma),

(B) the HA -IFA mixture with 25µg of B7-DC-Ig, or

15 (C) the HA -IFA mixture with 25µg of an isotype control antibody. 7 days later, draining LNs nodes were harvested; 1.5 x 10⁵ LN cells were incubated in round-bottom 96-well tissue culture plates with the indicated concentration of synthetic HA peptide. Proliferation assays were performed by pulsing 48 h cultures with 1 µCi [³H]thymidine and incubating an additional 12 h before harvest and determination of the amount of incorporated radioactivity.

20

EXAMPLE II

Identification and Characterization Of B7-DC

B7-DC was isolated from a subtracted library between DCs and activated macrophages.

The two populations used for cDNA subtraction were bone marrow-derived GM-CSF cultured

25 DCs as the "tester" population and γ-interferon + LPS activated adherent bone marrow-derived

M-CSF macrophages as the "driver" population. Day 8 MHC class II^{hi}B7^{hi} "mature" DCs were sorted to >93% purity as the source of tester cDNA. DCs were characterized by flow cytometry

as having roughly 50 fold higher MHC class II levels than macrophages. Both populations

expressed B7.1 and B7.2 although B7.2 levels were significantly higher in the DCs. F4/80 and

CD16 were expressed at higher levels on the macrophage population. Functional comparison of

30 the two populations demonstrated that the DC population was roughly 100 fold more potent than

the macrophage population in stimulating an allogeneic mixed lymphocyte reaction.

After RNA extraction from both populations, we used a PCR based cDNA synthesis system followed by the PCR based subtraction procedure, PCR Select. One of the differentially expressed clones encoded a novel immunoglobulin supergene family member, which we name B7-DC. The murine B7-DC cDNA is ~ 1.7kb in length encoding a 247 amino acid (aa) precursor protein with a 23 aa N-terminal signal peptide and a predicted molecular weight of ~ 25kd (Table 1). The putative leader sequence and transmembrane domain were identified using the SOSUI program(31). Two charged aa are found within the 23 aa transmembrane domain of mB7-DC, suggesting a possible binding partner. At the aa level, murine B7-DC is 70% identical to the human B7-DC indicating that they are orthologues (See Tables below). The hB7-DC differs slightly from the murine B7-DC in that it has a longer cytoplasmic tail.

Through a homology search, it was found that B7-DC has significant homology to B7-H1 (34% identity, 48% similarity) (Table 2), to a lesser extent butyrophilin (30% identity, 45% similarity), and <20% identity to B7.1 and B7.2 (Table 3). Phylogenetic studies indicate that butyrophilin is likely related to the B7 family through exon shuffling(32, 33). They each possess the canonical IgV-IgC structure and a transmembrane domain. In contrast to the other B7 family members, murine B7-DC has an extremely short cytoplasmic tail (4 aa).

TABLE 1

Amino acid sequence comparison of murine B7-DC and human B7-DC. The mB7-DC putative leader and transmembrane domain are overlined. The alignment was done using Clustalw-Gonnet Pam250 matrix. The [*] indicates identical amino acids and [:] shows conservative substitutions. Cysteine residues that may be important in the formation of disulfide bonds inside the immunoglobulin V or C domains are italicized..

		<i>Putative leader sequence</i>
10	mB7 -DC	M <small>LL</small> LLPILNL <small>S</small> LQLHPVAALFTVTAPKEVYTVGVSSVSLECDFDRRECTELEGIRASLQ
	hb7 -DC	M <small>IF</small> LLLMLSLELQLHQIAALFTVTVPKELYI <small>E</small> HGSNTLECNFDTGSHVNLA <small>T</small> IASLQ
		::: ;.*.***** :*****.***: * : *.*:***: ** . .: * .* ***
	mB7 -DC	KVENDTSLQSERATLLEEQLPLGKALF <small>H</small> IPS <small>V</small> QVRDSGQYRCLVICGAAWDYKYLTVKV
15	hb7 -DC	KVENDTSPHRERATLLEEQLPLGKASF <small>H</small> IPQVQVRDEGQYQCIIIYGVAWDYKYLTLKV
		***** : *****.*****.*****: *; : * .*****:****:***
	mB7 -DC	ASYMRIDTRILEVPGTGEVQLTCQARGYPLAEVSWQNVSVPANTSHIRTPEGLYQVTSVL
	hb7 -DC	ASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVL
		*** :*;*:***:*** .***:***** *****.*****.*****:*****
		<i>Putative TM domain</i>
20	mB7 -DC	RLKPQPSRN <small>F</small> CMFWNAHMKELTSAIIDPLSRM E PKVPR <small>T</small> WPLHVF <small>I</small> PACTIALIFLAIV
	hb7 -DC	RLKPPPPGRNFSCVFWNTHVRELTLASIDLQSQM E PRTHPTWLLHIFIPSCIIAFIFIATV
		***** * .*****:***:***:*** * ** :***:. ** :***:***: * ***:***: * *
25	mB7 -DC	<u>IIQRKRI-----</u>
	hb7 -DC	<u>IALRKQLCQKL</u> YSSKDTTKRPVTTKREVNSAI
		* ***:

TABLE 2

Amino acid sequence comparison of mB7-DC and mB7-H1.

30	mB7 -DC	M <small>LL</small> LLPILNL <small>S</small> LQLHPVAALFTVTAPKEVYTVGVSSVSLECDFDRRECTELEGIRASLQ
	mB7 -H1	-MRIFAGIIFTACCH-LLRAFTITAPKDLYVVEGNSVTMECRFPVERELDLLALVVYWE
		: : . : : * : *;:*****:.*: **.*:*** * .. :* .. :
35	mB7 -DC	K-----VENDTSLOSE----RATLLEEQLPLGKALEHIPS <small>V</small> QVRDSGQYRCLVIC
	mB7 -H1	KEDEQVIQFVAGEE D LKPQHSNFRGRASLPKDQLLKGNAAQITDVKLQDAGVYCCIIY
		* :* . * . ***: * :*** * :* :***..*:***: * * :*
40	mB7 -DC	GAAWDYKYLTVKVKA <small>S</small> YMRIDTRILEVPGTGEVQLTCQARGYPLAEVSWQN-----VSVP
	mB7 -H1	GGA-DYKRITLKVNAPYR <small>R</small> KINQRISVDPATSEHELICQAEGYPEAEVIWTNSDHQPVS <small>G</small> K
		. *** :***:*. * :* ** .*. * :* ***.*** *** * * **
45	mB7 -DC	ANTSHIRTPEGLYQVTSVIRLKQPSRN <small>F</small> CMFWNAH--MKELTSAIIDPLSRM E PKVPR
	mB7 -H1	RSVTTSRTEGM <small>LL</small> NVTSSLRVNATANDVFYCTFWRSQPGQNH <small>A</small> ELIIPELPATHPPQNR
		..: ** * :*** *:.. . * * ***.: . ..: ** *. . * *
	mB7 -DC	T-WPLHVF <small>I</small> PACTIALIFLAIVIIQRKRI-----
	mB7 -H1	THWVLLGSI <small>LL</small> FLIVVSTVLLFLRKQVRMLDVEKCGVEDTSSKNRNDTQFEE
		* * * * .: : ..: :*

50

TABLE 3
Amino acid sequence comparison of B7-DC to the B7 family members.

<u>Reference B7 Protein</u>	<u>Compared to:</u>	<u>% identity¹</u>	<u>% similarity²</u>
mB7-DC	hB7-DC	70	80
	hBT3.1	25	41
mB7-DC	mB7-H1	34	48
	mBT ⁴	30	45
	mB7.1	-	- ³
	mB7.2	-	-
	mB7RP-1/B7h	-	-
MBT	mB7.1	24	48
	mB7.2	24	40
MB7.1	mB7.2	27	45
MB7-H1 ⁵	mB7.1	23	40
	mB7.2	25	49
	mB7RP-1/B7h	24	41
	mBT	24	45

Comparison were done using NCBI blast2 search (matrix BLOSUM62).

1. Identical amino acids at corresponding positions
2. Similar amino acids at corresponding position - grouped as follows: (A, G); (S, T); (E, D); (R, K, H); (Q, N); (V, I, L, M); (Y, F); (W); (C); (P)
3. no significant similarity was found using matrix BLOSUM62
4. BT=butyrophilin
5. =PDL-1

10

To determine the genomic structure of mB7-DC, the present inventors isolated a genomic clone by screening a pooled Bacterial Artificial Chromosome (BAC) library using probes from the 5' and 3' UTRs. Chromosome location mapping was performed using the BAC clones. Chromosome localization of B7-DC was done using fluorescent *in situ* hybridization (FISH). Measurements of 10 specifically labeled chromosomes 19 demonstrated that mB7-DC is located at a position which is 47% of the distance from the heterochromatic-euchromatic boundary to the telomere of chromosome 19, an area that corresponds to the interface between bands 19C2 and 19C3. Specific hybridization signals were detected by incubating the hybridized slides in fluoresceinated antidigoxigenin antibodies followed by counter staining with DAPI.

15

This locus corresponds to a region of human chromosome 9, where hB7-H1 has been mapped.

20

hB7-DC was found to be located on two chromosome 9 BAC clones. In addition, both hB7-DC and hB7-H1 were found to be located on a single chromosome 9 BAC clone with an insertion size of approximately 164kb (Figure 1). The genomic proximity of B7-DC and B7-H1 is reminiscent of the B7.1/B7.2 pair, which map to within one megabase of each other.

5

EXAMPLE III

B7-DC is selectively expressed in dendritic cells

In order to determine the expression pattern of B7-DC, virtual Northern analysis was performed using RNA extracted from multiple tissues, macrophage cell lines, macrophage cultures and dendritic cells derived from both bone marrow and spleen. While strong hybridization was detected using a B7-DC probe in immature (day 4,6) and mature (day 8 and sorted MHC II^{hi}B7^{hi}) bone marrow derived DC and splenic DC, no signal was detected in any of 10 4 macrophage cell lines, activated BM macrophages or peritoneal macrophages (Figure 2). Strong expression of hB7-DC was detected in human DCs grown from peripheral blood 15 mononuclear cells with GM-CSF plus either IL-4 or Flt-3L (Figure 3). In order to verify cell surface expression of B7-DC protein, anti-mB7-DC antibodies were used to stain DCs. Staining, blockable with soluble B7-DC-Ig, was observed on DC (Figure 4).

B7-DC does not bind to CD28 or CTLA-4 but does bind to PD-1

20 Although B7-DC has structural and sequence homology to the B7 family, it does not contain the putative CD28/CTLA-4 binding sequence, SQDXXXELY [SEQ ID NO:13] or XXXYXXRT [SEQ ID NO:14] (34) (where X=any amino acid). To directly assess binding, the ability of dimeric CD28-Ig and CTLA-4-Ig to stain 293T cells transfected with either B7-DC or B7.1 was investigated. Whereas strong binding was observed with B7.1 transfectants, there was 25 no binding to B7-DC transfectants (Figure 5). Based on homology and genomic proximity between B7-DC and B7-H1/PD-L1, experiments were conducted to test PD-1 as a candidate binding partner for B7-DC. Indeed, PD-100IG bound to B7-DC transfectants but not to B7..1 transfectants. The binding of BPD-1-Ig to B7.1 transfectants was lower than that of CTL-4-It and CD28-Ig to B7.1 transfectants, although it was specific. Further confirmation of 30 the binding of PD-1 to B7-Dc was obtained from positive staining of stable B7-DC-GFP

transflectants with PD-1-Ig. It was concluded that, as with B7-H1 and B7h/B7RP-1, B7-DC does not use CD28 or CTLA-4 as receptors. Rather, PD-1 appears to be a receptor for B7-DC.

EXAMPLE IV

5

B7-DC Functions as a Costimulatory Molecule for T Cells

A soluble B7-DC-Ig fusion protein which could be added to T cell stimulation assays was produced for use in testing whether B7-DC possessed costimulatory activity. The proliferative response of T cells was measured to stimulation by increasing amounts of immobilized anti-CD3 in the presence of either B7-DC-Ig, B7.1-Ig or an isotype control. Figure 10 6 (left) shows that, in the presence of suboptimal anti-CD3 concentration, B7-DC costimulated a greater T cell proliferative response than did B7.1. Furthermore, B7-DC costimulated proliferative responses were higher in CD4 than in CD8 cells (Figure 6, right). B7-DC failed to stimulate T cells in the absence of a TCR-focused stimulus, indicating that B7-DC was providing a true costimulatory signal.

15

B7-DC also costimulated a proliferative responses when "signal 1" was provided by an MHC-peptide complex. RENCA cells (which express no endogenous B7.1, B7.2 or B7-DC by RT-PCR analysis) were treated with γ -IFN to induce MHC class II expression. These cells were loaded with the I-E^d restricted HA 110-120 peptide (FERFEIFPKE)(35) [SEQ ID NO:15]. Purified splenic T cells from an I-E^d + HA 110-120 specific TCR transgenic mouse line were 20 added and the proliferative response was measured in the presence of either B7-DC-Ig, B7.1-Ig or an isotype control. Figure 7 shows that B7-DC possessed greater costimulatory activity than did B7.1.

Patterns of lymphokine production costimulated by B7-DC

25

The best characterized T cell responses to costimulation by the B7 family molecules is lymphokine production. These lymphokines are important mediators of T cell effects. Studies were done to analyze production of a number of different lymphokines by T cells that had been stimulated with anti-CD3 or HA antigen (Figure 8) costimulated with either B7-DC-Ig, B7.1-Ig or an isotype control. Patterns of lymphokine costimulation were fairly consistent whether anti-CD3 or an MHC-peptide complex was utilized as "signal 1". Significantly, B7-DC costimulated greater levels of γ -IFN than did B7.1. B7-DC also costimulated significant amounts of IL-6 production whereas B7.1 costimulated virtually none. While both molecules costimulated IL-2

production, B7.1 did so more efficiently than did B7-DC. Thus, the patterns of costimulation by B7-DC and B7.1 are distinct, with B7-DC being more efficient in costimulating important proinflammatory lymphokines.

5

EXAMPLE V

B7-DC Enhances In Vivo immune Responses

In order to determine whether B7-DC possesses *in vivo* biologic activity, the inventors asked whether B7-DC-Ig enhanced immune responses to peptide vaccines. B7-DC-Ig or an isotype control antibody was added to the immunogenic cocktail of HA 110-120 peptide and IFA. To permit enumeration of HA-specific CD4 T cells *in vivo*, 2.5×10^6 anti-HA 6.5 T cells were transferred into the mice 3 days before immunization. Seven days after immunization, draining LN cells were harvested and the cells stimulated *in vitro* for 2 days with varying amounts of HA110-120 peptide. Figure 9 shows that addition of B7-DC-Ig indeed dramatically enhanced the proliferative response to HA. The total number of HA-specific T cells in draining LN was increased by roughly 2 fold in groups receiving B7-DC-Ig relative to isotype antibody controls.. It was therefore concluded that B7-DC had the ability to enhance antigen-specific responses even on a per cell basis.

10

15

20

EXAMPLE VI

Discussion and Conclusions

The present inventors have discovered and characterized a new B7 family member with expression highly restricted to DCs and having unique costimulatory properties for T cells. The human orthologue of B7-DC is also expressed in DCs.

25

30

This restricted expression pattern contrasts with the previously described B7 family members, suggesting that B7-DC participates in different immune responses than the known B7.1/2 pathways. While a weak B7-DC signal was detected by RT-PCR in activated macrophages, preliminary realtime RT-PCR analysis indicated that B7-DC mRNA expression in DCs was >15-fold higher than in activated macrophages. Antibody staining likewise detected very low levels of B7-DC on the surface of activated macrophages. It is unclear whether this is sufficient for significant T cell activation.

The unusual pattern of lymphokine production that B7-DC costimulates implies a unique biologic role compared to other B7 family members. The traditional classification of cytokines is as follows: Th1 cytokines include IL-2, γ -IFN and lymphotoxin; Th2 cytokines include IL-4, IL-5, IL-6 and IL-13 (36). B7-DC does not induce either a classic Th1 or Th2 lymphokine profile. B7-DC induces very little IL-4 and no IL-10. However, IL-6 is considered a Th2 cytokine. The lower IL-2 and higher γ -IFN costimulated by B7-DC relative to B7.1 does not conform to a classic Th1 pattern. Nonetheless, the high γ -IFN production suggests that B7-DC evokes important T cell effector function.

B7-DC is noteworthy in its ability to costimulate IL-6. The robust proliferative response of T cells induced by B7-DC is explained in part by its strong costimulation of IL-6 production, which is not observed with B7.1. IL-6 is a potent amplifier of T cell proliferation (in conjunction with other proliferative stimuli) (37, 38). IL-6 is a multifunctional cytokine that regulates not only T cell function but also proinflammatory responses, monocyte differentiation, B cell differentiation, thrombopoiesis, bone resorption, and the growth of certain hematopoietic tumors (39, 40). IL-6 can function in concert with soluble IL6 receptors (sIL-6R) in the induction of chemokines and leukocyte recruitment(41). It can mediate potent antiapoptotic effects via Stat-3 activation. IL-6 dependent Stat-3 activation in T cells has been reported to be an important pathway for the survival of activated T cells (42, 43) although other reports suggest that Stat-3 exerts its effect on resting T cells.

While B7-DC fails to bind CD28 or CTLA-4, it does bind PD-1, a receptor for B7-H1/PD-L1 (22, 47, 48). It has not yet been determined whether it binds ICOS, a receptor for B7h/B7RP-1(23-25, 44-46). The marked homology between B7-DC and B7-H1/PDL-1 (greater than that between B7.1 and B7.2), the close physical linkage of hB7-H1/PD-L1 and hB7-DC and their binding to a common receptor, suggests that they are related by a relatively recent gene duplication event. This is analogous to the relationship between B7.1 and B7.2, which both map to within one megabase on mouse chromosome 16 and on human chromosome 3 (49).

It will be important to discern the relative biologic roles of B7-DC vs B7-H1/PD-L1 as mediated by PD-1 and other putative receptor(s). PD-1 is expressed subsequent to,, and appears to inhibit, T cells activation. PD-1 induces apoptosis under conditions of T cell stimulation with high concentrations of anti-CD3. PD-1 knockout mice develop an autoimmune syndrome (22) characterized by clinical manifestations of hypertrophic cardiomyopathy. In contrast, Dong

et al. (21) reported that B7-H1/PD-L1 co-stimulated T cell proliferation and cytokine release at lower concentrations of anti-CD3. By analogy to the relationship of CD28/CTLA-4, PD-L1 may be a counterreceptor for an as yet unidentified activating receptor. Despite sharing the property of binding to PD-1, B7-DC and B7-H1 are distinct in their lymphokine costimulation patterns; B7-H1 costimulated T cell IL-10 production whereas B7-DC does not. The distinct cellular expression patterns and costimulatory functions of B7-DC suggest a unique role in immune function.

10 The references cited above and below are all incorporated by reference herein, whether specifically incorporated or not.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

15 While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

Documents Cited

25 *In addition to documents cited fully in the text, certain documents are cited by number only (parenthetical); the latter are listed below.*

1. Hathcock, K.S., G. Laszlo, C. Pucillo, P. Linsley, and R.J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. *J Exp Med* 180, no. 2:631.
2. Razi-Wolf, Z., G.J. Freeman, F. Galvin, B. Benacerraf, L. Nadler, and H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. *Proc Natl Acad Sci U S A* 89, no. 9:4210.
3. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol* 9:271.
4. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392, no. 6673:245.
5. Patterson, S. 2000. Flexibility and cooperation among dendritic cells. *Nature Immunol.* 1, no. 4:273.
6. Langenkamp, A., M. Messi, A. Lanzavecchia, and S. Federica. 2000. Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. *Nature Immunol.* 1, no. 4:311.

7. Thompson, C.B., T. Lindsten, J.A. Ledbetter, S.L. Kunkel, H.A. Young, S.G. Emerson, J.M. Leiden, and C.H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. *Proc Natl Acad Sci U S A* 86, no. 4:1333.
8. Harding, F.A., J.G. McArthur, J.A. Gross, D.H. Raulet, and J.P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. *Nature* 356, no. 6370:607.
9. Linsley, P.S., W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, and J.A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. *J Exp Med* 173, no. 3:721.
10. Fraser, J.D., B.A. Irving, G.R. Crabtree, and A. Weiss. 1991. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. *Science* 251, no. 4991:313.
11. Lindstein, T., C.H. June, J.A. Ledbetter, G. Stella, and C.B. Thompson. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. *Science* 244, no. 4902:339.
12. Linsley, P.S., W. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle, and J.A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. *J Exp Med* 174, no. 3:561.
13. Waterhouse, P., L.E. Marengere, H.W. Mittrucker, and T.W. Mak. 1996. CTLA-4, a negative regulator of T-lymphocyte activation. *Immunol Rev* 153:183.
14. Kuchroo, V.K., M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner, N. Nabavi, and L.H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. *Cell* 80, no. 5:707.
15. Lanier, L.L., S. O'Fallon, C. Somoza, J.H. Phillips, P.S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. *J Immunol* 154, no. 1:97.
16. Van Parijs, L., M.P. Sethna, A.N. Schweitzer, F. Borriello, A.H. Sharpe, and A.K. Abbas. 1997. Functional consequences of dysregulated B7-1 (CD80) and B7-2 (CD86) expression in B or T lymphocytes of transgenic mice. *J Immunol* 159, no. 11:5336.
17. Abbas, A.K., and A.H. Sharpe. 1999. T-cell stimulation: an abundance of B7s [news; comment]. *Nat Med* 5, no. 12:1345.
18. Borriello, F., M.P. Sethna, S.D. Boyd, A.N. Schweitzer, E.A. Tivol, D. Jacoby, T.B. Strom, E.M. Simpson, G.J. Freeman, and A.H. Sharpe. 1997. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. *Immunity* 6, no. 3:303.
19. Sharpe, A.H. 1995. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. *Curr Opin Immunol* 7, no. 3:389.
20. Green, J.M., P.J. Noel, A.I. Sperling, T.L. Walunas, G.S. Gray, J.A. Bluestone, and C.B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. *Immunity* 1, no. 6:501.
21. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [see comments]. *Nat Med* 5, no. 12:1365.
22. Freeman, G.J., A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. Okazaki, M.C. Byrne, H.F. Horton, L. Fouster, L. Carter, V. Ling, M.R. Bowman, B.M. Carreno, M. Collins, C.R. Wood, and T. Honjo. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 192, no. 7:1027.
23. Swallow, M.M., J.J. Wallin, and W.C. Sha. 1999. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF α . *Immunity* 11, no. 4:423.
24. Wang, S., G. Zhu, A.I. Chapoval, H. Dong, K. Tamada, J. Ni, and L. Chen. 2000. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. *Blood* 96, no. 8:2808.
25. Yoshinaga, S.K., J.S. Whoriskey, S.D. Khare, U. Sarmiento, J. Guo, T. Horan, G. Shih, M. Zhang, M.A. Coccia, T. Kohno, A. Tafuri-Bladt, D. Brankow, P. Campbell, D. Chang, L. Chiu, T. Dai, G. Duncan, G.S. Elliott, A. Hui, S.M. McCabe, S. Scully, A. Shahinian, C.L. Shaklee, G. Van, T.W. Mak, and et al. 1999. T-cell co-stimulation through B7RP-1 and ICOS. *Nature* 402, no. 6763:827.
26. Inaba, K., W.J. Swiggard, R. Steinman, N. Romani, and G. Schuler. 1998. Isolation of dendritic cells. John Wiley & Sons, Inc., New York.
27. Fortier, A.H., and L.A. Falk. 1994. Isolation of murine macrophages. John Wiley & Sons, Inc., New York.

28. Orimoto, K., H. Tsuchiya, J. Sakurai, M. Nishizawa, and O. Hino. 1998. Identification of cDNAs induced by the tumor suppressor Tsc2 gene using a conditional expression system in Tsc2 mutant (Eker) rat renal carcinoma cells. *Biochem Biophys Res Commun* 247, no. 3:728.

5 29. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P.O. Fritsch, R.M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. *J Exp Med* 180, no. 1:83.

10 30. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108, no. 2:193.

15 31. Hirolawa, T., S. Boon-Chieng, and S. Mitaku. 1998. SOSUI: Classification and secondary structure prediction system for membrane proteins. *Bioinformatics* 14, no. 4:378.

32. Linsley, P.S., R. Peach, P. Gladstone, and J. Bajorath. 1994. Extending the B7 (CD80) gene family. *Protein Sci* 3, no. 8:1341.

15 33. Henry, J., M. Ribouchon, D. Depetris, M. Mattei, C. Offer, R. Tazi-Ahnini, and P. Pontarotti. 1997. Cloning, structural analysis, and mapping of the B30 and B7 multigenic families to the major histocompatibility complex (MHC) and other chromosomal regions. *Immunogenetics* 46, no. 5:383.

34. Fargeas, C.A., A. Truneh, M. Reddy, M. Hurle, R. Sweet, and R.P. Sekaly. 1995. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4. *J Exp Med* 182, no. 3:667.

20 35. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. *J Exp Med* 180, no. 1:25.

36. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 7:145.

25 37. Suda, T., A. O'Garra, I. MacNeil, M. Fischer, M.W. Bond, and A. Zlotnik. 1990. Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. *Cell Immunol* 129, no. 1:228.

38. Suda, T., R. Murray, C. Guidos, and A. Zlotnik. 1990. Growth-promoting activity of IL-1 alpha, IL-6, and tumor necrosis factor-alpha in combination with IL-2, IL-4, or IL-7 on murine thymocytes. Differential effects on CD4/CD8 subsets and on CD3+/CD3- double-negative thymocytes. *J Immunol* 144, no. 8:3039.

30 39. Taga, T., and T. Kishimoto. 1997. Gp130 and the interleukin-6 family of cytokines. *Annu Rev Immunol* 15:797.

40 40. Chomarat, P., J. banchereau, J. Davoust, and A.K. Palucka. 2000. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. *Nature Immunol* 1, no. 6:510.

41. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, F. Bussolino, V. Poli, G. Ciliberto, and A. Mantovani. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity* 6, no. 3:315.

35 42. Takeda, K., T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto, and S. Akira. 1998. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. *J Immunol* 161, no. 9:4652.

43. Teague, T.K., B.C. Schaefer, D. Hildeman, J. Bender, T. Mitchell, J.W. Kappler, and P. Marrack. 2000. Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. *J Exp Med* 191, no. 6:915.

40 44. Coyle, A.J., S. Lehar, C. Lloyd, J. Tian, T. Delaney, S. Manning, T. Nguyen, T. Burwell, H. Schneider, J.A. Gonzalo, M. Gosselin, L.R. Owen, C.E. Rudd, and J.C. Gutierrez-Ramos. 2000. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. *Immunity* 13, no. 1:95.

45 45. Hütloff, A., A.M. Dittrich, K.C. Beier, B. Eljaschewitsch, R. Kraft, I. Anagnostopoulos, and R.A. Kroczeck. 1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. *Nature* 397, no. 6716:263.

46. Yoshinaga, S.K., M. Zhang, J. Pistillo, T. Horan, S.D. Khare, K. Miner, M. Sonnenberg, T. Boone, D. Brankow, T. Dai, J. Delaney, H. Han, A. Hui, T. Kohno, R. Manoukian, J.S. Whoriskey, and M.A. Coccia. 2000. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. *Int Immunol* 12, no. 10:1439.

47. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *Embo J* 11, no. 11:3887.

48. Shinohara, T., M. Taniwaki, Y. Ishida, M. Kawaichi, and T. Honjo. 1994. Structure and chromosomal localization of the human PD-1 gene (PDCD1). *Genomics* 23, no. 3:704.

5 49. Reeves, R.H., D. Patch, A.H. Sharpe, F. Borriello, G.J. Freeman, S. Edelhoff, and C. Distefano. 1997. The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. *Mamm Genome* 8, no. 8:581.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule that encodes a mammalian protein termed B7-DC that is selectively expressed on dendritic cells as compared to activated macrophages.

5 2. The nucleic acid molecule of claim 1 that comprises a nucleotide sequence selected from SEQ ID NO:1 or SEQ ID NO:5.

3. An isolated nucleic acid molecule that hybridizes with the nucleic acid molecule of claim 1 or 2 under stringent hybridization conditions.

10 4. The nucleic acid molecule of claim 2 that comprises the nucleotide sequence SEQ ID NO:1.

5. The nucleic acid molecule of any of claims 1-4 that encodes a protein having an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4 or encodes a biologically active fragment, homologue or other functional derivative of said protein.

15 6. The nucleic acid molecule of claim 6 that encodes said protein having the sequence SEQ ID NO:2 or encodes said biologically active fragment, homologue or other functional derivative of SEQ ID NO:2.

7. A fragment of the nucleic acid molecule of any of claims 5 or 6 that encodes all or part of the extracellular domain of said B7-DC protein.

20 8. The nucleic acid molecule of claim 5 that encodes a B7-DC fusion polypeptide, which molecule comprises:

- (a) a first nucleic acid sequence encoding a first polypeptide that is all or a part of a B7-DC protein SEQ ID NO: 2 or SEQ ID NO:4;
- (b) optionally, fused in frame with the first nucleic acid sequence, a linker nucleic acid sequence encoding a linker peptide; and
- 25 (c) a second nucleic acid sequence that is linked in frame to said first nucleic acid sequence or to said linker nucleic acid sequence and that encodes a second polypeptide.

9. The nucleic acid molecule of claim 8 wherein said second polypeptide consists of one or more domains of an Ig heavy chain constant region.

10. The nucleic acid molecule of claim 11 wherein said second polypeptide consists of two domains of a human IgG constant region.

5 11. An expression vector comprising the nucleic acid of any of claims 1-10 operatively linked to:

- (a) a promoter and
- (b) optionally, additional regulatory sequences that regulate expression of said nucleic acid in a eukaryotic cell.

10 12. The expression vector of claim 11 which is a plasmid.

13. The expression vector of claim 11 which is a viral vector.

14. A vector composition comprising

- (a) a first recombinant expression vector having incorporated in its nucleic acid a nucleotide sequence encoding an antigen of interest against which an immune response is to be induced; and
- (b) a second recombinant expression vector having incorporated in its nucleic acid one or more nucleotide sequences encoding a co-stimulator polypeptide, at least one of which co-stimulator polypeptides is B7-DC, or is a biologically active fragment, homologue or other functional derivative thereof,

15 20 wherein the expression vectors are able to co-infect or co-transfet a host cell resulting in co-expression of the antigen and the costimulator polypeptide, fragment, homologue or derivative.

15. The vector of claim 14 wherein said second vector comprises SEQ ID NO:1 or SEQ ID NO:5.

16. The vector of claim 14 or 15 wherein said second vector comprises SEQ ID NO:1.

25 17. A cell transformed or transfected with the nucleic acid molecule of any of claims 1-1

18. A cell transformed or transfected with the expression vector of any of claims
claim 1-16.

19. The cell of claim 19 which is a mammalian cell.
20. The cell of claim 19 which is a human cell.
21. The cell of claim 19 which is a dendritic cell or a progenitor thereof.
22. The cell of claim 19 which is a tumor cell.

5 23. An isolated mammalian tumor cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-DC protein or a biologically active fragment, homologue or other functional derivative thereof, such that when said protein, fragment, homologue or derivative is expressed by said tumor cell, and said tumor cell is contacted with T cells

- (i) said B7-DC protein, fragment, homologue or derivative binds to said T cells; and
- 10 (ii) said tumor cell costimulates said T cells to proliferate and/or to produce and secrete cytokines.

24. The tumor cell of claim 23 wherein said exogenous nucleic acid molecule comprises SEQ ID NO:1, SEQ ID NO:5 or a fragment of said sequence.

15 25. A polypeptide that is selectively expressed on dendritic cells as compared to activated macrophages and has the following functional properties:

- (a) binds to a binding partner on T cells; and
- (b) costimulates T cells to proliferate and/or to produce and secrete cytokines.

20 26. The polypeptide, fragment, homologue or functional derivative of claim 25 encoded by a nucleic acid molecule having the sequence SEQ ID NO:1 or SEQ ID NO:5, or a fragment, homologue or equivalent of said nucleic acid molecule.

27. The polypeptide of claim 26 having the amino acid sequence SEQ ID NO:2 or SEQ ID NO:4, or a fragment, homologue or equivalent of said polypeptide.

25 28. A polypeptide or a biologically active fragment, homologue or other functional derivative of said polypeptide produced by recombinant expression of the nucleic acid of any of claims 1 - 10.

29. The polypeptide of any of claims 25-28 comprising the extracellular domain of the B7-DC protein, which domain comprises amino acid residues 26-221 of SEQ ID NO:2 or SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of said domain.

5 30. The polypeptide of any of claims 25-28 consisting essentially of the extracellular domain of B7-DC which domain includes amino acid residues 26-221 of SEQ ID NO:2 or SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of residues 26-221.

10 31. A B7-DC fusion polypeptide having a first fusion partner comprising all or a part of a B7-DC protein which

- (i) is fused directly to a second polypeptide or,
- (ii) optionally, is fused to a linker peptide sequence that is fused to said second polypeptide.

15 32. A B7-DC fusion polypeptide comprising the polypeptide of any of claims claim 25-30 fused to a second polypeptide.

33. The fusion polypeptide of claim 32, that binds to a binding partner molecule on T cells and co-stimulates said T cells in the presence of an adequate stimulus to the T cell receptor.

34. The fusion polypeptide of claim 33 wherein said binding partner molecule is PD-1.

20 35. The fusion polypeptide of any of claims 31-33 wherein said second polypeptide is one or more domains of an Ig heavy chain constant region.

36. The fusion polypeptide of any of claims 31-35 wherein said first fusion partner comprises amino acids 26-221 of SEQ ID NO:2 or of SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative thereof.

25 37. The fusion polypeptide of claim 36 wherein said first fusion partner comprises amino acids 26-221 of SEQ ID NO:2, or a co-stimulatory fragment, homologue or other functional derivative thereof.

38. The fusion polypeptide of claim 35 wherein said polypeptide has an amino acid sequence corresponding to the hinge, C_H2 and C_H3 regions of a human immunoglobulin C_γ1 chain.

5 39. A dimeric or trimeric fusion polypeptide which is a tandemly linked dimer or trimer of the fusion polypeptide of any of claims 31-38.

40. The fusion polypeptide of any of claims 31 - 38, comprising a linear multimer of two or more repeats of monomers of said first fusion partner linked end to end, directly or with a linker sequences present between said monomer repeats.

10 41. An antibody that is specific for an epitope of a B7-DC protein, which epitope is not present in a known member of a B7 family protein.

42. The antibody of claim 41 wherein said epitope is a linear or conformational epitope of a polypeptide of SEQ ID NO:2 or SEQ ID NO:4.

43. The antibody of claim 42 wherein said epitope is a linear or conformational epitope of a polypeptide of SEQ ID NO:2.

15 44. The antibody of any of claims 41-42 that is a monoclonal antibody.

45. The antibody of claim 43 that is a human or humanized monoclonal antibody.

46. A method of identifying or quantitating cells expressing a B7-DC polypeptide on their surface in a cell population, comprising

20 (a) contacting cells of said population with the antibody of any of claims 41-45, so that said antibody binds to cells expressing said epitope;

(b) assessing the presence of, or quantitating the number of, cells to which said antibody is bound.

47. A method of isolating cells expressing a B7-DC polypeptide on their surface from a cell population, comprising

25 (a) contacting cells of said population with the antibody of any of claims 41-45, so that said antibody binds to cells expressing said epitope;

(b) positively selecting cells to which said antibody has bound or negatively selecting cells to which said antibody has not bound,
thereby isolating said cells.

48. A method of detecting the presence or quantitating a B7-DC polypeptide,
5 fragment or homologue in a sample, comprising the steps of:

- (a) contacting the sample with the antibody of any of claims 41-45, such that the antibody binds to any polypeptides or fragments bearing said epitope;
- (b) detecting the presence of, or quantitating the polypeptides or fragments bound to said antibody.

10 49. A method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of said cell to co-stimulate T cells *in vitro* or *in vivo* in the presence of an adequate stimulus to the T cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is
15 induced or increased on said cells.

20 50. A method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of said cell to co-stimulate T cells *in vitro* or *in vivo* in the presence of an adequate stimulus to the T cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is
induced or increased on said cells.

51. The method of claim 49 or 50 wherein said antigen presenting cells are dendritic cells and said progenitors are dendritic cell progenitors.

25 52. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of cells according to any of claims 17-24, in conjunction with an antigen, wherein said cells are effective to increase the T cell response of said subject to said antigenic stimulation.

53. A method for increasing the T cell response of a mammalian subject to antigenic stimulation with a tumor-associated antigen, comprising administering to said subject an effective amount of tumor cells according to any of claims 22 -24, wherein said tumor cells express said antigen, said administration of said tumor cells being effective to increase the T cell
5 response of said subject to said tumor antigen stimulation.

54. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of a polypeptide, fragment, homologue or functional derivative according to any of claims 25-30 in conjunction with an antigen, wherein the administration of said polypeptide is effective to increase the T cell
10 response of said subject to said antigenic stimulation.

55. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of a fusion polypeptide according to any of claims 31-40, in conjunction with an antigen, wherein the administration of said polypeptide is effective to increase the T cell response of said subject to
15 said antigenic stimulation.

56. A method for inhibiting a T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of an antibody according to any of claims 41-45, wherein the administration of said antibody is effective to block stimulation of T cells or to eliminate antigen-reactive T cells, thereby inhibiting the T cell
20 response.

57. The method of claim 56 wherein said T cell response is directed to a tissue transplant or to an autoantigen such that said method inhibits transplant rejection or an autoimmune reaction.

58. A method for increasing the immune response of a mammalian subject to
25 antigenic stimulation comprising:

- (a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;

(b) contacting said T cells *ex vivo* with an effective amount of cells according to any of claim 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and

(c) administering said T cells of step (b) to said subject,

5 thereby increasing said immune response of said subject.

59. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:

(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;

(b) contacting said T cells *ex vivo* with an effective amount of cells according to any of claims 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and

(c) administering said T cells of step (b) to said subject,

15 thereby increasing said immune response of said subject.

60. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:

(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;

(b) contacting said T cells *ex vivo* with an effective amount of the polypeptide, fragment, homologue or functional derivative of any of claims 25-30, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and

20 (c) administering said T cells of step (b) to said subject,

25 thereby increasing said immune response of said subject.

61. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:

(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;

(b) contacting said T cells *ex vivo* with an effective amount of a the fusion polypeptide of any of claims 31-40, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and

(c) administering said T cells of step (b) to said subject,

thereby increasing said immune response of said subject.

62. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising

(a) the transformed or transfected cells of any of claims 17-24 which optionally express said antigen;

(b) if the cells of (a) do not express said antigen, an additional source of said antigen;

(c) optionally, a general immunostimulatory agent or adjuvant; and

(d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

63. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising

(a) a source of antigen to which an immune response is desired;

(b) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30;

(c) optionally, a general immunostimulatory agent or adjuvant; and

(d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

64. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising

(a) a source of antigen to which an immune response is desired;

(b) the fusion polypeptide of any of claims 31-40;

(c) optionally, a general immunostimulatory agent or adjuvant; and

(d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).

65. A co-stimulatory composition for use with an antigen or a vaccine to increase the immunogenicity of the antigen or vaccine, comprising:

5 (a) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30; and
(b) a pharmaceutically and immunologically acceptable excipient or carrier.

66. A co-stimulatory composition for use with an antigen or a vaccine to increase the immunogenicity of the antigen or vaccine, comprising:

10 (a) the fusion polypeptide of any of claims 31-40; and
(b) a pharmaceutically and immunologically acceptable excipient or carrier.

67. A method for inducing or enhancing an immune response to an antigen in a mammalian subject comprising administering to said subject an effective amount of the vaccine composition of any of claims 62-64.

15 68. A method for potentiating an immune response to an antigen or a vaccine in a mammalian subject, comprising administering to said subject, in combination with said antigen or vaccine, the costimulatory composition of claim 65 or 66.





Fig. 1

act. peritoneal M ϕ
act. BM M ϕ
Spleen DC.
sorted BM -DC
BM DC (day 8)
BM DC (day 6)
BM DC (day 4)
BM
WEHI
PU 5-18
RAW 264-7
J774 A1



B7-DC

G3PDH

FIG. 2




Fig. 3




Fig. 4







Fig. 5



**Fig. 8**




Fig. 9

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/13430

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/12	C12N15/62	C12N5/10	C07K14/705	C07K16/28
	A61K38/17	A61K39/00	A61K39/395		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>TSENG SU-YI ET AL: "B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 193, no. 7, 2 April 2001 (2001-04-02), pages 839-845, XP002189416 ISSN: 0022-1007 the whole document</p> <p>---</p> <p>-/-</p>	1-68

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

8 February 2002

Date of mailing of the International search report

20.02.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Madruga, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/13430

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EM_MUS [Online] EMBL; Accession NO: AF142780, 1 June 1999 (1999-06-01) TSENG S Y ET AL: "Mus musculus Butyrophilin-like protein (Btdc) mRNA, complete cds." XP002189417 cited in the application the whole document	1-3,5-7, 25-28
Y	---	4,8-24, 29-68
X	DATABASE EM_HUM [Online] EMBL; Accession NO: AK001872, 22 February 2000 (2000-02-22) ISOGAI T ET AL: "Homo sapiens cDNA FLJ11010 fis" XP002189418 abstract	3,5,7, 26-28
E	WO 01 34629 A (HUMAN GENOME SCIENCES INC ;BAKER KEVIN P (US); RUBEN STEVEN M (US)) 17 May 2001 (2001-05-17)	1-7, 11-13, 17-22, 25-28, 41-48
	SEQ ID NO:11, SEQ ID NO: 33 and SEQ ID NO:41 claims	
P,X	EP 1 074 617 A (HELIX RES INST) 7 February 2001 (2001-02-07) SEQ ID NO:12622 and SEQ ID NO:4320 & DATABASE GSN [Online] Accession NO:AAH14818, 26 June 2001 (2001-06-26) OTA T. ET AL.: "Human cDNA sequence" the whole document	3,5-7, 26-28
P,X	WO 00 61612 A (CORIXA CORP ;FAN LIQUN (US); WANG TONGTONG (US)) 19 October 2000 (2000-10-19) SEQ ID NO: 264	3,5-7, 26-28
P,X	WO 00 55375 A (ALPHAGENE INC) 21 September 2000 (2000-09-21) SEQ ID NO:81 page 440; claim 90	3,5-7, 26-28

	-/-	

INTERNATIONAL SEARCH REPORT

Inte
ntal Application No
PCT/US 01/13430

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEN L ET AL: "COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR OF THE T LYMPHOCYTE MOLECULES CD28 AND CTLA-4" CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 71, 24 December 1992 (1992-12-24), pages 1093-1102, XP000941406 ISSN: 0092-8674 page 1094, left-hand column, paragraph 2 -page 1096, left-hand column, paragraph 1 page 1100, right-hand column, paragraph 2 ---	14-20, 22-24, 52,53, 58,59
A	US 5 861 310 A (GRAY GARY S ET AL) 19 January 1999 (1999-01-19) cited in the application claims; examples ---	14-20, 22-24, 52,53, 58,59
Y	GERSTMAYER BERNHARD ET AL: "Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein." CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 45, no. 3-4, November 1997 (1997-11), pages 156-158, XP002932422 ISSN: 0340-7004 the whole document ---	8-13, 31-40, 55,61, 64,66
Y	HENRY J ET AL: "Structure and evolution of the extended B7 family" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 20, no. 6, June 1999 (1999-06), pages 285-288, XP004169718 ISSN: 0167-5699 the whole document ---	4
Y	WO 92 00092 A (SQUIBB BRISTOL MYERS CO) 9 January 1992 (1992-01-09) claims ---	29,30, 41-48, 54,56, 57,60, 63,65, 67,68
Y	WO 97 24447 A (VIAGENE INC) 10 July 1997 (1997-07-10) page 2, paragraph 2 page 4, line 25 - line 26 page 19, line 23 -page 21, line 18 ---	21, 49-51,62
		-/-

INTERNATIONAL SEARCH REPORT

Inter	al Application No
PCT/US 01/13430	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>YOSHINAGA S K ET AL: "T-cell co-stimulation through B7RP-1 and ICOS" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 402, 16 December 1999 (1999-12-16), pages 827-832, XP002157212 ISSN: 0028-0836 cited in the application the whole document</p> <p>---</p>	31-38
A	<p>WO 95 05464 A (ARCH DEV CORP) 23 February 1995 (1995-02-23) claims; examples</p> <p>---</p>	1-68
A	<p>TOWNSEND S E ET AL: "TUMOR REJECTION AFTER DIRECT COSTIMULATION OF CD8+T CELLS BY B7-TRANSFECTED MELANOMA CELLS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 259, 15 January 1993 (1993-01-15), pages 368-370, XP000943266 ISSN: 0036-8075 cited in the application the whole document</p> <p>-----</p>	8-24,52, 53,58, 59,62,67

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/13430

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 49-61, 67 and 68 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 4,6,16,37,43 and in part: 1-3, 5, 7-15, 17-36, 38-42 and 44-68

Human B7-DC nucleic acid, polypeptide and uses thereof

2. Claims: In part: 1-3, 5, 7-15, 17-36,38-42 and 44-68

Murine B7-DC nucleic acid, polypeptide and uses thereof

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte r	al Application No
PCT/US	01/13430

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0134629	A	17-05-2001	AU 1473501 A WO 0134629 A1	06-06-2001 17-05-2001
EP 1074617	A	07-02-2001	AU 6180800 A AU 6180900 A AU 6181000 A AU 6181100 A AU 6181200 A AU 6181300 A AU 6181400 A AU 6181500 A AU 6181600 A AU 6315800 A EP 1074617 A2 WO 0109315 A1 WO 0109345 A1 WO 0109316 A1 WO 0109349 A1 WO 0109317 A1 WO 0109318 A1 WO 0109319 A1 WO 0109346 A1 WO 0109320 A1 WO 0109321 A1 WO 0109322 A1 WO 0109323 A1	19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 19-02-2001 07-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001 08-02-2001
WO 0061612	A	19-10-2000	AU 4069200 A EP 1169347 A2 WO 0061612 A2	14-11-2000 09-01-2002 19-10-2000
WO 0055375	A	21-09-2000	AU 3899700 A WO 0055375 A1 AU 2883500 A EP 1153121 A2 WO 0049134 A1	04-10-2000 21-09-2000 04-09-2000 14-11-2001 24-08-2000
US 5861310	A	19-01-1999	AU 7405294 A AU 9699198 A CA 2167091 A1 EP 0711345 A1 JP 9500788 T WO 9503408 A1 US 6130316 A US 6084067 A	20-02-1995 18-02-1999 02-02-1995 15-05-1996 28-01-1997 02-02-1995 10-10-2000 04-07-2000
WO 9200092	A	09-01-1992	CA 2086325 A1 EP 0537293 A1 JP 6508501 T WO 9200092 A1 US 5521288 A US 5580756 A	03-01-1992 21-04-1993 29-09-1994 09-01-1992 28-05-1996 03-12-1996
WO 9724447	A	10-07-1997	EP 0871747 A1 WO 9724447 A1	21-10-1998 10-07-1997
WO 9505464	A	23-02-1995	AU 7526894 A WO 9505464 A1	14-03-1995 23-02-1995

This Page Blank (uspto)